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Iron is used as a co-factor in a range of biological reactions and is an essential nutrient 
across all domains of life. During infection, pathogens must acquire iron from their host 
environment. The tetrameric oxygen transport protein, haemoglobin A (Hb), represents 
the largest pool of mammalian iron, accounting for ~ 65 % of iron in a healthy individual. 
Genes encoding for Hb receptors are found in the genomes of Gram-positive and Gram-
negative pathogens and their deletion results in attenuated virulence, suggesting that Hb is 
an important source of iron during host colonization. As yet, the mechanisms by which 
these receptors interact with Hb and capture the haem co-factor (containing the iron) are 
largely unknown. 
 
Staphylococcus aureus is a Gram-positive human pathogen and is a significant health 
burden in both community and health care settings. S. aureus expresses an elaborate 
system of proteins known as the iron regulated surface determinant (Isd) system, which is 
specialized to strip iron from Hb. Two related Hb receptors have been identified in the 
staphylococcal genome, IsdB and IsdH. IsdB and IsdH bind to Hb on the bacterial cell 
surface, actively remove the haem cofactor and relay it to the down stream haem binding 
proteins IsdA and IsdC in the cell wall. IsdB and IsdH are multi-domain proteins, with 
separate domains dedicated to Hb binding and haem binding. Recent structural studies 
have revealed how Hb and haem are bound by the isolated domains, however, as the 
isolated domains do not liberate the haem cofactor from Hb these studies provide limited 
insight into the receptor mechanism. The aim of this project was to characterize the 
structure and function of the intact Hb receptors and reveal the molecular mechanism by 
which they capture the haem from Hb and relay it through the Isd pathway. 
 
Small angle X-ray scattering studies were used to show that a conserved three-domain 
region of IsdB and IsdH, which includes one Hb-binding and one haem-binding domain, 
adopts a conserved bi-lobed structure. Two X-ray crystal structures of IsdB and IsdH at 
4.2 Å and 3.7 Å resolution, respectively, indicate that this architecture is maintained upon 
binding to Hb. Each ! and " Hb globin chain is bound independently by one receptor 
molecule and functional studies confirmed that haem is captured from all four globin 
haem pockets, suggesting a mechanism where the receptors can access all the globin 
haem groups regardless of the Hb oligomeric state. 
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The Hb-binding domains of the full-length receptors bind to a surface of Hb that is distant 
from the globin haem coordination site. The haem-binding domain is positioned via a 
scaffolding linker domain directly adjacent to the globin haem pocket suggesting that a 
second set of specific interactions is involved in liberating the haem cofactor. As this 
interface is not well resolved in the low-resolution structures, rational mutagenesis was 
used to alter the Hb-binding properties of IsdH. A version of IsdH that bound through 
only the ! subunit of Hb yielded crystals that diffracted to 2.5 Å resolution.  The higher 
resolution structure revealed specific contacts on the haem transfer interface, and a 
conformational change in the globin haem pocket, which begin to illustrate how the haem 
cofactor is extracted from the globin.  
 
To investigate the mechanism of haem relay through the Isd pathway, haem transfer 
assays were designed. IsdH and IsdB captured haem from Hb with similar efficiency. 
However, IsdB showed superior activity in transferring haem to IsdA and IsdC. Haem 
capture from Hb required the specific recognition of Hb though the Hb-targeting domain, 
but, the speed of haem relay to IsdA/C was inversely related Hb-binding affinity 
suggesting that haem relay activity relies on a weak interaction with the Hb molecule. 
Using site directed mutagenesis, Hb binding affinity was attenuated or enhanced in a 
range of IsdB constructs. The activity of these mutants in haem relay experiments was 
consistent with the hypothesis that Hb binding affinity is fine tuned to allow for a specific 
interaction while maximizing the transfer speed of the haem cargo. 
 
Hb utilization is a common strategy employed by pathogenic bacteria to enhance growth 
and survival during infection. This work has contributed to our understanding of how the 
human pathogen, S. aureus, interacts with and utilizes host Hb, and is the first study to 
characterize the molecular mechanism by which the haem ligand is captured from Hb by 
a bacterial receptor. !
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The element iron is a vital nutrient across all domains of life. The ability to cycle between 
stable oxidation states, together with a redox potential that can be tuned across a broad 
range (+300 mV to -500 mV) by binding to protein ligands, allows iron to act as a 
catalyst for many important biochemical reactions1. Iron-containing proteins are involved 
in vital processes such as: metabolism, including electron transport; oxygen transport and 
storage; generation of and detoxification of reactive oxygen species; DNA synthesis and 
regulation of gene expression. Thus iron is crucial to many aspects of organism function. 
 
Most pathogens display the same requirements for iron as their host and, hence, 
competition for iron ensues during infection2,3. In a mammalian host, several systems act 
to limit the accessibility of host iron; however, pathogens employ a range of machinery to 
access these reservoirs. The ability of a pathogen to grow and survive in the host 
environment is linked to its fitness to access host iron4. Iron-uptake pathways that target 
specific iron-containing proteins of the host provide a significant advantage to the 
infecting organism. Such targeted iron-acquisition systems are often unique to pathogenic 
strains and are only expressed under conditions of infection, making them ideal targets 
for novel antibiotic therapies5,6. The iron-regulated surface determinant (Isd) system of 
the human pathogen Staphylococcus aureus has evolved to target iron found in human 
haemoglobin (Hb)7,8, the largest pool of iron in the body. The mechanisms behind Hb 
receptor function in the Isd pathway form the focus of this thesis. 
5:=(!"#$%&'()())*+,#*-.*+,
 
Alexander Ogston first identified the pathogenic bacterial genus, Staphylococcus, in the 
early 1880s9. Ogston observed that Staphylococcus and other bacteria were consistently 
present in abscesses that formed at surgical wounds and demonstrated that 
Staphylococcus was a causative agent of abscess formation and bacteremia10. Soon after 
Anton J. Rosenbach distinguished the major human pathogen Staphylococcus aureus 
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from the less virulent strain Staphylococcus albus (now epidermidis), and named it such 
to reflect its characteristic golden pigmentation11. S. aureus is now recognised as the 
leading cause of surgical site infections, skin and soft tissue infections and infective 
endocarditis12. 
 
S. aureus is a Gram-positive bacterial pathogen that persistently and asymptomatically 
colonises the anterior nares of 20-30% of the population13. Upon dissemination, S. aureus 
can produce infections of the skin and invasive disease in many tissues and organs.  
Before the penicillin class of antibiotics was available, up to 80% of individuals with 
invasive S. aureus infection succumbed to the disease, hence S. aureus is a highly 
effective and virulent pathogen14. Contributing to the success of S. aureus is the ability to 
rapidly acquire antibiotic resistance genes. The penicillins prevent bacterial growth by 
binding to the bacterial transpeptidase, known as penicillin-binding protein, and 
inhibiting peptidoglycan (cell wall) synthesis. Resistance to the penicillins is afforded by 
penicillinase, enzyme that hydrolyses the "-lactam ring of the penicillin. Penicillin-
resistant strains of S. aureus, expressing penicillinase, began to emerge in the early-
1940s, only two years the antibiotic was introduced, and S. aureus resistance to penicillin 
remains high today15. 
 
Methicillin, a variant of penicillin that is not cleaved by penicillinase, was developed in 
1960. In 1961, Patricia Jevons isolated the first methicillin-resistance clone of S. aureus 
from one of her patients16. The incidence of methicillin-resistant S. aureus (MRSA) 
infection now ranges from ~25 % to almost 70 % globally14 and MRSA strains that are 
resistant to all "-lactam antibiotics are a leading cause of nosocomial infections and have 
high mortality rates17,18. 
 
The gene responsible for methicillin resistance (mecA) encodes for an alternative 
transpeptidase enzyme, penicillin-binding protein 2a (PBP2a), which is not bound by 
penicillins or methicillin19,20. MecA is found on the staphylococcal chromosome in a 
mobile genetic element known as the staphylococcal cassette chromosome mec 
(SCCmec). Horizontal gene transfer is thought to allow for the rapid spread of SCCmec 
between staphylococcal strains and uses the activity of sight specific recombinases, also 
encoded for in the SCC21. 
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"-lactam antibiotics are derived from fungi, which naturally produce and secrete these 
molecules. The mecA gene is thought to have evolved to allow Staphlococci to grow 
alongside "-lactam secreting fungi, however, was lost upon human colonisation where the 
immune system eliminates such fungi22. S. fleurettii, an ancient staphylococcal species 
which is found as a commensal of a number of animals, encodes for a homologue of the 
mecA gene with ~99% sequence identity to SCCmec23. Importantly mecA in S. fleurettii is 
found in region of its chromosome that is not associated with SCC and hence S. fleurettii 
is thought to be the origin of methicillin resistance in present day MRSA23. 
 
Eleven variants of SCCmec, have been described, to date22. Hospital-associated strains of 
MRSA commonly carry SCCmec types I-III24, which in addition to the mecA gene, carry 
resistance genes for a number of additional classes of antibiotics, including quinolones, 
tetracyclines, macrolides and aminoglycosides25. SCCmec may also carry other fitness 
genes for adaptation to varied environments22. 
 
In the early 1990’s new strains of MRSA emerged amongst healthy individuals in the 
community. These strains were called community-associated (CA) MRSA as they 
infected healthy individuals with no known risk factors for MRSA infection including no 
prior exposure to health care environments. CA-MRSA is genetically distinct from 
traditional health care associated MRSA strains26. The CA strains typically harbor the 
smaller SCCmec types IV, V and occasionally VII, which carry resistance only to 
methicillin. Despite providing narrow antibiotic resistance, these smaller mobile elements 
are thought to provide other advantages including reduced metabolic demand and reduced 
doubling times when compared with the larger SCCmec type I27.  In addition the compact 
size allows for rapid spread between staphylococcal strains. Furthermore, the ability for 
CA-MRSA strains to cause invasive disease in healthy young individuals is attributed to a 
plethora of additional virulence factors, not present in the HA-MRSA strains, for example 
the toxin Panton-Valentine leukocidin (PVL)26,28,29. 
 
CA-MRSA infections are of particular importance to indigenous health in Australia. One 
of the earliest reported outbreaks of CA-MRSA occurred in a remote Aboriginal 
community in Western Australia in 199330.  Since then, several CA-MRSA strains have 
spread around Australia31 and cause invasive disease with appreciable mortality32,33. The 
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spread of CA-MRSA around Australia is reflected globally26. In addition, the distinction 
between HA- and CA-MRSA infections is beginning to break down as MRSA with CA 
genetic backgrounds become established in hospitals.  
 
Since the 1980s, vancomycin, a glycopeptide antibiotic, has been used to treat multi-drug 
resistant MRSA infections. It is not surprising that vancomycin resistance has since been 
established34,35. As the reserve of effective antibiotics dwindles and pharmaceutical 
companies shy away from new drug discovery and development, new antibacterial 
treatments are urgently needed, but their development requires a better understanding of 
the mechanisms that underlie S. aureus pathogenesis36,37. In this thesis I present a 
structure-function study of an iron-uptake protein from S. aureus that contributes to 
pathogenesis.  
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Under normal conditions, an adult human contains ~4–5 g of iron and significant 
deviations from this value lead to a variety of disease states.  Despite this large reservoir 
of iron, under normal conditions, the concentration of free iron within a mammalian 
system is extremely low: in the order of 10-24 M38. Iron is highly reactive in the presence 
of oxygen and, without proper regulation, it is toxic to the organism. To prevent toxicity, 
iron is coordinated to specific iron-binding proteins allowing for the modulation of its 
reactivity, i.e., its reduction potential and accessibility to ligands39. The majority of iron is 
also contained within cells and compartmentalised to ensure that reactions only occur in 
the appropriate context. In the subsequent sections, the most abundant iron-binding 
proteins are introduced, followed by a brief discussion of their relevance to infection.  
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When considering the forms of iron available to infecting pathogens, biological iron can 
be divided into two main pools: haem-iron and non-haem-iron. Haem is a macrocyclic 
molecule that is synthesised in the liver and bone marrow and binds approximately 80% 
of mammalian iron. Haem consists of protoporphyrin IX complexed with iron, and is a 
prosthetic group for many proteins. Protoporphyrin IX bound to Fe(III) is called haemin, 
while haem may refer to protoporphyrin IX bound to Fe(III) or Fe(II); the term haem is 
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used throughout this thesis to refer to both species and the oxidation state is specified 
where necessary. The aromatic ring of protoporphyrin IX is made up of four pyrrole 
rings, joined together by methine groups and is decorated by four methyl, two vinyl and 
two propionic acid functional groups, (Fig. 1.1). Both Fe(II) and Fe(III) species (which 
are the common species found in biology) prefer an octahedral coordination geometry. 
Iron is chelated in the centre of the porphyrin ring by the four pyrrole nitrogens and the 
available axial coordination sites may be bound by the side chains of histidine, tyrosine, 
methionine or cysteine residues, allowing for incorporation into the haem protein. Non-
haem iron is directly coordinated to protein side chains or found in motifs such as iron-
sulphur (Fe-S) clusters, which play structural or enzymatic roles in a range of 
proteins40,41.  
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Iron-binding proteins are present in intracellular and extracellular locations. Iron that is 
absorbed in the gut, or released in cell lysis, is transported in complex with extracellular 
iron-binding proteins. Dietary iron entering the duodenum is reduced by duodenal 
cytochrome b to Fe(II) iron42 and imported into the intestinal epithelium via divalent 
metal transporter 1 (DMT1/NRAMP2)43. Inside enterocytes, iron is oxidised back to the 
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ferric state by hephaestin44,45 and released into the circulation by ferroportin 1, an iron 
exporter expressed by duodenal enterocytes, hepatocytes and macrophages46,47. In the 
serum, ferric iron is immediately complexed to transferrin, a carrier protein that transports 
iron to cells in the periphery or to the liver for storage. The transferrin protein contains 
two homologous lobes, designated the N- and C-lobe, which each contain a single iron-
binding site (Fig. 1.2 A)48. Each lobe is further divided into two subdomains (N1/N2 and 
C1/C2), which both contribute iron coordinating side chains to a central binding site. 
Transferrin has an exceptionally high affinity for iron (greater than 1020 M-1)49,50, and 
under normal conditions, the circulating pool is only 25–40% saturated, pushing the 
equilibrium state towards no free iron and providing a buffer against changes in iron 
concentration. Iron-loaded transferrin binds to the transferrin receptor 1, which is present 
on all cells, and the complex is internalised via receptor-mediated endocytosis51,52. Acidic 
conditions in the early endosomes promote release of iron from transferrin through 
protonation of several basic residues at the inter-domain interface. This has the effect of 
destabilising the iron-bound (or closed) conformation48,53 (Fig. 1.2 A), hence transferrin 
shows decreasing affinity for iron with decreasing pH54. Lactoferrin is a homologue of 
transferrin that is found in lymph and mucosal secretions and is released by neutrophils 
under conditions of infection (Fig. 1.2 B)55. Lactoferrin has an even higher affinity for 
iron 1022–1024 M-1 than transferrin49,50. Both apo-lactoferrin and apo-transferrin have a 
bacteriostatic effect by limiting iron availability while lactoferrin has additional 
bactericidal activity mediated by a direct interaction with bacterial membranes and 
protease activity56,57. 
 
 
Figure 1.2. Ribbon diagrams of the human iron-binding proteins, transferrin (A) 
and lactoferrin (B). Transferrin (PDB 3QYT) is shown with the N-lobe (blue and cyan) 
in the open conformation and the C-lobe (yellow and orange) in the closed conformation. 
Both the N- (green and lime) and C- (pink and purple) lobes of lactoferrin are in the 
closed conformation (PDB 1LFG). Iron is shown as brown spheres and the iron-
coordinating residues are shown as red sticks. Figure adapted from Mizutani et. al.48. 
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Transferrin only accounts for ~0.1 % of total body iron and lactoferrin accounts for a 
much smaller percentage56,58, however, both proteins are used as a source of iron by 
pathogenic bacteria. These proteins are iron sources for bacteria that thrive 
extracellularly, as well as intracellular bacteria, such as Mycobacterium tuberculosis, 
which can access transferrin in endosomal compartments59,60. 
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The largest demand on iron availability is the process of erythropoiesis, during which 
erythrocytes, the cells responsible for oxygen transport, are made. Erythroblasts take up 
circulating transferrin and use the released iron in the production of haemoglobin (Hb). 
Hb is a haem protein and, under normal circumstances, accounts for ~ 65–75 % of the 
total iron pool61. It is a tetrameric protein, consisting of two ! Hb and two " Hb chains, 
which each coordinate a haem cofactor (Fig. 1.3 A). One oxygen molecule can be bound 
reversibly to each the four prosthetic haem groups allowing oxygen delivery from the 
lungs to the tissues. Each globin chain has a conserved !-helical fold with the " chains 
comprised of eight helical regions (A–H; Fig. 1.3 B),  and the ! chains containing seven 
helical regions (A–C and E–H by homology with sperm whale myoglobin; Fig. 1.3 C). 
The haem group is bound in a pocket between the E and F helices and is coordinated by a 
single histidine residue that lies on the F-helix (His87 in ! Hb and His92 in " Hb; Fig. 1.3 
B,C). Oxygen binds to the remaining axial coordination position on the distal side of the 
haem plane and is stabilised by a hydrogen bond with the imidazole ring of the distal 
histidine (His58 in ! Hb and 63 in " Hb; Fig. 1.3 B,C). The monomeric oxygen storage 
protein, myoglobin (Mb), is found in muscle cells, and has a similar fold with eight 
!-helices (A–H), coordinating the haem group via His94. Hb utilisation has been 
demonstrated in bacterial62, protozoan63 and fungal pathogens64,65, illustrating the 
importance of Hb as a nutrient source during infection in a mammalian host environment. 
 
Figure 1.3. The structure of human Hb. (A–C) ! chains are shown in pink and " 
chains are shown in red. Each chain binds to a single haem group (yellow) and the central 
iron (brown sphere) is coordinated by the imidazole group of the proximal histidine. 
Oxygen (red spheres) is coordinated to the remaining axial position and is held in place 
be a hydrogen bond to the distal histidine. The helical globin fold of a single " or ! chain 
are shown in (B) and (C) respectively. 
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Inside cells, the iron storage protein, ferritin, accounts for ~30% of total body iron under 
normal iron loading conditions58,61. Ferritin is made up of 24 heavy and light chains that 
form a cage-like shell66. Iron enters the cavity inside the shell and is oxidised at a 
catalytic site present in the heavy chains and then undergoes mineralisation to be stored 
as ferrihydrite67,68. In this way, up to 4500 iron atoms can be stored by a single ferritin 
molecule. Pathogens such as Bacillus cereus make use of this iron store69,70. 
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As well as minimising iron toxicity, mechanisms for limiting the concentration of free 
iron in the body are also up-regulated during infection.  Pro-inflammatory cytokines 
induce iron-restricting proteins, and can target the response to the intracellular or 
extracellular location of the pathogen59,71. Mechanisms to limit iron availability during 
infection are found in plants72, insects73, birds74 and reptiles75 and, hence, are recognised 
as a conserved innate immune defence strategy. 
 
The innate immune system recognises pathogen-associated molecular patterns through 
pattern recognition receptors (PRRs) that are expressed by a range of cell types. Signaling 
via PRRs leads to secretion of the pro-inflammatory cytokines IL-1 and IL-6, which in 
turn lead to the production and secretion of hepcidin by the liver59. Hepcidin is a peptide 
hormone that acts to decrease iron uptake from the gut, as well as secretion of iron from 
macrophages and hepatocytes into the plasma. Hepcidin interacts directly with ferroportin 
1 leading to the internalisation and degradation of ferroportin 176. With reduced levels of 
ferroportin 1 to release iron into circulation, iron accumulates inside cells and, as a result, 
transferrin saturation drops below 20% limiting its utility to pathogens3. While effective 
at limiting iron from extracellular pathogens, this response is inappropriate for pathogens 
that reside in intracellular compartments, such as Mycobacterium tuberculosis, 
Chlamydia psittaci and Legionella pneumophila59,60. These pathogens persist inside 
macrophages and induction of hepcidin leading to macrophage iron loading has been 
shown to enhance the growth of Chlamydia psittaci and Legionella pneumophila77. In 
contrast, activation of macrophages though IFN-# signaling leads to up-regulation of 
ferroportin 1 and down-regulation of the transferrin receptor71.  This activity of IFN-# was 
shown to decrease macrophage iron levels resulting in decreased bacterial iron uptake and 
reduced survival of Salmonella enterica Typhimurium inside the activated phagocytes. 
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Cytokine signaling during infection also leads to production of acute phase proteins 
(proteins expressed in the acute phase of infection) involved in sequestering iron from 
infective agents. The role of these proteins is to minimise harmful effects of free iron, 
haem or iron/haem binding proteins that are released from their appropriate compartments 
during tissue damage. These proteins also act to withhold iron from pathogens and 
subvert attempts to access iron through induced tissue degradation. One such acute phase 
protein is haptoglobin (Hp), a serum glycoprotein that complexes with haemoglobin that 
is released from lysed erythrocytes. The Hp:Hb complex is rapidly cleared by 
macrophages of the spleen expressing the CD163 receptor78. Haemopexin is another 
acute phase glycoprotein and binds to free haem with extremely high affinity (Kd of 0.1 
pM)79. The haem-haemopexin complex is internalised after binding to its receptor, which 
is expressed on most cell types but primarily in the liver80. The haemopexin structure 
consists of two domains, each with a "-propeller fold (Fig. 1.4). Extensive loop regions 
form a contact surface between the two domains. The haem-binding site is situated at the 
domain interface and contains two histidines that coordinate the haem iron (Fig. 1.4)79. 
Like other haem-binding proteins in the host, haemopexin can be exploited as a source of 
iron by pathogens such as Haemophilus influenza81.   
 
To overcome these strategies used by the host to withhold iron, many pathogens have 
acquired aggressive iron uptake pathways that strip iron directly from the host proteins. S. 
aureus can utilise transferrin iron82, Hb, Hb:Hp complexes and Mb, but not 
haemopexin83,84. Multiple iron uptake pathways are commonly found in the genomes of 
both Gram-positive5,85,86 and Gram-negative87 bacterial pathogens, highlighting the 
importance of iron to bacterial survival and infection. 
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Figure 1.4. The structure of rabbit haemopexin. Haem (yellow sticks) is bound 
between the N (yellow) and C (blue) domains. The two haem-coordinating histidine 
residues (red) are contributed by extensive loops. The loop joining the two domains is 
coloured green.  
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Evidence that the availability of iron can be a determinant of disease severity is seen 
under conditions of iron overload. In animal models of infection, administration of iron or 
iron-containing compounds to artificially elevate iron levels has been shown to enhance 
infection by Escherichia coli88, Pasteurella pestis89, Listeria monocytogenes90 and Vibrio 
vulnificus91 as well as numerous other bacterial, fungal and protozoan pathogens92. 
 
Individuals with iron overload diseases have increased risk of infection. Hereditary 
haemochromatosis is associated with an increase in iron absorption from the gut and a 
concomitant increase in transferrin saturation as well as iron loading in the liver, heart 
and pancreas.  Individuals with haemochromatosis have higher susceptibility to bacterial, 
viral and fungal pathogens and are at risk of infection from bacterial strains that are 
avirulent in healthy individuals4,93. For example, an attenuated strain of Yersinia pestis 
lacking genes involved in uptake of iron from host iron proteins, was able to cause 
opportunistic and lethal infection in an individual with haemochromatosis as well as in a 
mouse model of haemochromatosis94. In contrast, macrophages from individuals with 
hereditary haemochromatosis may be deficient in iron and M. tuberculosis, which has an 
intracellular lifestyle, shows attenuated growth in macrophages from individuals with 
haemochromatosis95. Additionally, numerous studies have observed a correlation between 
increased risk of infection and iron supplementation in human infant and adult 
populations3.  
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Low iron conditions, such as those experienced during infection, signal through bacterial 
iron-sensing proteins such as the ferric uptake regulator (Fur) and the iron-dependent 
diphtheria toxin repressor (DtxR). Fur and DtxR respond to changes in environmental 
iron concentrations by regulating the expression of a large number of bacterial proteins 
(~390 in S. aureus)96-99.  The Fur protein is found in both Gram-positive and Gram-
negative bacteria where it regulates genes involved in iron uptake, stress response 
pathways and other virulence factors involved in host colonisation. Under iron-replete 
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conditions, Fur complexes with iron and binds to its consensus sequence, resulting in 
transcriptional repression100. Iron-limiting conditions lift Fur/DtxR mediated repression of 
gene expression. Many of the well-known toxins responsible for the “morbidity and 
mortality” of infection are regulated this way. For example, the diphtheria toxin, 
expressed by Corynebacterium diphtheriae during infection, is regulated by DtxR101 
while the Shiga-like toxin, expressed by Escherichia coli, is regulated by Fur102. Genomic 
and proteomic studies have shown that, in S. aureus, Fur regulates the expression of 
toxins involved in tissue degradation (cytotoxins and hemolysins) and genes involved in 
metabolism, immunomodulation, biofilm formation, and iron uptake98,103. 
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Pathogenic bacteria employ multiple mechanisms to access host iron. Some of these 
mechanisms, such as the production of siderophores (iron chelators discussed in Section 
1.5.1) are shared with free-living bacteria. Other mechanisms have evolved to specifically 
target haem and haem/iron-proteins of a host.  
 
Highly successful pathogens express surface-exposed or secreted receptors that bind to 
the host protein and remove the iron/haem for transport into the cell. Several obligate 
pathogens, such as, Gram-negative Neisseria spp., Moraxella catarrhalis and 
Haemophilus influenza, rely entirely on targeted interactions with host proteins and do 
not produce siderophores104-106. These pathogens exclusively colonise humans and 
produce receptors highly evolved to use human Hb, transferrin, lactoferrin or 
haemopexin105,107. 
 
Gram-negative bacteria are encased by a lipopolysaccharide-rich outer membrane, 
whereas Gram-positive bacteria lack a second outer membrane and are instead 
surrounded by a much thicker peptidoglycan cell wall of ~15–50 nm (~40 nm in 
staphylococci108). Hence, the cell-surface proteins that interact with the host are different 
for Gram-negative (Sections 1.5.2, 1.5.3) and Gram-positive (Section 1.5.4) bacteria. A 
haem uptake system of S. aureus that specifically targets human Hb is the subject of this 
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thesis and is described in detail in Section 1.5.4. and in the introduction sections of the 
results chapters. 
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Fe(II) is relatively soluble at neutral pH (10-2 M), while Fe(III) is sparingly soluble (10-18 
M). In an oxygenated environment, Fe(II) is oxidised to Fe(III) and deposited in insoluble 
compounds such as iron oxides and iron hydroxides. However, the concentration of 
soluble iron may be higher in niche environments: anaerobic conditions limit oxidation of 
Fe(II) to less soluble Fe(III), while acidic conditions (pH < 5) increase the solubility of 
both Fe(II) and Fe(III). Low oxygen conditions are found in the mammalian stomach and 
gastrointestinal tract, and the stomach is also highly acidic. Fe(II) is thought to diffuse 
through the Gram-positive cell wall and through porins in the Gram-negative outer 
membrane (Fig. 1.5 A,B). Import of Fe(II) across the plasma membrane proceeds by the 
ferrous iron transporter, FeoB109, which is an integral membrane protein with 8–12 
membrane-spanning helices and a cytoplasmic G-protein domain110,111. GTPase activity 
of the cytoplasmic domain provides the energy required for import of Fe(II) across the 
inner membrane. Under anaerobic conditions Fe(III) can be reduced to Fe(II) through the 
action of bacterial assimilatory ferric reductases112. Fe(III) reduction can occur 
extracellularly or in the periplasm allowing for uptake via the Feo system. Secreted, 
membrane-bound, periplasmic and cytoplasmic reductases have been identified112. 
 
The Feo import system is the primary iron uptake system of Helicobacter pylori113 
reflecting adaptation of the bacteria to growth in the acidic conditions of the stomach, 
where Fe(II) is bioavailable. The Feo system is required for H. pylori virulence as genetic 
deletion of the Feo operon reduced colonisation in mouse models of infection113. 
Similarly, FeoB contributes to intestinal colonisation by Escherichia coli and Salmonella 
enterica Typhimurium reflecting the availability of Fe(II) under the anaerobic conditions 
experienced in the gastrointestinal tract114,115.  
 
A strategy employed by terrestrial, marine, and pathogenic bacteria to import iron is the 
secretion of iron-binding molecules, known as siderophores116. Siderophores are chelating 
agents (< 2000 Da) that bind to Fe(III) with extremely high affinity (up to 1030 M)56,117; 
siderophores capture free iron in the environment, or iron that is released from host 
proteins, to form almost irreversible Fe(III)-siderophore complexes. Fe(III)-siderophore 
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complexes freely diffuse across the Gram-positive cell wall or are recaptured by Gram-
negative outer membrane receptors (Fig. 1.5 A,B). The Gram-negative siderophore 
receptors use the TonB-ExbB-ExbD system to actively transport captured siderophores 
across the outer membrane (Fig. 1.5 A). TonB is a periplasmic protein that is anchored 
via an N-terminal domain to the cytoplasmic membrane. TonB interacts with numerous 
classes of outer membrane receptors and with the integral membrane proteins ExbB and 
ExbD located in the cytoplasmic membrane (Fig. 1.5 A)118. ExbB and ExbD use the 
proton gradient across the inner membrane to drive transport of a substrate (in this case a 
siderophore) into the periplasm where it is bound by a specific substrate binding protein, 
and ferried to a transporter in the plasma membrane (Fig. 1.5 A; Section 1.5.3). 
Siderophore import across the cytoplasmic membrane is conserved in both Gram-positive 
and Gram-negative bacteria and utilises an ABC transporter permease complex (transport 
across the cytoplasmic membrane is described in Section 1.5.3; Fig. 1.5 A,B). In the 
cytoplasm iron is release by enzymatic degradation of the siderophore or reduction of the 
iron. While hundreds of different siderophores have been described, these commonly bind 
iron though catechol, hydroxamate or !-hydroxy carboxylate functional groups119.  
 
In a pathogenic setting, siderophores provide a non-specific iron acquisition system 
allowing infection in a wide range of hosts and have been shown to strip iron from a 
range of mammalian proteins including transferrin, lactoferrin and ferritin119. Exploitation 
of siderophores produced by other microorganisms can provide an advantage for growth 
in bacterial communities and expression of uptake pathways for xeno-siderophores is 
common120,121.  
 
S. aureus synthesises the !-hydroxy carboxylate siderophores, Staphyloferrin A and 
Staphyloferrin B122; however, is also able to use hydroxamate siderophores that are 
secreted by other bacterial species123. In addition, S. aureus favours fermentative 
metabolism under conditions of low iron availability, producing lactate as a by-
product103,124. Lactate is secreted from the cell, reducing the local pH and increasing iron 
solubility and taking advantage of the accelerated rates of iron loss from transferrin with 
decreasing pH54,103.  
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Figure 1.5. Non-specific iron uptake pathways of Gram-negative (A) and 
Gram-positive (B) bacteria. Fe(III) may be reduced to Fe(II) by ferric reductase 
enzymes (yellow) allowing for diffusion through porins in the Gram-negative outer 
membrane (A) or through the Gram-positive cell wall (B). Fe(II) is actively imported 
across the cytoplasmic membrane via the conserved transmembrane protein, FeoB (blue). 
Alternatively, free Fe(III) or Fe(III) derived from host proteins may be bound by 
chelating siderophores that are secreted by the bacteria or other microorganisms. In 
Gram-negative bacteria siderophores are actively imported across the outer membrane 
(OM) via siderophore-receptor-TonB-ExbBD complexes (A). In Gram-positive bacteria 
siderophores freely diffuse through the cell wall (B). Once in the periplasm, siderophores 
are bound by periplasmic binding proteins (A) or lipoproteins (B) that deliver the 
siderophore to a conserved ABC-transporter complex in the cytoplasmic membrane. 
Transport across the cytoplasmic membrane requires the use of energy in the form of 
ATP hydrolysis. Inside the cell, the siderophores are either degraded or reduced to release 
iron. 
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Haemophores are secreted or surface proteins that capture haem-iron via competition with 
host proteins and are retrieved from the extracellular environment by haemophore 
receptors. Unlike siderophores, haemophores may make defined interactions with specific 
host proteins and are not imported into the bacterial cell but instead offload their cargo to 
the surface-exposed haemophore receptors119. Gram-negative bacterial species produce 
haemopores with no homology existing between the different protein families. 
 
HasA, one of the best-characterised haemophores of Gram-negative bacteria, is secreted 
by Serratia marcescens125, Pseudomonas aeruginosa87, and Yersinia pestis126. HasA 
acquires haem that is passively released from Hb127, haemopexin and myoglobin128 by 
virtue of its very high affinity for haem Kd << 10-8 M 129. The HasA fold is formed from 
two structural motifs, one composed of seven "-strands and the other of four !-helices130. 
Haem is bound at the interface between the two motifs and residues of two extended 
loops provide the haem ligands. The iron is coordinated by one histidine and one tyrosine 
sidechain. A second histidine is involved in a stabilising interaction with the tyrosine 
phenolyate. Haem-loaded HasA delivers its ligand to a surface-exposed receptor, HasR 
(which belongs to the family of outer membrane receptors described below). The 
haemophore and its receptor form a stable interaction (Kd of 5 nM). While HasR has a 
lower affinity for haem than free HasA, receptor binding sterically destabilises the HasA-
haem interaction, allowing for haem transfer131. The haem is then imported into the 
periplasm by the outer membrane receptor and HasA is recycled in an energy-dependent 
manner132. 
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Gram-negative bacteria have a family of outer membrane receptors that capture host 
haem-containing proteins, remove the haem and import it into the periplasm (Fig. 1.6)133-
135. These outer membrane receptors show homology to outer membrane siderophore 
receptors136 and outer membrane haemophore receptors132. 
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The receptors may be highly specific for one host protein, such as the Hb receptor, 
HmbR, from Neisseria meningitidis135,137. Other outer membrane receptors can utilise a 
range of host proteins, such as HemR from Yersinia enterocolitica, which can use Hb, 
Mb, human or bovine serum albumin, haemopexin and Hb:Hp complexes137. Each 
member of the outer membrane receptor family shows a high degree of structural 
homology consisting of a 22-stranded " barrel that spans the membrane, a periplasmic 
plug domain and a Ton-B box (a sequence of seven hydrophobic residues that is 
recognised by TonB; Fig. 1.6 A,B)118,135,137. The substrate-binding site may consist of 
surface-exposed loops, the interior of the barrel and/or extracellular surface of the plug 
domain133-136,138,139. Energy required for passage of the bound substrate through the 
membrane is provided by an interaction with the TonB-ExbB-ExbD system.  
 
Recent advances have been made in understanding how the outer membrane receptors 
recognise and interact with host proteins. Haemoglobin receptors have been identified in 
a number of Gram-negative pathogenic and commensal bacteria133,135,137-139. The function 
of haem release from Hb has been attributed to extracellular loop 7 of HemR137, HgbA 
from Haemophilus ducreyi134,139, ShuA in Shigella dysenteriae and both loop 7 and 
neighbouring loop 6 of HmbR from Neisseria meningitidis135. Loop 7 contains two motifs 
(FRAP/YRVP, NXXL) and an intervening histidine residue, which are highly conserved 
amongst outer-membrane Hb receptors. A combination of these elements (and 
occasionally the plug domain) have been shown to be important for utilisation of haem 
from Hb. Interestingly, this region is not involved in Hb binding, and the two functions of 
Hb capture and haem removal, are carried out at distinct interfaces. Mutagenesis studies 
have indicated that Hb binding is mediated by loops 2 and 3 in HmbR135 and loop 5 in 
HgbA134, however, it is currently unknown which surface of Hb is targeted or by which 
molecular mechanism the haem group is released.  
 
HxuC of Haemophilus influenzae is an outer membrane receptor that can import free 
haem or haem from Hb81.  In the presence of the receptor HxuA, HxuC can also import 
haem from haemopexin. HxuA is an extracellular protein that is linked to the outer 
membrane. HxuA binds with high affinity to both apo- and holo-haemopexin but does not 
bind directly to haem81. Instead, binding of HxuA to holo-haemopexin induces 
haemopexin to release haem into the solution. As yet it is unknown how HxuA causes 
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haem release from haemopexin but possible mechanisms include steric interactions with 
the haem or a conformational change in the haemopexin haem pocket. The liberated haem 
group may be used by any available haem importer. As HxuA does not bind haem and 
binds with high affinity to apo-haemopexin it has been suggested that the primary role of 
this protein may be to deactivate haemopexin to prevent clearance of haem by the host. 
Alternatively, HxuA may directly associate with a haem transporter such as HxuC to 
ensure that the released haem is channeled for uptake. 
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Neisseria. spp. do not express siderophores but capture iron through direct binding to 
transferrin140. The transferrin outer membrane receptor, TbpA and co-receptor TbpB are 
highly specific for human transferrin107,141. Structural studies have recently revealed the 
molecular mechanism by which TbpA releases iron from transferrin. TbpA interacts with 
the C-lobe of human transferrin, over a very large interface (Fig. 1.6 B)142. A small 
helical segment on surface-exposed loop 3 reaches into the iron-binding cleft formed 
between the C1 and C2 lobes of transferrin and weakens the interaction between the iron 
and the coordinating side-chains (Fig. 1.6 B). The co-receptor, TbpB, binds to a distinct 
surface of the transferrin C-lobe and enhances the efficiency of transferrin utilisation. 
TbpB is linked to the outer membrane via a long unstructured polypeptide chain and is 
proposed to provide an advantage in transferrin capture. In addition, TbpA and TbpB can 
simultaneously bind to transferrin encasing the iron coordination site in a chamber, 
assumed to direct the iron towards the TbpA transport channel. 
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Protein networks transport haem across the cell wall in Gram-positive Firmicutes 
bacteria143,144. These networks start with secreted or surface-exposed haem-binding 
proteins that capture haem from host proteins (Fig. 1.6 C). The captured haem molecule is 
then relayed through the cell wall via one or more intermediate haem carrier proteins to 
an inner membrane transporter complex for passage into the cell. The best-characterised 
Gram-positive haem import system is the iron regulated surface determinant (Isd) system 
of S. aureus, which specifically targets Hb, and is discussed below. 
 
 23 
/010=0/,>%.,8-(6,-.7*'#".?,+*-<#).,?.".-486#6",+&+".4,(<,!0,#*-.*+,
To access Hb found in erythrocytes, S. aureus produces haemolytic toxins, including !-
toxin/!-haemolysin, "-haemolysin and #-haemolysin, which cause erythrocyte lysis and 
release Hb into the serum. Two surface-exposed receptors, IsdB and IsdH, capture the 
released Hb from the serum and remove the haem ligand (Fig. 1.6 D)7,84,145-147. The haem 
is then transferred to the cell-wall haem-binding proteins IsdA and IsdC, which relay the 
ligand to the haem-binding lipoprotein, IsdE, and membrane permease IsdF148,149; 
transport across the inner membrane is described in section 1.5.3.  
 
IsdA, B, C and H are anchored to the cell wall by sortase enzymes, which catalyse the 
formation of a covalent linkage between the C-terminal amide group of the protein and 
the peptide crossbridge of the cell wall. IsdA, B and H are substrates of the constitutively 
expressed sortase A, which is ubiquitous amongst Firmicutes bacteria150. In contrast, IsdC 
is the only substrate of sortase B151, which recognises a distinct sorting motif present in 
the C-terminal domain of IsdC7,151,152. Sortase A and sortase B attach their substrates to 
different cell wall building blocks153, locating IsdA/B/H on the extracellular surface of the 
cell wall and IsdC closer to the periplasmic space7. As IsdC has a higher affinity for haem 
than IsdA/B/H, this distribution of Isd proteins polarises the cell wall to favour movement 
of haem towards the cytoplasmic membrane (Fig. 1.6 D). 
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Figure 1.6. Targeted iron uptake pathways of Gram-negative (A, B) and Gram-
positive (C, D) bacteria. (A) In Gram-negative bacteria, outer membrane receptors bind 
to host iron/haem containing proteins or secreted haemophores. These receptors show 
homology to the outer membrane siderophore receptors. The outer membrane receptors 
remove the haem/iron from the host protein or haemophore and together with the TonB-
ExbBD complex import the haem/iron through an energy dependent mechanism. In the 
periplasm the haem/iron is bound by a periplasmic substrate binding protein and 
delivered to a cytoplasmic membrane ABC transporter complex for passage into the cell.  
(B) The structure of the outer membrane transferrin receptor, TbpA, of Neisseria 
meningitides, bound to human transferrin (PDB 3V8X). The "-barrel domain is coloured 
green while the plug domain is shown in purple. A short helical segment (red) in one of 
the extracellular loops interacts with the iron-binding site (red spheres) of the transferrin 
C-lobe (orange and yellow). The transferrin N-lobe (blue and cyan) does not contact the 
bacterial receptor. Once inside the periplasm, Fe(III) is bound to FbpA (grey; PDB 1O7T) 
for transport to a cytoplasmic membrane ABC-transporter complex. (C) Schematic 
diagram showing the elements that make up the haem import pathways of Gram-positive 
Firmicutes bacteria. Surface-exposed or secreted receptors interact with Hb (red and 
pink) and remove the haem cofactor. Haem is then relayed through a series of haem 
carrier proteins attached to the cell wall before being offloaded to a haem binding 
lipoprotein. Finally haem is imported though the cytoplasmic membrane by an ABC-
transporter complex in a step that is conserved across bacteria. (D) The Isd haem import 
pathway of S. aureus. Hb (red and pink) is bound on the bacterial surface by the cell wall 
anchored receptors IsdH and IsdB (blue), which capture the haem cofactor via an 
unknown mechanism. Haem is then passed to the haem relay proteins IsdA and IsdC in 
the cell wall, before being transferred to IsdE, the substrate-binding component of an 
ABC-transporter permease. The known structures of the haem binding-proteins IsdA and 
IsdC (cyan and green respectively; PDB 2ITF, 2O6P) and the haem binding lipoprotein 
IsdE (grey; PDB 2Q8Q) are shown as ribbon diagrams.   
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Haem relay through the Isd pathway is mediated by NEAr Transporter (NEAT) domains. 
The NEAT domain was originally identified in genes located in or near an operon 
encoding for a putative iron ABC transporter143. Subsequently, it was shown that NEAT 
domain containing proteins bind to haem or Hb and are involved in uptake of haem from 
Hb7. NEAT domains are ~130 residues in length and have an immunoglobulin like fold 
comprising an 8-stranded "-sandwich and one or more short helical segments (Fig. 1.7 
A)154-160. The majority of characterised NEAT domains bind to either haem or Hb; 
however, they may also make additional interactions with other host factors83,161-163. 
 
IsdA, B, C and H all contain one NEAT domain that mediates binding to haem 
(Fig. 1.7 B, black box)147,155,156,159,160,162,164. Two highly conserved tyrosine residues on 
the "7–"8 hairpin are involved in haem binding (Fig. 1.7 A). Structural and spectroscopic 
studies indicate that one tyrosine phenolate directly coordinates the iron and the second 
acts to position the first155,156,159,160,164. In most cases, the sixth axial coordination site 
remains empty. The haem group is bound in a hydrophobic pocket, formed between the 
"7–"8 hairpin, and a short helical segment, with the two propionate groups pointing out 
of the pocket into the solvent. The haem group is partially exposed on the surface of the 
protein (~35–45% solvent exposed in IsdA/B/C and H), which is consistent with a role in 
haem transport, and differs from proteins such as Hb that bind haem as a functional 
cofactor and largely bury the haem group. 
 
Proteins belonging to the NEAT domain family are widely distributed in (and exclusive 
to) Gram-positive bacteria of the phylum of Firmicutes suggesting that these bacteria 
have evolved for growth in environments abundant in haem. Numerous significant human 
pathogens, including S. aureus, S. pyogenes, Listeria monocytogenes, B. anthracis, B. 
cereus, Clostridium perfringens, and Clostridium tetani, contain NEAT domains in their 
genome143,144.  
 
/010=02,C.)%#68+4,(<,%#.4,"-#6+<.-,:."D..6,@AB>,?(4#86+,
A direct transfer of haem between Isd proteins was determined by UV visible 
spectrophotometry and mass spectrometry148,149,165. Only IsdH or IsdB can capture haem 
from Hb. IsdH and IsdB can transfer haem to IsdA or to IsdC. IsdA can transfer haem to 
 27 
IsdC. Several independent measurements of the affinity of the Isd proteins for haem have 
been made, giving values from µM to sub-nM, depending upon the technique 
used149,155,165-167. However, in each case the relative ranking of affinities was the same, 
with the affinity of IsdB for haem being ~10 fold greater than Hb, IsdA being ~2.5 fold 
greater than IsdB and IsdC being ~2–10 fold greater than IsdA. Hence the haem transfer 
process may be thermodynamically driven by an increase in the relative affinity for haem. 
Only IsdC can transfer haem to the lipoprotein IsdE149,168. Taken together these data 
suggest that the pathway for haem uptake proceeds from Hb to IsdB/H, directly to IsdC or 
via IsdA, and finally to IsdE (Fig. 1.6 D).  
 
Kinetic studies of haem transfer in the Isd pathway have shown that the rate of haem 
transfer between NEAT domains is much faster than the spontaneous dissociation of 
haem from the donor protein149,155,165. IsdB captures haem from Hb, at ~2000$ and 80$ 
the rate of passive haem dissociation from the ! and " chains of the Fe(III)-Hb dimer, 
respectively149,169. Transfer of haem from IsdB to IsdC occurs 8000-fold faster than 
passive haem loss from IsdB, and to IsdA ~2–8 fold greater again149,155. Finally, transfer 
of haem from IsdA to IsdC is > 70 000 times faster than passive haem loss from IsdA165. 
Hence Hb:Isd and Isd:Isd complexes must form in order to rapidly and directly transfer 
haem.  
 
The Isd:Isd interactions that achieve rapid haem transfer are extremely weak (Kd > 5 mM 
in the case of IsdA and IsdC) making them difficult to characterise170,171. Low-affinity or 
transient interactions are common in ligand relay pathways, allowing for rapid and 
repeated turnover of the cargo172,173. Paramagnetic resonance excitation NMR and 
crosslinking studies, which can detect or capture very weak interactions, have shown that 
IsdA and IsdC form homo- and hetero-associations in a ‘handclasp’ conformation, which 
juxtaposes the haem pockets of the two proteins170,171. The haem pocket "7–"8 hairpin of 
IsdC is also the binding site used in transient interactions with IsdE170. Interestingly, 
similar NEAT:NEAT interactions are observed in the crystal packing in X-ray 
crystallography structures of haem bound IsdA, IsdB, IsdC and IsdHN3 (Fig. 1.7 C; PDB 
2ITF, 3RTL, 3QUG, 3QUH). This suggests that a similar mode of haem pocket 
interactions may be common to all haem-binding NEAT domains.  
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Figure 1.7. The cell wall anchored Isd proteins bind haem and Hb via NEAT 
domains. (A) The haem binding NEAT domain of IsdC (PDB 2O6P) showing the 
"-sandwich domain fold common to all NEAT domains. The haem cofactor (yellow 
sticks) is bound between a short helical segment in loop 2 (blue) and the "7–"8 hairpin. 
The haem coordinating tyrosine (Tyr132) and supporting tyrosine (Tyr136) are shown as 
cyan spheres. (B) The domain architecture of the four cell wall anchored Isd proteins. 
Haem-binding domains are represented by black rectangles while Hb binding domains are 
represented by white rectangles. Helical linker domains are coloured grey. Small while 
squares indicate cell wall anchoring motifs. (C) Haem pocket interactions between 
adjacent NEAT domains in the crystal packing of IsdC (red; PDB 2O6P), IsdH (pink; 
PDB 3QUG), IsdB (yellow; PDB 3RTL) and IsdA (orange; PDB 2ITF). The haem pocket 
tryosines are shown in stick representation and coloured cyan. Helical regions are 
coloured blue. 
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Unlike IsdA and IsdC, which are comprised of a single NEAT domain, IsdB and IsdH, 
both contain one (IsdBN1) or two (IsdHN1 and IsdHN2) additional N-terminal NEAT 
domains respectively (Fig., 1.7 B and 1.8 B, white boxes). While IsdBN1, IsdHN1 and 
IsdHN2 adopt the conserved "-sandwich fold, common to all NEAT domains, the haem-
binding tyrosine motif is absent and these NEAT domains do not bind to haem147,174. 
Instead the isolated IsdHN1 and IsdHN2 have been shown to bind to Hb146,147,158. The 
affinity of IsdHN1 for Hb has been measured to be 17–30 nM145,147. The full-length IsdB 
protein or an N-terminal fragment of IsdB (containing IsdBN1) also binds to Hb7,83,145,174. 
The full-length IsdB protein has a similar affinity for Hb (Kd ~55 nM) as IsdHN1 145 
IsdHN1 and IsdHN2 each bind to the ! chain of Hb, while a second, weaker, binding site 
for IsdHN2 exists on " chain of Hb146. IsdBN1 has greater primary sequence homology 
with IsdHN2 (65 % identity) than IsdHN1 (46 % identity) predicting that it will show 
similar interactions with ! and " Hb chains to IsdHN2. Mutagenesis studies of IsdHN1 and 
structural studies with isolated IsdHN1 and IsdHN2 have identified the Hb binding surface, 
which includes a short ! helix in loop 2 as well as loops 4, 6 and 8 (Fig. 1.8 A, 
orange)146,147,175. This is the same surface that is used by the haem-binding NEAT 
domains to contact haem. Interactions of the Hb-binding NEAT domains are discussed in 
more detail in Section 3.1 where it is directly relevant to the aims of the chapter. 
 
IsdB and IsdH capture haem from Hb at faster rates than can be explained by the passive 
loss of haem from Hb alone149,167. In addition, IsdB has been shown to catalyse the 
transfer of haem from Hb to the haem carrier protein IsdC149 and hence perform all of the 
functions expected for a Hb receptor involved in haem uptake in vitro. Enzymatic relay of 
haem from Hb to IsdA/C by IsdH has not yet been demonstrated. However, the isolated 
haem-binding NEAT domain of IsdH was shown to transfer haem to IsdC148 and to IsdA 
176, predicting that IsdH will also function in haem relay. As yet, the mechanism by which 
IsdB and IsdH extract haem from Hb and function in haem relay is unknown. 
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Proteins containing NEAT domains have been identified as Hb receptors in Firmicutes 
bacteria, other than S. aureus. These proteins have a range of domain architectures that 
are dissimilar from IsdB and IsdH (Fig. 1.8 B).  
 
Shr from Streptococcus pyogenes is anchored in the cytoplasmic membrane via a 
C-terminal tail that spans the distance of the cell wall and is exposed on the cell 
surface177. A large protein at 145 kDa, Shr contains an N-terminal region with two 
domains of unknown function (DUF1533), two NEAT domains, a series of leucine rich 
repeats and an EF hand163; the domain architecture is shown in Figure 1.8 B. The two 
NEAT domains bind to haem163,178, and the full-length protein was shown to bind to Hb 
with a Kd of ~50 nM, measured by ELISA, which is comparable to IsdH and 
IsdB145,147,163,179. A region in the N-terminus of the protein, adjacent to the N-terminal 
NEAT domain, was implicated in Hb binding163; however, the sequence and structure of 
the Hb-binding site is currently unknown. Shr captures haem from Hb at rates that are 7 
and 60 fold faster than passive haem release from the " and ! chains of Fe(III)-Hb 
respectively179 supporting a physical interaction between the receptor and Hb that 
facilitates haem transfer. Shr can also catalyse the transfer of haem from Hb to Shp178,179. 
Shp is a functional homologue of IsdC, which despite limited sequence identity to the S. 
aureus protein also has a NEAT domain fold180. Like IsdC, Shp can relay haem to HtsA, 
the haem binding lipoprotein component of an ABC membrane permease181. Hence, Shr 
can promote haem release from Hb and catalyse its transfer to Shp, and appears to 
perform an analogous function in haem uptake in S. pyogenes to that of IsdB and IsdH in 
S. aureus. 
 
IlsA from Bacillus cereus comprises a single NEAT domain, a series of leucine rich 
repeats and three SLH domains that are predicted to embed the receptor in the 
proteinaceous S-layer, which is associated with the cell wall (Fig. 1.8 B)69. IlsA was 
shown to bind to Hb by ELISA, with an estimated affinity of 3 nM, and also to haem. 
Haem binding is likely to occur through the single NEAT domain of IlsA as the primary 
sequence contains the haem-coordinating tyrosines and other recognised haem pocket 
residues. Both IlsA and Shr contain leucine rich repeats (LRR). LLR are known to 
mediate protein-protein interactions in many other proteins182 and are candidates for Hb 
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binding domains. Interestingly, IlsA was also shown to interact with ferritin in vitro and 
assist in iron uptake from ferritin69,70. B. cereus can infect both insect and mammalian 
hosts and the IlsA protein has been suggested to mediate haem/iron uptake in both host 
environments through Hb and ferritin interactions.  While direct haem uptake from Hb 
has not be shown, IlsA was required for in vitro growth on Hb as an iron source and an 
Isd-like operon was identified in the B. cereus genome, providing a potential haem relay 
network for IlsA to function in. 
 
The B. anthracis proteins, IsdX1 and IsdX2, contain one or five NEAT domains 
respectively (Fig. 1.8 B). Unlike the S. aureus and S. pyogenes Hb receptors, the IsdX 
proteins are secreted, although a small percentage of IsdX2 may remain associated with 
the cell wall183. The B. anthracis proteins also differ from IsdB/H and Shr, in that single 
NEAT domains can perform both Hb and haem binding functions. For example four of 
the five NEAT domains of B. anthracis IsdX2 bind to both haem and Hb with Hb binding 
affinities ranging from ~ 2 µM to 41 nM. Two of these NEAT domains can bind haem 
derived from Hb and three can transfer the haem to B. anthracis IsdC184. The single 
NEAT domain of the B. anthracis receptor, IsdX1, was also shown to interact weakly 
with Hb with a Kd of ~8 µM, and transfer haem to IsdC183,185. Importantly, IsdX2 and 
IsdX1 have not yet been demonstrated to accelerate haem release from Hb and little is 
known about the IsdX-Hb interaction. The X-ray crystal structures of IsdX1 and 
IsdX-NEAT5 reveal a conserved structure and mechanism of haem binding to the 
S. aureus haem binding NEAT domains154,157. In contrast, residues involved in Hb 
binding, which were identified though mutagenesis studies, are absent from the S. aureus 
receptors, indicating that the mechanism behind haem scavenging is likely to be 
distinct154,157.  
 
B. anthracis also encodes for a cell wall associated putative Hb receptor, Hal186. Hal 
contains a single NEAT domain, with homology to IsdX2-NEAT5 and a series of leucine 
rich repeats (Fig. 1.8 B). Like IsdX2-NEAT5, the NEAT domain of Hal binds to haem 
and Hb, and can extract haem from Hb; however, no structural or kinetic information is 
available. The relative roles IsdX1, IsdX2 and Hal in growth using Hb as an iron source 
have not been determined although each have been implicated in this function in 
vitro154,183,186.  
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L. monocytogenes produces two secreted NEAT domain containing proteins, Hbp1 and 
Hbp2, that are implicated in haem uptake from Hb. Hbp2 (also called SvpA) contains 
three NEAT domains (Fig. 1.8 B) and, like IsdX2, a small portion of this protein may be 
associated with the cell wall187. Hbp2 binds to haem and contributes to haem utilisation 
under conditions of low haem abundance188. In addition, the cell wall anchored form of 
Hbp2 is involved in growth on Hb as an iron source in vitro188. However, interaction 
between Hbp1 or Hbp2 and Hb is yet to be demonstrated.  
 
Of the above putative Hb receptors, evidence for direct haem transfer from Hb to the 
receptor in a protein complex is available for Shr, which has been shown accelerate haem 
release from Hb. Evidence of facilitated haem release is missing for IlsA, IsdX1, IsdX2, 
Hal and Hbp2. Further characterisation of the interaction between the putative receptors 
and Hb is required to determine whether they function like the Hb receptors of S. aureus 
or form a family of Gram-positive haemophores, which compete for but do not directly 
liberate haem from the host protein. 
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Figure 1.8. Putative Hb receptors of Gram-positive Firmicutes bacteria (A) The 
structure of the first Hb-binding NEAT domain of IsdH (IsdHN1; PDB 3SZK). The 
Hb-binding face (orange) is the same face used by the haem-binding NEAT domains to 
bind haem. (B) The domain architecture of putative Hb receptors. One or more NEAT 
domains are present in each. Domains shown to bind to haem are coloured black. All 
proteins contain a secretion signal (small black circle). The Hb-binding proteins may be 
anchored to the cell wall via a sortase anchoring motif (small white square), imbedded in 
the cell membrane via a transmembrane domain (TM) or in the S-layer via S-layer 
homology domains (SLH). Shr, IslA and Hal also contain leucine rich repeat domains 
(LLR). 
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The machinery used to import haem or Fe(III)-siderophore complexes across the 
cytoplasmic membrane is conserved across Gram-negative and Gram-positive bacteria 
(Fig. 1.5&1.6). Despite significant differences in the chemical composition of haem and 
siderophores, the inner membrane transporters for both of these substrates are structurally 
related and belong to the same protein families. Gram-negative and Gram-positive inner 
membrane transporters consist of one or more substrate-binding proteins and an 
adenosine tri-phosphate (ATP) binding cassette (ABC) transporter permease comprising 
one or two trans-membrane proteins and one or two ATPases.  
 
The periplasmic substrate-binding proteins belong to the helical backbone metal receptor 
superfamily, characterised by a bi-lobed structure bridged by a backbone formed from 
one or more !-helices189-191. The substrate-binding site is formed between the two lobes, 
however residues involved in contacts with substrate vary to allow for diverse ligand 
transport. In Gram-negative bacteria these substrate-binding proteins diffuse though the 
periplasm, shuttling the cargo from the outer membrane to the inner membrane. In Gram-
positive bacteria, the substrate binding proteins are lipoproteins and are displayed on the 
periplasmic surface of the inner membrane. The substrate binding protein docks to an 
adenosine tri-phosphate (ATP) binding cassette (ABC) transporter permease allowing 
substrate transport though membrane.  
 
Seven operons encoding for putative ABC iron/haem transporter systems (including a 
substrate binding protein and homo- or hetero-dimeric permease) are found in the 
S. aureus genome82. Several of these operons have now been characterised, including four 
involved in the uptake of siderophore iron, as follows. The staphylococcal iron regulated 
(SirABC) transporter is responsible for the uptake of Staphyloferrin B (also called 
Staphylobactin)189. The haem transport system (HtsABC) was originally suggested to act 
as a haem importer82, but subsequently shown to bind to Staphyloferrin A in structural 
studies190,192. The ferric hydroximate uptake system (FhuCBG-D1/D2) has broad 
substrate specificity allowing for uptake of a range of ferric hydroxamate siderophores123. 
The Staphylococcal siderophore transporter (SstABCD) has unknown substrate 
specificity144,193. In addition, two ABC transporter permease complexes are involved in 
haem uptake:  the iron regulated surface determinant transporter (IsdEF)7, and the haem 
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regulated transporter HrtAB103. Interestingly, the only ATPase component to be 
characterised is FhuC of the ferric hydroximate uptake system. FhuC has been shown to 
perform the ATPase role for FhuCBG, SiaABC194 and HtsABC192, and may be important 
for the functioning of all seven S. aureus ABC transporter iron uptake systems195. 
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Once haem reaches the bacterial cytoplasm it can either be directly incorporated into 
bacterial haem-binding proteins or broken down to release iron. Haem-degrading 
enzymes, known as haem oxygenases, are found in bacteria through to humans. The haem 
oxygenases of Gram-negative bacteria show structural homology to the human haem 
oxygenase 1196 and use a conserved mechanism for haem catabolism197. In contrast, the 
Gram-positive haem oxygenases are structurally distinct to haem oxygenase 1, and 
degrade haem via several unique mechanisms198-200. IsdG and IsdI of S. aureus fall into 
the latter category and degrade haem to produce free iron, staphylobillin (a 
chromophore), and formaldehyde200,201.  
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Proteins of Isd system are highly up-regulated in response to conditions of iron restriction 
in vitro5,98,202, during growth in human blood and serum6 and during infection5. In 
addition, S. aureus strains in which the isdA, isdB, isdC, isdH, sortB genes or the haem 
oxygenase genes (isdG and isdI) have been deleted show impaired growth in animal 
infection models, suggesting that the ability to utilise haem is important for full 
virulence84,174,203-205.  
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It was originally observed that gene deletion of isdB but not isdH causes a significant 
defect in growth using Hb as a sole iron source in vitro8,84. However, Hurd et al., did not 
observe a growth defect for S. aureus strains inactivated for isdB, isdH or IsdA, when 
grown in the presence of Hb as a sole iron source206. In the latter studies, Hb that had 
been lyophilised was provided at ~80 nM. It was subsequently shown that lyophilised Hb 
but not Hb purified fresh from blood could sustain growth of %isdB strains when provided 
at ~40 nM207. Lyophilised Hb is known to release free haem due alterations in the Hb 
structure and free haem has been shown to support S. aureus growth independently of 
IsdB and IsdH activity84,207. More recently, it was demonstrated that haem uptake from 
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Hb by IsdB is only required in the presence of low concentrations of Hb (10–20 nM)208. 
This is consistent with a role for IsdB in Hb utilisation in vivo, where extracellular Hb 
concentrations are expected to be in the nanomolar range under physiological conditions 
and may be further limited depending up the site of infection. In these studies, deletion of 
isdB virtually abolishes growth on human Hb, suggesting that IsdB is the primary 
receptor for haem uptake from Hb207,208. 
 
Despite the difference observed in in vitro growth assays, IsdB and IsdH each contribute 
to bacterial virulence based on the following observations. Deletion of either isdB or isdH 
from S. aureus increased survival time of mice after systemic infection174,205. In addition, 
passive transfer of antibodies raised against IsdB into S. aureus-infected mice caused 
increased survival rates following lethal infection. The protection provided by passive 
immunisation was attributed to loss of Hb receptor function, as anti-IsdB antibodies 
blocked IsdB binding to Hb but did not enhance phagocytosis and killing during growth 
in mouse blood174. Hence haem uptake by the Isd system is an important aspect of S. 
aureus virulence and an understanding of the mechanisms behind this pathway may 
inform targeted drug design. Interestingly, while IsdB and IsdH are both important for 
pathogenesis, they appear to play distinct roles in infection, as IsdB but not IsdH is 
involved in abscess formation in spleen and kidneys84,174,203. This suggests that the Hb 
binding and haem capture functions of these two proteins may not be redundant but 
contribute to different aspects of the infection process. 
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The Isd proteins may play other roles in infection, in addition to iron uptake. This may 
explain why different Isd proteins are more, or less, important for the colonisation of 
different of organs. For example, IsdA has been proposed to have a role in cell adhesion, 
skin and nasal colonisation, and innate immune evasion. These activities are mediated 
through binding to a diverse range of ligands, including fibrinogen162, lactoferrin57 and 
extracellular matrix proteins cytokeratin K10, loricrin, and involucrin161 and by reducing 
the hydrophobicity of the bacterial surface to prevent the antimicrobial activity of fatty 
acids present in the skin209. IsdB has been found to induce aggregation of platelets 
through direct binding to the platelet integrin !IIb"3210. The integrin-binding activity of 
IsdB was also shown to promote bacterial entry into a range of non-immune cells for 
intracellular growth, and was independent of Hb binding activity211. An alternative role in 
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immune evasion has also been suggested for IsdH. S. aureus cells expressing IsdH show 
reduced phagocytosis and increased survival in whole blood when compared to a %isdH 
strain205,212. The increased survival was linked to enhanced degradation of complement; 
however, binding of IsdH to Hb may still be involved as residues on the IsdH Hb-binding 
interface were necessary for S. aureus survival in human blood205. Hence, while the Isd 
proteins have a primary role in haem uptake from Hb, they also carry out a range of other 
roles that contribute to infection.  
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Currently, little is known about the structural mechanisms that achieve iron uptake from 
host haem proteins. Although progress has been made in understanding the structure, 
function and haem transfer mechanism of the haem binding Isd proteins, there is a 
significant gap in our knowledge of the Isd Hb receptors and the mechanism of haem 
capture from Hb at the top of the Isd pathway. This project had two broad aims. The first 
aim was to determine the molecular mechanisms used by the Hb receptors, IsdB and IsdH 
to liberate haem from Hb. The second aim was to investigate how haem is relayed to IsdA 
and C, following haem capture by IsdB and IsdH. 
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1 kb DNA ladder     Invitrogen (Mount Waverley, VIC) 
Acetone      Merk millipore (Kilsyth, Vic) 
Acetonitrile (HPLC grade)   Merk millipore (Kilsyth, Vic) 
Acetic Acid     Merk millipore (Kilsyth, Vic) 
Acrylamide     Bio-Rad (Gladesville, NSW) 
Agar      Oxoid (Thebarton, SA) 
Additive screen     Hampton Research (Aliso Viejo, CA, USA) 
Agarose (DNA grade)    Astral Scientific (Caringbah, NSW) 
Ammonium persulfate (APS)   Sigma-Aldrich (Castle Hill, NSW) 
Ammonium sulphate    Sigma-Aldrich (Castle Hill, NSW) 
Ampicillin (AMP)    Sigma-Aldrich (Castle Hill, NSW)  
Antarctic phosphatase    New England Biolabs (Ipswich, MA, USA) 
BamHI      New England Biolabs (Ipswich, MA, USA) 
Bovine serum albumin (BSA)   Sigma-Aldrich (Castle Hill, NSW)  
1-butanol     Merk millipore (Kilsyth, Vic) 
Casein peptone     Oxoid (Thebarton, SA) 
Cat whiskers      Lucy (Ingleside, NSW) 
Chloramphenicol (CAM)    Sigma-Aldrich (Castle Hill, NSW)  
Complete, EDTA-free protease inhibitor tablets  Roche Diagnostics (Castle Hill, NSW) 
Coomassie® Brilliant Blue R   Sigma-Aldrich (Castle Hill, NSW) 
Diammonuim citrate    Sigma-Aldrich (Castle Hill, NSW) 
Disodium hydrogen orthophosphate  Sigma-Aldrich (Castle Hill, NSW) 
Dithiothreitol (DTT)    Gold Biotechnology (St. Louis, MO, USA) 
dNTPs      New England Biolabs (Ipswich, MA, USA) 
Dpn1      New England Biolabs (Ipswich, MA, USA) 
Ethanol (HPLC grade)    Merk millipore (Kilsyth, Vic) 
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich (Castle Hill, NSW) 
Ethylene glycol     Hampton Research (Aliso Viejo, CA, USA) 
Glycerol      Sigma-Aldrich (Castle Hill, NSW)  
Glycine      Sigma-Aldrich (Castle Hill, NSW)  
Guanidine hydrochloride    Astral Scientific (Caringbah, NSW) 
His-select® Ni Affinity Gel   Sigma-Aldrich (Castle Hill, NSW)  
Hydrochloric acid    Sigma-Aldrich (Castle Hill, NSW)  
Imidazole     Sigma-Aldrich (Castle Hill, NSW)  
Isopropyl "-D-thiogalactopyranoside (IPTG) Gold Biotechnology (St. Louis, MO, USA) 
Isopropanol     Merk millipore (Kilsyth, Vic) 
Kanamycin sulphate    Sigma-Aldrich (Castle Hill, NSW) 
Methanol (HPLC grade)    Ajax Finechem (Taren Point, NSW) 
Mark 12® protein standards   Invitrogen (Mount Waverley, VIC) 
NeXtal Classic suite    Qiagen (Doncaster, VIC) 
NeXtal JCSG+ suite    Qiagen (Doncaster, VIC) 
NeXtal Pact suite     Qiagen (Doncaster, VIC) 
Nickel sulphate     Sigma-Aldrich (Castle Hill, NSW)  
PEG-3350     Hampton Research (Aliso Viejo, CA, USA) 
Phusion DNA polymerase    New England Biolabs (Ipswich, MA, USA) 
PMSF      Sigma-Aldrich (Castle Hill, NSW)  
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Potassium chloride    Sigma-Aldrich (Castle Hill, NSW) 
QIAprep® Spin miniprep kit    Qiagen (Doncaster, VIC) 
SmaI      New England Biolabs (Ipswich, MA, USA) 
SnakeskinTM 3500 MWCO pleated dialysis tubing Quantum Scientific (Lane Cove West, NSW) 
Sodium dihydrogen orthophosphate  Sigma-Aldrich (Castle Hill, NSW) 
Sodium chloride     Sigma-Aldrich (Castle Hill, NSW)  
SYBR safe     Invitrogen (Mount Waverley, VIC) 
T4 DNA ligase     New England Biolabs (Ipswich, MA, USA) 
T4 Polynucleotide Kinase     New England Biolabs (Ipswich, MA, USA) 
N,N,N’,N’-tetramethyldiamine (TEMED)  Sigma-Aldrich (Castle Hill, NSW)  
Tris(hydroxymethyl)methylamine (TRIS)  Sigma-Aldrich (Castle Hill, NSW) 
Trifluoroacetic acid (TFA)    Sigma-Aldrich (Castle Hill, NSW)   
Tryptone T     Oxoid (Thebarton, SA) 
XhoI       New England Biolabs (Ipswich, MA, USA) 
Yeast extract     Oxoid (Thebarton, SA) 
Zero blunt® TOPO® PCR Cloning Kit  Invitrogen (Mount Waverley, VIC) 
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Single-stranded DNA oligonucleotides for cloning and site directed mutagenesis were 
purchased from Sigma Genosys (Castle Hill, NSW; see Appendix A for sequences). 
Genomic DNA from the Staphylococcus aureus strain TCH1516 was purchased from 
ATCC (Manassas, VA, USA). 
 
The IsdHN1, pRM208 and pRM216 vectors were a kind gift from Dr Rob Clubb. The 
pRM208 vector consists of the IsdH gene (residues 326-660) cloned into the pHis-SUMO 
backbone vector, which encodes for a Kanamycin resistance gene. pRM216 was 
generated from pRM208 and carries a Tyr642 to Ala mutation. Details of the construction 
of these vectors can be found in Spirig, et al.,167. 
  
Cloning and mutagenesis was performed in the Escherichia coli DH5! strain (F- 
!80lacZ"M15 "(lacZYA-argF) U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44 thi-
1 gyrA96 relA1 #-). 
 
The E. coli Rosetta2 (DE3) pLysS strain (F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pLysSRARE2 (CamR)) was used for recombinant protein production. 
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The genes encoding for IsdA, B, C and H were amplified from Staphylococcus aureus 
strain TCH1516 genomic DNA by polymerase chain reaction (PCR). The forward and 
reverse primer sequences contained a XhoI or a BamHI restriction endonuclease cleavage 
site respectively. Primer sequences can be found in Appendix A. A typical PCR reaction 
contained 1–100 ng template DNA, 0.5 µM primes, 0.25 mM dNTPs, 1$ Phusion HF 
polymerase buffer and of 1U Phusion polymerase. Thermocycling was carried out in a 
T100 Thermal cycler (Bio Rad, Gladesville, NSW) and conditions included an initial 
incubation at 98 °C for 45 sec, followed by thirty cycles of (98 °C for 30 sec, 55 °C for 
30 sec and 72 °C for 15–30 sec/kb) and a final incubation at 72 °C for 10 min. 
 
For blunt insertion into the pBluescript cloning vector, 5’ phosphates were added to the 
PCR products in a 2 h incubation with T4 Polynucleotide Kinase at 37 °C. T4 
Polynucleotide Kinase was heat inactivated at 65 °C for 20 min.  The vector was 
linearized in a 2-h incubation with SmaI at 25 °C and the 5’ phosphate groups were 
removed by incubation with Antarctic phosphatase for 1h at 37 °C. Antarctic phosphatase 
was heat inactivated at 65 °C for 20 min. The PCR products were then ligated to the blunt 
ends of pBluescript in a 1-h incubation with T4 DNA ligase at room temperature.  
 
The IsdB gene was cloned blunt into the pCR®-Blunt II-TOPO® vector using the Zero 
blunt® TOPO® PCR Cloning Kit (Invitrogen). 
 
For direct cloning or sub-cloning into pET15b (Novagen) the PCR products or parent 
vectors containing the gene of interest were digested with XhoI/BamHI for 2 h at 37 °C. 
The pET15b vector was similarly treated and the digestion products were purified via 
agarose gel electrophoresis. To prevent re-ligation of partially digested vector, the 
digested plasmid was incubated with Antarctic phosphatase for 1 h at 37 °C. The digested 
products were then ligated as above.  
 
Plasmids were transformed into E. coli DH5! cells for colony screening. Single colonies 
were grown overnight at 37 °C in LB broth containing 100 µg"ml–1 ampicillin. Plasmid 
DNA was isolated via the alkaline lysis method according to Sambrook et al.,213 or using 
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the Qiagen QIAprep® Spin Miniprep Kit and confirmed to be correct by DNA 
sequencing (AGRF, Westmead, Sydney). 
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The modified QuikchangeTM method of Liu and Naismith was used to introduce single 
or multiple mutations, insertions and deletions in a single step into the Isd expression 
vectors214. Primer sequences and parent vectors can be found in Appendix B. Forward 
and reverse primers contained a complementary sequence with a Tm (Tmpp) 5–10 °C 
lower than the non-complementary 3’ overhangs (Tmno). Reaction components were the 
same as for standard PCR, with the modification of 2–10 ng template vector. The reaction 
conditions included an initial incubation at 95°C for 5 min, twelve cycles of (95 °C for 1 
min, Tmno – 5 °C for 1 min and 72 °C for 10–15 minutes) followed an annealing step 
Tmpp – 5 °C for 1 min and a final extension step at 72 °C for 30 min.  
 
To remove template DNA, the PCR reaction products were incubated with 5U Dpn1, an 
enzyme that only digests methylated DNA, for 2 h at 37°C. E. coli DH5! cells were then 
transformed with 250 ng of the Dpn1 digested DNA for colony screening. All mutations 
were confirmed by DNA sequencing (AGRF, Westmead, Sydney). 
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For recombinant protein overexpression, expression vectors were transformed into E. coli 
Rosetta2 (DE3) pLysS cells and grown overnight on LB-agar plates containing 34 µg"ml–
1 Chloramphenicol and either 100 µg"ml–1 Ampicillin for pET15b backbone vectors or 50 
µg"ml–1 Kanamycin for pHis-SUMO backbone vectors. Several colonies were inoculated 
into 20 mL of LB broth and were grown overnight with shaking at 37 °C. The overnight 
culture was diluted 50–100 fold into 2 L of LB broth to give a starting OD600 of ~ 0.05 
and grown with shaking at 37 °C. When the OD600 had reached ~0.7 the culture was 
equilibrated to the expression temperature and induced with 1 mM IPTG. For production 
of haem binding proteins in their holo form, 5-10 µg"ml–1 haem was also added to the 
culture at induction. 
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IsdA, IsdC and IsdH constructs were expressed at 37 °C for 4 hours before harvesting by 
centrifugation. IsdB was degraded over time in the growing cells. Expression trials were 
conducted and the highest yield of intact protein was achieved in a 30–45 minute 
induction at 37 °C before harvesting. IsdBN2 was expressed for 4–5 h at 22 °C. Cell 
pellets were resuspended in 50 mM NaP, pH 7.4, 10 mM imidazole, 300 mM NaCl, 0.1 
µM PMSF. For IsdB constructs, 1$ complete mini-EDTA free protease inhibitor cocktail 
(Roche) was also included. Cell suspensions were snap frozen in liquid nitrogen and 
stored at –80 °C. 
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Proteins cloned into the pET15b vector were expressed with an N-terminal affinity tag 
with the sequence MGSSHHHHHHSSGLVPRGSHMLE. Similarly, proteins expressed 
from the pHis-SUMO vector contained an N-terminal fusion including a hexa-His tag 
with the sequence MGSSHHHHHHSSGLVPRGSHMAS followed by the 11.3 kDa, 
ubiquitin-like protein, SMT3, from Saccharomyces cerevisiae.  
 
The His-tagged proteins were purified at 4 °C over 5 mL IMAC resin (HIS-Select Nickel 
Affinity gel, Sigma) and the eluted proteins were analysed by SDS-PAGE (see Section 
3.2.1, Fig. 3.3, 3.4). For IsdH constructs, the load condition was 50 mM NaP, pH 7.4, 300 
mM NaCl, 20 mM imidazole. The bound protein was washed in equilibration buffer 
containing 20 mM imidazole and eluted with 100 mM imidazole. IsdB constructs were 
applied to the Ni-resin in 50 mM NaP pH, 7.4, 300 mM NaCl, 10 mM imidazole and 
washed in equilibration buffer containing 20 mM imidazole. Apo-proteins were eluted in 
equilibration buffer containing 100 mM imidazole, while the holo-protein was eluted in 
250 mM imidazole. IsdA was loaded onto the Ni-resin in 50 mM NaP, pH 7.4, 300 mM 
NaCl, 10 mM imidazole. IsdA was washed in the load buffer and eluted in 50 mM NaP, 
pH 7.4, 300 mM NaCl, 30 mM imidazole. Finally, IsdC was loaded onto the Ni-resin 50 
mM NaP, pH 7.4, 300 mM NaCl, 10 mM imidazole, washed in equilibration buffer 
containing 30 mM imidazole, and eluted in 100 mM imidazole. 
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Fractions eluted off Ni-resin containing His-Sumo tagged proteins were identified by 
SDS-PAGE. Pooled fractions were mixed with 1/100 His-tagged ubiquitin-like protein 1 
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(Ulp1) protease for 1 h at room temperature. An overnight dialysis step at 4 °C was then 
used to buffer exchange the protein into 20 mM Tris, pH 8.0, 300 mM NaCl. The 
dialysed protein was applied to a 5 mL IMAC column equilibrated in 50 mM NaP pH, 
7.4, 300 mM NaCl, 10 mM imidazole and washed 5x 1CV of equilibration buffer. The 
cleaved recombinant protein was obtained in the flow through and wash fractions, while 
the His-SUMO tag and His-Ulp1 were maintained on the column. The SUMO tag and 
Ulp1 were eluted from the Ni-resin in 50 mM NaP pH, 7.4, 300 mM NaCl, 250 mM 
imidazole. A representative SDS-PAGE analysis of the Sumo tag cleavage and separation 
can be found in Figure 3.9. 
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Additional purification of IsdHN1N2N3 and IsdHN2N3 was performed by anion-exchange 
chromatography (Q-sepharose, GE Healthcare). Proteins were loaded in 10 mM NaP, 
pH 7.0 and eluted over a gradient of 100–250 mM NaCl.  
 
IsdHN2 was subject to cation exchange chromatography over SP-sepharose resin (GE 
Healthcare). The load condition was 50 mM NaP, pH 6.5 and extensive washing of the 
bound protein was performed in the same condition. IsdHN2 was eluted in 50 mM NaP, 
pH 6.5, 50 mM NaCl. 
 
IsdC was subject to anion exchange chromatography over DEAE sepharose resin (GE 
Healthcare). The protein was loaded onto the column in 10 mM Tris, pH 8.0 and washed 
in the same condition. For preparations of IsdC that were expressed without the addition 
of exogenous haem, apo-IsdC could be collected in the flow through and wash fractions. 
The holo protein was eluted in 20 mM Tris, pH 8.0, 200 mM NaCl. 
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A final gel filtration step over a Superose 12 column, (GE Healthcare) equilibrated in 150 
mM NaP pH 7.0, was performed where necessary.  
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Haem saturation was measured by first unfolding the protein in 0.1 M NaOH, or 6 M 
guanidine hydrochloride, to release the haem. The concentration of haem was then 
determined from the absorbance at 390 nm using the reported extinction coefficients for 
haem (Table 2.1). The contribution of haem to the absorbance at 280 nm was back 
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calculated from its concentration and subtracted from the observed A280 value. The 
resulting A280 was used to determine the protein concentration using the theoretical 
extinction coefficient calculated from the primary protein sequence (appendix A).  This 
method of determining the protein concentration was validated with refractive index 
measurements made during SEC. 
 
Table 2.1. Extinction coefficients of haem at 280 and 390 nm 
Wavelength (nm) &  (M-1!cm-1) 
 6M guanidine HCl NaOH 
390 47700 58400 
280 17530 18080 
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Haem was removed from IsdA, IsdB, IsdC and IsdH constructs by acid acetone haem 
extraction method of Ascoli et al.,215. The haem bound proteins were desalted via buffer 
exchange over a 10 mL G-25 Sepharose column (IsdHN2N3 and IsdBN1N2) or dialysis 
(IsdHN1N2N3 and IsdC) into MQW or 10 mM Tris, pH 8.0. Proteins were concentrated to 
~1 mM haem and added drop-wise to 10 mL acetone containing 25 µL of 2 M HCl that 
had been precooled to –20 °C. The reaction was carried out on ice with constant stirring. 
The precipitated protein was recovered by centrifugation at 6000 rpm for 20 min at –10 
°C. The supernatant containing the extracted haem was discarded and the protein pellet 
dissolved in 2 mL of MWQ. The apo protein was dialysed or buffer exchanged into 150 
mM NaP, pH 7.0.  
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Human haemoglobin was prepared from blood as described previously216. Briefly, red 
blood cells from freshly collected blood were washed in saline solution and then lysed 
under hypotonic conditions. Hb was purified from the haemolysate via cation exchange 
chromatography over an SP-sepharose column, followed by anion exchange 
chromatography over Q-sepharose resin (Fig. 2.1 A). Oxygenated Hb can undergo 
autooxidation, a reaction producing superoxide (O2–) and Fe(III) haem217. The oxidised 
iron can participate in further reduction-oxidation reactions, producing a range of reactive 
oxygen species that can damage the polypeptide chains39. During Hb purification the 
globin was maintained in the carbon monoxide (CO)-liganded state to inhibit 
autooxidation and limit protein degradation218. HbCO was formed by bubbling CO 
through the red blood cells before lysis. This procedure avoids the excessive frothing that 
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would occur if gas was bubbled through the highly concentrated protein solution obtained 
after cell lysis. CO and O2 exchange rapidly across the red blood cell membrane and the 
~220-fold higher affinity of Hb for CO compared to O2219 results in essentially complete 
conversion to HbCO. At all subsequent protein purification steps Hb solutions were re-
charged with CO. The concentration of purified HbCO was determined by UV-visible 
absorption spectroscopy using the published absorption coefficients of 192000 and 13900 
M–1"cm–1 at 419 and 539 nm (Fig. 2.1 B, Table 2.2)220.  
 
When red blood cells become lysed in the body, the iron centre of Hb that is released is 
rapidly oxidised to Fe(III), and so it is likely that the Hb receptors will predominantly 
encounter oxidised Hb. Both IsdH and IsdB can capture haem from Fe(III)-Hb149,167. In 
addition, IsdH has much higher affinity for Fe(III)-haem (values between 2 µM and 40 
nM have been obtained)167,176,221 than Fe(II) haem (which does not show specific binding 
to IsdH), indicating that haem capture is likely to be more effective from oxidised Hb. To 
prepare Fe(III)-Hb, HbCO was first converted to HbO2 by photolysis of the CO ligand. 
This involved passing a stream of pure oxygen over the HbCO solution, which was held 
on ice and illuminated with a focussed beam from a LED lamp (11,000 lux at 1 m). HbO2 
was reacted with a five-fold molar excess of potassium ferricyanide at ~10 °C and 
monitored using UV-visible spectrophotometry at 5 min intervals. When the spectrum 
resembled that of Fe(III)-Hb, the oxidant was removed by buffer exchange over G-25 
sepharose (GE Healthcare Life Sciences). The spectrum of Fe(III)-Hb is shown in Figure 
2.1 B. 
 
Table 2.2. Visible absorption properties of human Hb in different ligation and oxidation 
states 
Hb  ligation state Wavelength (nm) &280nm (M-1!cm-1) * 
HbCO 419 192000 
 539 13900 
 569 13900 
HbO2 515 129000 
 576 14900 
Fe(III)-Hb 405 169000 
 500 9000 
*Values are from Eaton and Hofrichter220 
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Haem transfer was monitored by UV-visible spectroscopy. Hb at 1.5 µM tetramer 
concentration, equivalent to 6 µM haem, was mixed with apo-Isd proteins at the ratios 
indicated in Results. Reactions were performed in 150 mM NaP, pH 7.0 at 4 °C. 
Absorbance spectra (350–700 nm) were recorded at 40-second intervals on a JASCO 
UV-630 spectrophotometer equipped with a temperature controlled sample chamber. To 
determine the percentage of haem transferred from Hb to the Isd protein at each time 
point, the acquired UV-visible spectrum was fit to a linear combination of Fe(III)-Hb and 
fully haem-loaded holo-IsdHN2N3 spectra . 
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Size exclusion chromatography (SEC) experiments were performed on a Superose 12 or 
Superose 6 columns (GE Healthcare Life Sciences) equilibrated in 150 mM NaP pH 7.0. 
Proteins were mixed at the concentrations indicated in the results chapters and 100 µL 
samples loaded onto the column. Elution of protein samples was monitored at 280 nm 
with a Jasco UV2070 detector. 
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The molecular weight of proteins eluting from a gel filtration column was determined 
from in-line measurements of static (Rayleigh) light scattering based on the relationship 
 
where      and      
In the above expressions: R(!) is the excess Rayleigh ratio, which is the excess scattering 
intensity of the sample over that of the pure solvent, divided by incident light intensity; c 
is the solute concentration (g"mL–1); n0 is the refractive index (dimensionless) of the 
solvent; dn/dc is the specific refractive index increment with respect to sample 
concentration (g"mL–1); NA is Avogadro’s number; ' is the wavelength of incident light 
(nm). This method yields the weight-average molecular weight (MW) of protein species in 
the solution, which is defined 
! 
R(") = K # c # M
W
! 
K = K f " n0
2
" dn dc( )
2
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where ci is the weight concentration of each species with molecular weight Mi.  
Right-angle light scattering (RALS) intensity and refractive index (RI) were measured on 
a Viscotek 305 Triple Detector Array (TDA) instrument (Malvern). The detectors in this 
instrument are housed in an insulated oven, which was set to maintain a temperature of 
30 °C. Gel filtration columns were placed outside of the detector/column oven, which led 
to some baseline drift if there were large changes in laboratory temperature. Runs with 
excessive baseline drift were discarded. The light scattering cell had a volume of 18 µL 
and was illuminated by a Laser diode (670 nm). Light scattered at an angle of 90° was 
measured by a photodiode detector. The refractive index detector was a dual cell design 
in which one compartment is filled solvent from the equilibrated column and sealed, and 
the other compartment receives solvent/solute mixtures eluting from the column during 
the experiment. At the interface between the two compartments a light beam is deflected 
due to differences in refractive index of the solution and solvent. Calibration of the 
detectors and calculation of sample MW was performed using the OMNISEC software 
(Malvern). The detectors were calibrated (by D. Gell) using the following standards and 
data: BSA (Sigma A1900), &279 = 0.667 mL"g–1"cm–1, MW = 66,300 Da, dn/dc (670 nm) = 
0.185 mL"g-1; ! Hb stabilizing protein (AHSP, residues recombinant), &280 = 11,460 M–
1"cm–1, MW = 10810 Da; hen egg lysozyme (Hampton Research HR7110), &281.5 = 2.64 
mL"g–1"cm–1, MW = 14,600 Da; and polyethylene oxide (PEO) Viscotek TDA calibration 
standard, 20.17 mg vial (Malvern), MW = 22,252, dn/dc (670 nm) = 0.132. The dn/dc 
values of AHSP and lysozyme were not obtained from physical data and were assumed to 
be 0.185 mL"g-1.  
To calibrate the RI detector, a known mass (m, units g) of standard was injected. The total 
RI signal – (RI) – was obtained by summing the detector voltage across the whole peak 
volume using OMNISEC. A calibration constant for the RI detector (KRI), which is an 
instrument constant that incorporates geometric properties of the cell and detector 
response, was obtained from a plot of m against (RI) for multiple samples according to   
! 
M
W
=
"
i
c
i
M
i
"
i
c
i
 52 
 
A straight line fit with a coefficient of determination, r2 = 0.998, gave KRI = 9.648 $ 106. 
The calibration constant for the RALS detector (KLS) was obtained by plotting MW"(RI) 
against (LS) – the total RALS signal summed over the peak – according to the formula 
MW =
(LS)
(RI ) !
KRI !KLS
n03 !K f ! dn dc( )
 
A straight-line fit with a coefficient of determination, r2 = 0.997, gave KLS = 4.415 $ 10–8. 
The above procedure assumes that samples of carefully prepared concentration elute from 
the chromatography column with zero loss of material. It was noted that some material 
binds to new in-line filters, so it was necessary to inject multiple standards or samples 
after replacing any components of the system, or after in-place cleaning, prior to 
commencing measurements or calibration runs. To calculate sample MW across a peak, 
OMNISEC software accounts for dilution (peak spreading) between the RI and RALS 
detectors using additional parameters that were obtained from BSA standard runs. The 
value of dn/dc (670 nm) was assumed to be 0.185 mL"g-1 for all experimental protein 
samples. Although calibration was performed only once, BSA was used periodically to 
monitor system performance. The value of MW for BSA obtained from repeated 
measurements over the course of these analyses was 67.3 ± 1.7 kDa (n = 14). 
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Samples of IsdHN2N3(Y642A) were buffer exchanged by gel filtration into 20 mM NaP, 
pH 7.5, 500 mM NaCl and matched buffer controls were collected from the same column 
flow through. SAXS data were collected at the University of Sydney on an Anton Paar 
SAXSess instrument with line collimation (10-mm slit and integration width) and CCD 
detector; details of the experimental setup can be found in222. Data were collected from 
the buffer control, followed by the protein sample, which were sequentially loaded into 
the same quartz capillary (1 mm diameter). Images were collected at 10 °C over four, 15 
minute intervals, allowing for radiation damages to be assessed. SAXSquant2D (Anton-
Paar, Austria) was used to average the 2D images and generate I(q) versus q (q 
! 
(RI) = K
RI
"
m " dn dc( )
n
0
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= (4"#"sin$)/%, where 2$ is the scattering angle and % = 1.54 Å) profiles. Solvent 
subtraction was performed using SAXSquant1D (Anton Parr). I(0)’s and P(r) curves were 
calculated using GIFT (Anton Paar, Austria) and PRIMUS223 and experimental molecular 
weights were calculated from the calibrated I(0)’s224. Ab initio shape reconstruction was 
carried out as described in Chapter 3. 
 
IsdB(Y440A) samples formed aggregates which could be removed by gel filtration. To 
remove interference from aggregates, IsdB was subjected to SEC-SAXS at the Australian 
Synchrotron SAXS-WAXS beamline and data reduction was performed using 
SCATTERBRAIN (Australian Synchrotron). The experiment was performed at 27 °C 
and data were placed on an absolute scale by normalizing to the scattering of water. 
Twenty images of two-second exposures recorded across the main elution peak were 
averaged. The buffer control that was subtracted from the peak consisted of the average 
of 50 curves from a region of the SEC run with no scattering signal. The resulting 
scattering curve was processed with PRIMUS223. A camera distance of 1 m was used with 
an X-ray energy of 11 KeV giving a Q range from 0.01 to 0.5 Å–1. Data were collected on 
a Pilatus 1M detector (Dektris). 
 
Ensemble Optimization Method (EOM)225 was performed using the EOM web interface 
of ATSAS online. The structured domains used to generate a pool of 10000 conformers 
were taken from PDB files 4FC3, 2LHR, 2E7D and 3RTL. 
=:55(\C%&@('%@#$&--+0%&43@(
Isd proteins were mixed with Fe(III)-Hb at a 2:1 ratio, buffer exchanged into 20 mM 
HEPES pH 7.5 and concentrated so that the starting samples contained 5 mg"ml–1 Hb. 
Crystallisation was performed by hanging drop vapour diffusion. Initial crystallisation 
screens were performed in 24-well plates and included conditions in the NeXtal Classic, 
JCSG+ and Pact suites (Qiagen, Doncaster, VIC). Details of crystallisation conditions, 
data collection, molecular replacement and refinement are presented in Chapters 3 and 6. 
A comprehensive overview of the theory behind protein crystallography can be found in 
Bernhard Rupp’s ‘Biomolecular Crystallography’226. 
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The two Hb receptors of S. aureus, IsdB and IsdH, share a region of approximately 360 
amino acids with ~62% sequence identity (Fig. 3.1, indicated by red dashed line) and 
close to 80% sequence similarity. These regions of IsdB and IsdH, referred to hereafter as 
IsdBN1N2 and IsdHN2N3, each contain one NEAT domain that binds only to Hb145-147, a 
helical linker domain167, and one NEAT domain that binds only to haem147,155,160,227. 
IsdBN1N2 captures haem from Hb, at ~2000$ and 80$ the rate of passive haem 
dissociation from the ! and " chains of the Fe(III)-Hb dimer, respectively149,169. Studies 
by Spirig et al., suggest that IsdHN2N3 removes haem from Fe(III)-Hb at similar rates to 
IsdBN1N2 167. These rapid rates of haem transfer imply that haem is actively released from 
Hb via specific interactions with the receptor that destabilise the globin fold. All three 
domains of IsdHN2N3 are necessary for haem uptake from Hb, as the isolated domains, or 
protein constructs containing an unstructured linker in place of the helical linker domain, 
do not capture haem from Hb167. IsdH contains an additional N-terminal NEAT domain, 
not present in IsdB, which is attached via a 100-residue unstructured linker (Fig. 3.1). 
This additional domain of IsdH also has Hb binding functionality146,147, however, a role in 
haem capture from Hb has not been established.  
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Figure 3.1. Domain architecture of IsdH and IsdB. Schematic of the Isd protein 
domain architectures shows NEAT domains with Hb binding (white boxes) or haem 
binding (black boxes) activity. The sequence identity between domains is indicated by 
black dashed lines, and between the homologous three domain region by red dashed lines. 
Known structures of the isolated N-terminal Hb binding NEAT domains (PDB 4F3C and 
3SZK)146,147,175, the helical Linker (PDB 2LHR)167 and the C-terminal haem binding 
NEAT domain (PDB 2Z6F)160 of IsdH are shown. IsdH and IsdB, share a region of 
extended homology indicated by the red dashed line. IsdHN1, the first NEAT domain of 
IsdH relative to the N-terminus of the protein; IsdHN2, the second NEAT domain of IsdH; 
IsdHN3, the third NEAT domain of IsdH; IsdBN1, the first NEAT domain of IsdB relative 
to the N-terminus of the protein; IsdBN2, the second NEAT domain of IsdB. 
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Isolated NEAT domains from IsdB and IsdH have been structurally characterised, 
revealing how these NEAT domains bind to their ligands. The first (IsdHN1)146 and 
second (IsdHN2)175 NEAT domains of IsdH have been co-crystallized with Hb. In these 
structures IsdHN1 and IsdHN2 bind to a surface of ! Hb comprising the A and E helices, 
that is distant from the haem pocket, and the globin retains its native fold (Fig. 3.2 A, B). 
The ! Hb recognition face of IsdHN1 (and IsdHN2) consists of a short aromatic helix and 
three loops. Similar contacts are made with ! Hb by both NEAT domains.  
 
Several structures of IsdHN3 and a single structure of IsdBN2 have been reported that 
provide a detailed understanding of how these domains bind to the haem 
cofactor155,160,176. Both domains sandwich the haem ligand in a hydrophobic groove that 
exists between the "-hairpin formed by strands "7 and "8, and a short ! helix (!1) (Fig. 
3.2 C, D). This haem binding face corresponds to the same surface of IsdHN1 and IsdHN2 
that is used to contact Hb. Haem-iron is penta-coordinate, being bound to the protein 
through a conserved tyrosine side chain (Tyr642 in IsdH and Try440 in IsdB). Neither 
IsdHN3 nor IsdBN2 form a stable interaction with Hb, and although they can bind haem 
from solution they cannot remove haem from Hb (Section 3.2.4)167,174. 
 
The aim of this chapter was to investigate the functional and structural properties of the 
intact Hb receptors to answer the question: how do the structured domains of IsdBN1N2 
and IsdHN2N3 work together to free haem from Hb?  
 
 
 
 
 
 
Figure 3.2. Crystal structures of the isolated NEAT domains of IsdH and IsdB 
bound to Hb or haem. (A, B) Structures of the Hb-binding NEAT domains, IsdHN1 
(PDB 3SZK) (A) and IsdHN2 (PDB 4FC3) (B), bound through the ! chain of Hb (red). 
(C, D) Structures of the haem binding NEAT domains: IsdHN3 (PDB 2Z6F) (C) and 
IsdBN2 (PDB 3RTL) (D). Residues that line the haem pocket are shown as sticks. The 
haem group is coloured yellow and residues that directly coordinate the haem iron are 
coloured blue. Residues involved in hydrophobic interactions with the porphyrin ring are 
coloured green. 
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To obtain constructs of IsdH and IsdB for functional studies, a region of the isdH gene 
containing the three NEAT domains (to express IsdHN1N2N3) and the full-length isdB gene 
lacking the N-terminal secretion signal and C-terminal sortase anchor sequences (protein 
expressed from this construct is referred to simply as IsdB hereafter), were cloned from 
the S. aureus strain TCH1516 genomic DNA into pET15b (Novagen). Gene fragments 
corresponding to IsdBN1N2 and IsdHN2N3, and the isolated NEAT domains thereof, were 
then sub-cloned into pET15b (see Section 2.3 and table A1). Proteins were expressed 
from pET15b with an N-terminal histidine-tag MGSSHHHHHHSSGLVPRGSHMLE, 
which allows for binding to Ni-agarose resin. Optimised expression conditions can be 
found in Section 2.5.1. The Isd proteins were purified from bacterial lysates using Ni-
affinity chromatography and analysed by SDS-PAGE (Fig. 3.3 A, B, C and 3.4 A, B, C, 
D). Each of the recombinant proteins migrated as a single band of the expected molecular 
weight (arrowhead) except for IsdHN3, which migrated as three bands (Fig. 3.3 C). The 
abundance and relative ratio of the three bands did not change with expression time or 
protease inhibitor type and concentration. Elution fractions from the metal affinity step 
were subjected to RP-HPLC, however only a single polypeptide peak was detected. Mass 
spectrometry revealed that the major species corresponded to the expected protein 
construct lacking the N-terminal methionine, however two minor species were present 
with mass differences that corresponded to an alpha-N-6-glucononyl modification (178 
Da) and an alpha-N-6-phosphoglucononyl modification (258 Da) of the N-terminal 
histidine tag. Phosphoglucononylation of histidine tagged proteins expressed in E. coli is 
common and, as the modification occurs on the affinity tag rather than the protein, it is 
not expected to effect protein function228. His-tagged Isd proteins bind to Hb and haem, 
and transfer haem, with similar efficiency to the native untagged proteins and so the N-
terminal affinity tag was left un-cleaved following Ni affinity 
chromatography146,147,149,165. The Isd proteins were subjected to a final purification step 
involving ion-exchange chromatography, or gel filtration and were ~90–95% pure (See 
Sections 2.5.4 and 2.5.5; Fig. 3.3 D, E and Fig. 3.4 E, F, G).  
 $
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Figure 3.3. SDS-PAGE analysis of expression and purification of IsdH constructs. 
(A) Purification of IsdHN2N3 by Ni-affinity chromatography: lane 1, Mark 12 protein 
standards (Invitrogen); lane 2, bacterial lysate; lane 3, flow through; lane 4, 20 mM 
imidazole wash; lanes 5–8, 100 mM imidazole elution fractions. (B) Purification of 
IsdHN2 by Ni-affinity chromatography: lane 1, Mark 12 protein standards; lane 2, 
bacterial lysate; lane 3, flow through; lanes 4–5, 5 mM imidazole wash; lanes 6–10, 150 
mM imidazole elution fractions. (C) Purification of IsdHN3 by Ni-affinity 
chromatography: lane 1, Mark 12 protein standards; lane 2, bacterial lysate; lane 3, flow 
through; lane 4, 10 mM imidazole wash; lane 5, 25 mM imidazole wash; lane 6, 50 mM 
imidazole wash; lanes 7–8, 100 mM imidazole elution fractions, lanes 9–10, 175 mM 
imidazole elution fractions.  (D) Purification of IsdHN2N3 by anion exchange 
chromatography: lane 1, Mark 12 protein standards; lane 2, load condition; lanes 3–6, 
eluted fractions over a 100–250 mM NaCl gradient. (E) Purification of IsdHN2 by cation 
exchange chromatography: lane 1, Mark 12 protein standards; lane 2, load condition; 
lanes 3–6, flow through; lanes 7–11, wash fractions; lane 12, pooled fractions eluted in 
500 mM NaCl. Arrows indicate the positions of over-expressed recombinant proteins. 
Stars indicate fractions collected from the final purification step. 
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Figure 3.4. SDS-PAGE analysis of expression and purification of IsdB constructs. 
Purification of (A) IsdB, and (B) IsdBN1N2 by Ni-affinity chromatography: lane 1, Mark 
12 protein standards; lane 2, bacterial lysate; lane 3, flow through; lane 4, 20 mM 
imidazole wash; lanes 5–7, 250 mM imidazole elution fractions. (C) Purification of 
IsdBN1 by Ni-affinity chromatography: lane 1, Mark 12 protein standards; lane 2, 
bacterial lysate; lane 3, flow through; lane 4, 10 mM imidazole wash; lanes 5–7, fractions 
eluted in 150 mM imidazole. (D) Purification of IsdBN2 by Ni-affinity chromatography: 
lane 1, Mark 12 protein standards; lane 2, bacterial lysate; lane 3, flow through; lane 4, 
25 mM imidazole wash; lanes 5–8, fractions of apo-IsdBN2 eluted in 100 mM imidazole; 
lanes 9–10, fractions of holo-IsdBN2 eluted in 250 mM imidazole. (E) Purification of 
IsdB by cation exchange chromatography: lane 1, Mark 12 protein standards; lane 2, load 
condition; lane 3, flow through; lane 4, 50 mM NaCl wash; lane 5, 100 mM NaCl wash; 
lane 6–9, fractions eluted in 200 mM NaCl. (F) Purification of IsdBN1N2 by cation 
exchange chromatography: lane 1, Mark 12 protein standards; lane 2, load condition; 
lane 3, proteins present in precipitate; lane 4, flow through; lane 5, 100 mM NaCl wash; 
lane 6, 150 mM NaCl wash; lanes 7–10, fractions eluted in 250 mM NaCl. (G) 
Purification of IsdBN1 by SEC: lane 1, Mark 12 protein standards; lane 2, load; lanes 3–6, 
fractions collected from SEC. Arrows indicate the positions of over-expressed 
recombinant proteins. Stars indicate fractions collected from the final purification step. 
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Proteins that bind to haem absorb visible light in the region between 350 and 750 nm and 
display a major peak, known as the Soret band, at ~400 nm, which arises from a ( ) (* 
transition of the porphyrin ring220. IsdB and IsdH constructs that contained the haem 
binding NEAT domains bound to endogenous haem during expression in E. coli cells and 
the purified proteins displayed a peak in their UV-visible absorption spectra at ~ 400 nm, 
as reported previously156,229. To estimate the level of haem contamination the purified 
proteins were unfolded in 0.1 M NaOH and the concentration of haem and protein 
determined according to the extinction coefficients of free haem and protein at 390 and 
280 nm, respectively (See Section 2.5.6, Appendix A). When haem was added to the 
bacterial expression culture at a concentration of 5–10 µg"ml–1 IsdHN2N3 and IsdBN1N2 
obtained were 80–100% haem saturated (UV-visible absorption spectra of the holo-
proteins are shown in Figure 3.5). 
 
Apo-proteins were prepared either by chromatographic separation of apo- and holo-
protein fractions, or by haem extraction in acidified acetone. Apo-IsdBN2 was separated 
from the haem bound protein during Ni-affinity chromatography, as reported by Gaudin 
et. al., 2011 and Bowden et. al., 2014155,230. Both apo-IsdBN2 and holo-IsdBN2 bound to 
the Ni affinity resin. Apo-IsdBN2 eluted at low imidazole concentrations (100 mM) while 
the haem bound protein was collected in fractions containing 250 mM imidazole. Native 
histidine, tryptophan and cysteine residues can promote binding to Ni-affinity resin. 
IsdBN2 has three native histidine residues. The topology of the environment around a 
histidine residue affects its accessibility and pKa and hence ability to bind to Ni-resin231. 
The three histidine residues of IsdBN2 may contribute differently to the binding affinity 
for Ni resin in the apo and holo forms of the protein, allowing for separation of the two 
species during the chromatography. Similarly, apo-IsdHN3 could be separated from the 
haem bound protein by passage over Q-sepharose anion-exchange resin in a salt gradient 
of 0–1 M NaCl. Apo-IsdHN3 was eluted under low salt conditions, while the haem-
containing fraction (a mixture of partially-liganded IsdHN3 species) was recovered at 
higher salt concentrations. Apo-IsdBN1N2 and apo-IsdHN2N3 were prepared by extraction 
of the haem in acidified acetone (see Section 2.5.7). The acidic conditions caused 
unfolding of the protein and released the haem group to the organic solvent. The 
polypeptide chain was precipitated, recovered by centrifugation and dissolved in water. 
As a final step, remaining acetone was removed by extensive dialysis or gel filtration. 
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The percentage of contaminating haem remaining in each apo-prep was consistently less 
than 8 % (the apo proteins show negligible absorption from 350–750 nm; Fig. 3.5 A, B). 
 
To determine if the apo proteins retained function after solvent extraction of the haem 
group, their ability to re-bind to haem was assessed. The UV-visible absorption spectrum 
of a haem coordinating protein is extremely sensitive to chemical environment around the 
haem cofactor232, making it possible to distinguish between the spectrum of haem bound 
specifically to a haem coordination site and haem that is free in solution or bound 
non-specifically to the protein. Haem was titrated into unliganded IsdBN1N2, IsdBN2, 
IsdHN2N3 and IsdHN3. The spectrum was measured 2 minutes after each addition of haem 
and the absorbance at 400 nm (IsdH) or 404 nm (IsdB) was plotted against haem 
concentration (Fig. 3.5 C–F). The spectral change could be fit with two straight-lines, 
with a break point, suggesting that each addition of haem was quantitatively bound up to 
a point of haem saturation, where after the absorbance increased according to the molar 
absorptivity of free haem. The Isd:haem ratio at the break point of the curve (Fig. 3.5 C–
F, dashed line) suggested the formation of a complex with 1:1 stoichiometry for all 
proteins. 
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Figure 3.5. Haem binding properties of IsdHN2N3 and IsdBN1N2. (A) The UV-visible 
absorption spectra of holo- (black) and apo-IsdHN2N3 (grey). (B) The UV-visible 
absorption spectra of holo- (black) and apo-IsdBN1N2 (grey). Only Isd proteins bound to 
haem absorb visible light. (C–F) Haem titration experiments demonstrating specific 
binding to haem by IsdHN2N3 (C), IsdHN3 (D), IsdBN1N2 (E). Data points were fit, by linear 
regression, in two groups. A perfect 1:1 binding stoichiometry (assuming accurate 
concentration determination and Kd << working concentration) would see the linear fits 
intersect at the vertical dashed line. 
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Haem-bound IsdBN1N2 and IsdHN2N3 each have a distinct UV-visible absorption spectrum 
to Fe(III)-Hb (Fig. 3.6 A and 3.7 A), allowing haem transfer to the Isd proteins to be 
detected. To show that apo-IsdHN2N3 can capture haem from Hb, Fe(III)-Hb was mixed 
with excess apo-IsdHN2N3 and the UV-visible spectrum was recorded after a 10 min 
incubation. The spectrum resembled that of holo-IsdHN2N3 indicating that haem had been 
transferred from Fe(III)-Hb to IsdHN2N3 (Fig. 3.6 A).  
 
A single Hb tetramer contains four haem groups, one bound to each of the ! and " 
subunits. To determine whether IsdHN2N3 can interact with the haem sites of both ! and " 
Hb subunits, Fe(III)-Hb was mixed with a 1, 2, 3, 5 or 7-fold molar excess (per Hb 
tetramer) of apo-IsdHN2N3 and the UV-visible absorption spectra acquired at 40 s 
intervals. Representative spectra for a 5:1 mixing ratio (per globin haem) of IsdHN2N3 to 
Fe(III)-Hb are shown in Figure 3.6 B.  The change in absorbance at 406 nm, which 
represents the largest difference between the spectrum of Fe(III)-Hb and haem bound 
IsdHN2N3, plotted against time is shown in Figure. 3.6 C.  The reaction was essentially 
complete within ~10 min at all mixing ratios. The absorbance at 406 nm after 10 min was 
plotted against the apo-IsdHN2N3:Hb mixing ratio (Fig. 3.6 D). The spectral change at 
406 nm was linear up to an apo-IsdHN2N3:Hb molar ratio of ~3.5:1, suggesting an 
interaction with all four globin haem pockets. 
 
To determine whether all four haem groups of Fe(III)-Hb were transferred to IsdHN2N3, 
the fraction haem bound Hb contributing to the recorded spectrum was determined at 
different points across the time course. This was done by least squares fitting of the each 
of the measured spectra to a linear combination of the spectrum of Fe(III)-Hb and holo-
IsdHN2N3. The spectra of Fe(III)-Hb, recorded 10 min after mixing with a 1-, 2- or 5-fold 
excess of apo-IsdHN2N3, are shown in Figure 3.6 E (black); overlaid are the fitted curves 
generated from the sum of the spectra of Fe(III)-Hb and holo-IsdHN2N3 (red). Small 
residuals (blue) indicate that a combination of the two species provides a reasonable 
model for the reaction. Upon addition of 1, 2 or 5 molecules of receptor per Hb tetramer, 
23%, 49±0.3% or ~ 94±0.6% of haem was removed after 10 min at 4 °C (errors are given 
as ± S.E. from two experiments). In summary, IsdHN2N3 quantitatively captures haem 
from both chains of human Hb. 
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Figure 3.6. IsdHN2N3 rapidly captures haem from all four globin sites. (A) UV-visible 
absorption spectra of Fe(III)-Hb (6 µM haem, corresponding to 1.5 µM tetramer), holo-
IsdHN2N3 (6 µM) and apo-IsdHN2N3 (7.5 µM), showing that they are distinct. The 
spectrum of a mixture of Fe(III)-Hb (1.5 µM) and apo-IsdHN2N3 (7.5 µM) is shown after a 
10-min incubation at 4 °C (solid black line). (B) The figure shows spectra taken at 40-s 
intervals of a mixture of Fe(III)-Hb (1.5 µM) and apo-IsdHN2N3 (7.5 µM) incubated at 4 
°C. The spectrum of Fe(III)-Hb (1.5 µM) is overlaid for comparison (red, dashed line). 
Arrows indicate the direction of spectral change. (C) The figure shows absorbance at 406 
nm recorded over 35 min for the mixture in B. The spectral change is rapid, and 
essentially complete after 10 min at 4 °C.  (D) The plot shows absorbance at 406 nm, 
recorded after a 10-min incubation of apo-IsdHN2N3:Hb, prepared at different molar 
mixing ratios. The linear relationship between spectral change and [IsdHN2–N3]/[Hb] ratio 
is consistent with a model in which 3–4 IsdHN2–N3 molecules interact with four heme sites 
per Hb tetramer. (E) The figure shows spectra of Fe(III)-Hb (1.5 µM) recorded 10 min 
after mixing with a 1-, 2- or 5-fold excess of apo-IsdHN2N3. Overlaid are the fitted curves 
generated from a linear combination of the spectra of Fe(III)-Hb and holo-IsdHN2N3 (red). 
The residuals are shown in blue. 
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IsdBN1N2 was also able to capture haem from Fe(III)-Hb as the spectrum of a mixture of 
apo-IsdBN1N2 and Fe(III)-Hb, taken after a 10 min incubation, resembled that of 
holo-IsdBN1N2 (Fig. 3.7 A). The change in spectra for a 5:1 mixture (per globin haem) of 
IsdBN1N2 and Fe(III)-Hb are shown in Figure 3.7 B. The spectra recorded at 10 min for a 
2:1 and 5:1 mixture of apo-IsdBN1N2 and Fe(III)-Hb and their fitted curves (comprising a 
linear combination of the spectrum of Fe(III)-Hb and holo-IsdBN1N2) are shown in 
Figure 3.7 C. At 2:1 and 5:1 molar ratios of IsdBN1N2:Hb-tetramer 45±0.5% and 89±0.3% 
of total haem was transferred after ~10 min at 4 °C (errors are given as ± S.E. from three-
to-four experiments). Hence IsdB and the homologous region of IsdH both access all four 
globin haem groups and take up haem from Fe(III)-Hb with similar efficiency. 
 
 
 
 
 
Figure 3.7. IsdBN1N2 captures haem from all four globin sites. (A) UV-visible 
absorption spectra of Fe(III)-Hb (6 µM haem, corresponding to 1.5 µM tetramer), holo-
IsdBN1N2 (6 µM) and apo-IsdBN1N2 (7.5 µM), showing that they are distinct. The spectrum 
of a mixture of Fe(III)-Hb (1.5 µM) and apo-IsdBN1N2 (7.5 µM) is shown after a 10-min 
incubation at 4 °C. (B) The figure shows spectra taken at 40-s intervals of a mixture of 
Fe(III)-Hb (1.5 µM) and apo-IsdBN1N2 (7.5 µM) incubated at 4 °C. The spectrum of 
Fe(III)-Hb (1.5 µM) is overlaid for comparison (red, dashed line). Arrows indicate the 
direction of spectral change. (C) The figure shows spectra of Fe(III)-Hb (1.5 µM) 
recorded 10 min after mixing with a 2- or 5-fold excess of apo-IsdBN1N2. Overlaid are the 
fitted curves generated from a linear combination of the spectra of Fe(III)-Hb and holo-
IsdHN2N3 (red). The residuals are shown in blue. 
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The haem cofactor is necessary for correct folding of Hb chains146,233 and hence removal 
of a haem group from one subunit might cause disruption to Hb tertiary and quaternary 
structure. In turn, quaternary subunit interactions must have an important role in 
stabilising the globin:haem interaction because monomeric globin chains lose haem 
~30-fold more rapidly than Hb tetramers169,234. Thus, one possible mechanism through 
which IsdB/H could accelerate haem loss would be to disrupt Hb quaternary structure. 
Upon interaction with IsdH or IsdB, removal of the first globin haem may sufficiently 
destabilise the remaining globin haem interactions to accelerate passive haem loss. 
Hence, although IsdHN2N3 and IsdBN1N2 can quantitatively deplete haem from Hb, it was 
possible that haem can be released into solution from destabilised Hb and scavenged by 
Isd receptors that are not physically bound to Hb chains. To investigate if such a 
mechanism operates, I asked whether the isolated IsdHN3 haem-binding domain was able 
to scavenge haem from sub-stoichiometric (2:1) IsdHN2N3:Hb mixtures. The isolated 
IsdHN3 domain is fully functional to bind haem from solution (section 3.2.1, Fig. 3.4 E) 
but is unable to capture haem from native Fe(III)-Hb over the course of 10 min (Fig. 3.8 
A, grey circles), as previously shown by Spirig et al.167. When IsdHN2N3:Hb was mixed in 
a 2:1 ratio, in the presence or absence of additional IsdHN3, the haem transfer curves were 
identical, with ~50% of haem groups removed from Hb in each case (Fig. 3.8 A, compare 
dashed and solid curves). Similarly, the isolated IsdBN2 was also unable to liberate haem 
from Fe(III)-Hb. Again, haem was not released to IsdBN2 when it was added to a 2:1 
mixture of IsdBN1N2:Hb tetramer. (Fig. 3.8 B). Hence haem transfer from Hb to IsdBN1N2 
or IsdHN2N3 occurs through a specific complex and requires contacts mediated by the Hb 
binding NEAT domain (IsdBN1 or IsdHN2). 
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Experiments from Spirig et al., show that the three domains of IsdHN2N3 are needed to 
achieve haem capture from Hb, suggesting that a higher-order structural organisation of 
these domains may be involved167. To investigate the multi-domain structure of IsdHN2N3 
and IsdBN1N2, small-angle X-ray scattering (SAXS) analysis was performed.  
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In order to capture a stable complex of IsdHN2N3 or IsdBN1N2 bound to Hb for structural 
studies it was expected that haem transfer might need to be disabled to prevent complex 
dissociation. A Tyr-to-Ala mutation, which removes the haem coordinating side chain, 
has been characterised previously in both IsdH and IsdB and leads to a reduced affinity 
for haem155,167,221. The single mutation  (Tyr642-to-Ala in IsdH and Tyr440-to-Ala in 
IsdB) was introduced into the haem binding domains of IsdHN2N3 or IsdBN1N2 using the 
modified QuickChange mutagenesis protocol of Liu and Naismith214 (primer sequences 
can be found in Appendix B). IsdHN2N3(Y642A) was expressed from a pHis-SUMO 
vector (Appendix A; construct 216) and contained an N-terminal His tag followed by a 
SUMO tag. An initial Ni-affinity chromatography step was performed as for IsdHN2N3. 
The His-SUMO tag was then removed by incubation with ULP1 followed by a second 
affinity chromatography step, during which the IsdHN2N3(Y642A) was collected in the 
flow through and the SUMO and ULP1 proteins were retained on the Ni resin. SDS-
PAGE analysis of the IsdHN2N3(Y642A) purification is shown in Figure 3.9 A.  
 
Expression and purification of IsdBN1N2(Y440A) was performed as for the wild type 
protein. IsdBN1N2(Y440A) preparations were partially contaminated with porphyrin. IsdB 
has a distal Met in the haem pocket that may coordinate haem in the absence of Tyr440. 
In addition, haem may bind with low affinity into the hydrophobic pocket in the absence 
of a coordinating residue. The majority of the haem-bound IsdBN1N2(Y440A) protein 
could be separated from the apo protein during the Ni-affinity or cation exchange 
chromatography (see Section 2.5.2).  
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To assess haem capture activity, a five fold excess of IsdHN2N3(Y642A) or 
IsdBN1N2(Y440A) was mixed with Fe(III)-Hb (per tetramer) and the visible absorption 
spectra were monitored over time. A plot of the change in absorbance at 406 nm is shown 
in Figure 3.9 B. Unlike the wild type proteins, the constructs carrying the Tyr-to-Ala 
mutation produced a minimal change in the spectrum of Fe(III)-Hb over time. Hence the 
two proteins were largely attenuated in haem capture function as observed previously167. 
 
IsdHN2N3(Y642A) and IsdBN1N2(Y440A) were determined to be monomeric by 
SEC-RALS with weight-average molecular weights (MW) of 39.7 kDa and 46.3 kDa 
respectively (compared to theoretical molecular weights of 38.9 kDa and 42.2 kDa). 
SAXS data for IsdHN2N3(Y642A) were recorded at three concentrations (2, 4 and 7 
mg!ml-1). IsdBN1N2(Y440A) samples occasionally showed evidence of aggregation, which 
could be removed by gel filtration. To remove interference from aggregates, 
IsdBN1N2(Y440A) was subjected to SEC-SAXS at the Australian Synchrotron SAXS-
WAXS beamline. 
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Figure 3.9. Production and haem capture properties of SUMO-IsdHN2N3(Y642A) 
and IsdBN1N2(Y440A). (A) lane 1, Mark 12 protein standards; lane 2, bacterial lysate; 
lane 3, flow through; lane 4, fractions eluted with 100 mM imidazole and incubated with 
ULP1; lane 5, IsdHN2N3(Y642A) eluted in the flow through after reapplication to the Ni-
affinity column. (B) The figure shows absorbance at 406 nm recorded over 35 min for: 
Fe(III)-Hb (6 µM haem corresponding to 1.5 µM Hb tetramer; magenta); Fe(III)-Hb (1.5 
µM) mixed with 7.5 µM IsdHN2N3(Y642A) (blue); Fe(III)-Hb (1.5 µM) mixed with 7.5 
µM  IsdBN1N2(Y440A) (orange); Fe(III)-Hb (1.5 µM) mixed with 7.5 µM apo-IsdHN2N3 
(black); Fe(III)-Hb (1.5 µM) mixed with 7.5 µM apo-IsdBN1N2 (grey). These data are from 
single measurements. 
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No significant aggregation or inter-particle interference was detected by Guinier analysis 
for IsdHN2N3(Y642A) or IsdBN1N2(Y440A) (Fig. 3.10 A, B). Model-free analysis of the 
SAXS data collected for IsdHN2N3(Y642A) yielded the expected molecular weights for all 
samples (Table 3.1), which were within 10% of the theoretical molecular weight 
calculated from the sequence.  
 
Table 3.1. Molecular parameters from SAXS 
Structural 
parameters 
IsdHN2N3(Y642A)* 
 
 
IsdBN1N2 
(Y440A) 
SUMO-
IsdHN2N3 
(Y642A) 
Sample 
concentration  
(mg!ml-1) 
7 4.5 3 — 9.5 
I(0) (cm-1) (P(r) 
analysis) 
0.1770a 
0.183± 
0.001b 
0.1186a 
0.122 ± 
0.001b 
0.0807a 
0.0821 
±0.0006b 
0.0034 ± 
0.000056b 
0.3669 a 
0.366 ± 
0.005b 
Rg  (Å) (P(r) 
analysis) 
27.75a 
28.1 ± 0.2b 
28.96a 
30.4 ± 0.2b 
28.99a 
30.2 ± 0.02b 
32.6 ± 0.773b 45.4 a 
45.3 ± 1.2 b 
I(0) (cm-1) 
(Guinier 
analysis) 
0.183 ± 
0.001b 
0.121 ± 0.001 
b 
0.082 ± 
0.001b 
0.003 ± 0.000 0.358 ± 0.005 
b 
Rg  (Å) (Guinier 
analysis) 
27.7 ± 0.4b 29.5 ± 0.5b 29.6 ± 0.8b 31.05 ± 0.682 41 ± 0.9b 
Dmax (Å) 85a 90a 85a 120 b 165 b 
      
Molecular mass 
determination 
     
Partial specific 
volume (cm3 g-1) 
0.732 0.732 0.732  0.730 
Contrast (!" x 
1010 cm-2) 
2.808 2.808 2.808  2.831 
Mean molecular 
mass (from I(0)) 
36405a 
37639b 
36830a 
37575b 
38470a 
39090b 
 54455 a 
Mr calculated 
from primary 
sequence 
(monomer) 
38788 38788 38788  52500 
a Values generated with GIFT  
b Values generated with primus 
*The IsdHN2N3(Y642A) protein used for this experiment, was produced by G. Reza 
Malmirchegini. 
 
Both proteins had a bimodal pair-distance distribution function, P(r) with a major peak at 
~23 Å, which is consistent with the dimensions of an individual NEAT domain based on 
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X-ray crystallography, and a shoulder peak at around 40–50 Å, indicating that the two 
molecules have a similar compact bi-lobed shape (Fig. 3.10 C).  
 
Ab initio shape reconstruction of IsdHN2N3(Y642A) was carried out using the 
experimental scattering data and the program DAMMIF235. Ten independent models were 
averaged using the DAMAVER236. Although there was some variation between the 
models (normalised spatial discrepancy = 0.983), no outliers were identified and filtering 
of the average envelope to retain the most highly occupied area gave a dumbbell shaped 
molecule, with two lobes separated by a central rod (Fig.3.10 D). The rod shaped region 
of the envelope had dimensions similar to the NMR structure of the helical linker domain. 
This region of the envelope was more intimately associated with one of the two lobes, 
suggesting a more substantial interaction interface between the linker and one of the 
NEAT domains. As the IsdHN2 and IsdHN3 domains are similar in shape and volume it 
was not possible to designate which of the lobes corresponded to the IsdHN2 or IsdHN3 
domains.  
 
In an attempt to assign the two NEAT domains to the two lobes of the scattering envelope 
a SUMO-tagged IsdHN2N3(Y642A) was produced. It was reasoned that, with inclusion of 
the additional SUMO domain, an ab initio envelope would be asymmetrical allowing for 
unambiguous placement of the NEAT domains. Guinier and model free analysis of the 
scattering data (Table 3.1 and Fig. 3.10 E) indicated that the protein was free of 
aggregates, and had the expected molecular weight of 52.5 kDa. The P(r) curve for 
SUMO-IsdHN2N3(Y642A) contained two maxima at 23 and 43 Å respectively, consistent 
with IsdHN2N3(Y642A) and IsdBN1N2(Y440A), however the curve had a tail indicating a 
much more extended molecule (Fig. 3.10 F). Ab initio shape reconstruction was 
performed as for IsdHN2N3(Y642A), and produced an extended, symmetrical rod shape 
into which it was not possible to unambiguously place the four domains (Fig. 3.10 G).  
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Figure 3.10. SAXS analysis of the domain structure of IsdBN1N2 and IsdHN2N3. The 
solution scattering intensity distribution, I(q), is shown for: (A) IsdHN2N3(Y642A) (B) 
IsdBN1N2(Y440A). Insets show linear Guinier plots, indicating that there is no aggregation 
or inter-particle interference. (C) The pair distance distribution function, P(r), indicates 
that IsdHN2N3(Y642A) and IsdBN1N2(Y440A) are compact bi-lobed molecules with a Dmax 
of 85 and 120 Å. (D) Ab initio model of IsdHN2N3(Y642A). The average envelope of 10 
DAMMIF runs are shown as dots while the filtered average envelope is shown as spheres. 
(E) The solution scattering intensity distribution, I(q), of SUMO-IsdHN2N3(Y642A). The 
insert shows a linear Guinier plot. (F) The pair distance distribution function, P(r), of 
SUMO-IsdHN2N3(Y642A). IsdHN2N3(Y642A) is shown for comparison. (G) Ab initio 
model of SUMO-IsdHN2N3(Y642A). The average envelope of 8 DAMMIF runs are shown 
as dots while the filtered average envelope is shown as spheres. 
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To determine whether IsdB and IsdH contain unstructured regions a dimensionless 
Kratky plot, which is independent of protein size and molecular weight, was generated. A 
well-ordered globular protein is expected to have a maximum with an ordinate value of 
1.1 (at qRg = 1.73) (Fig. 3.11, dashed line). The curve for IsdHN2N3(Y642A) has the 
features of a globular protein with, a maximum of 1.2 at qRg = 2 (Fig. 3.11, grey). Small 
deviations from a single bell curve are consistent with a multi-domain structure237-239. 
IsdBN1N2(Y440A) displays similar features to IsdHN2N3(Y642A) indicating a similar 
proportion of structured residues (Fig. 3.11, grey dashed). For comparison, the Kratky 
plot for IsdHN1N2, which comprises two NEAT domains separated by an unstructured 
linker, is shown (Fig. 3.11, black). The structured and unstructured regions of IsdHN1N2 
give rise to an increase in the maximum of the bell-shaped portion of the curve and a 
trend to higher scattering ratios with increasing q; features that are clearly distinct from 
the IsdHN2N3(Y642A) and IsdBN1N2(Y440A) curves. 
 
 
 
 
 
 
 
 
Figure 3.11. Kratky analysis of the solution scattering of IsdBN1N2 and IsdHN2N3. The 
figure shows a dimensionless Kratky plot for IsdHN2N3(Y642A) and IsdBN1N2(Y440A). 
The Kratky plot obtained from SAXS data of IsdHN1N2, which is known to have an 
unstructured linker, is shown for comparison (data provided by K. Krishna Kumar). The 
dashed vertical line indicates the peak position of the bell curve expected for the case of a 
single-domain globular protein.  
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To further characterise the flexibility of IsdHN2N3(Y642A) and IsdBN1N2(Y440A), the 
distribution of conformations that was required to completely describe the scattering data 
was assessed using Ensemble Optimisation Method (EOM)225. A pool of 10000 random 
conformers consisting of two NEAT domains and the helical linker of IsdH were 
generated, and ensembles of structures from the pool were fit to the scattering data. The 
ensemble with the best fit to the scattering data for IsdHN2N3(Y642A) and 
IsdBN1N2(Y440A) had a narrow Rg distribution, indicating a similar spacing between the 
two NEAT domains in all members of the ensemble (Fig. 3.12 A–D, dashed lines). For an 
unbiased comparison with the IsdHN1N2 protein, the analysis was repeated with an 
ensemble generated from the two NEAT domains joined by a linker composed of dummy 
residues. A very similar Rg distribution was obtained if the !-helical linker was replaced 
with the dummy atom linker (Fig. 3.12 A–D, solid lines). In contrast, the ensemble that 
fits to scattering data for IsdHN1N2 has a bimodal Rg distribution. This distribution 
suggests that the IsdHN1N2 protein adopts compact and extended states (Fig. 3.12 E, F, 
black curve). Similar EOM size distributions have previously been observed for proteins 
that contain unstructured inter-domain linkers240. In summary these results show that 
IsdBN1N2 and IsdHN2N3 adopt a similar, compact, multi-domain architecture.  
 
 
 
 
Figure 3.12. IsdBN1N2 and IsdHN2N3 adopt compact structures. Ensemble optimization 
method (EOM) indicated that IsdHN2N3(Y642A) (A, B) and IsdBN1N2(Y440A) (C, D) are 
restricted to relatively compact conformers ("2=0.920, "2=0.272 respectively). Dashed 
lines indicate ensembles generated assuming a helical linker (PDB 2LHR) while solid 
lines represent ensembles generated with a dummy atom linker. For comparison, EOM 
indicated that a mixture of extended (Rg ~ 60 Å) and more compact (Rg ~ 40 Å) 
conformers was required to adequately describe the scattering data obtained from 
IsdHN1N2 ("2 =0.910) (E, F; data provided by K. Krishna Kumar). 
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Hb exists in equilibrium between dimeric and tetrameric states and binds weakly to IsdB 
and IsdH. Previous SAXS studies of mixtures of Hb with isolated NEAT domains, 
performed in our lab, have shown that these complexes are heterogeneous and give 
complicated SAXS profiles that cannot be directly interpreted. This was not predicted to 
be a problem for X-ray crystallography, which also provides higher information content 
and so crystallography was chosen to investigate the structure of IsdHN2N3 and IsdBN1N2 
in complex with Hb. To choose a suitable mixing ratio of IsdHN2N3 and Hb for 
crystallisation screening, SEC and static light scattering experiments were performed. 
IsdHN2N3(Y642A) and Fe(III)-Hb eluted as single peaks with MW’s of 40.7 and 30.3 kDa 
respectively (Fig. 3.13 A). When two IsdHN2N3(Y642A) molecules were mixed with one 
Hb tetramer a single peak was observed with a MW of 92.7. At a 4:1 mixing ratio, the MW 
of the complex peak was only moderately changed (MW: 95.3 kDa) and an additional 
peak of unbound IsdHN2N3(Y642A) was observed. This is consistent with a primary 
interaction site for the IsdHN2 domain on the ! chains of Hb and a much weaker 
interaction with a secondary site on the " chains of Hb146. Hence a 2:1 mixing ratio, with 
the receptors likely bound through the ! chains, was chosen for crystallisation. 
 
The complex of IsdHN2N3(Y642A) with Fe(III)-Hb was subject to sparse matrix 
crystallisation screening at 21 °C. Crystalline formations were obtained in three initial hit 
conditions but were only reproducible in 0.2 M diammonium citrate, pH 5.0, 20% (w/v) 
PEG3350, (see Materials and Methods section for details, Fig. 3.13 B). An initial grid 
screen changing pH by 0.2 pH units and precipitant concentration by 2% followed by a 
finer screen changing precipitant concentration by 1% resulted in crystals with a flaky 
appearance that did not diffract (Fig. 3.13 C). An additive screen (Additive screen HT; 
Hampton Research, Aliso Viejo, CA, USA) was used to identify conditions that would 
change the crystal habit. Large single crystals (200–500 µm) that diffracted to ~5 Å were 
grown when an organic solvent such as ethanol, 1-butanol or isopropanol was added to 
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0.2 M diammonium citrate, pH 4.6, 13% (w/v) PEG3350, (Fig. 3.13 D). Initial attempts 
to improve the diffraction properties of the crystals included streak seeding and changing 
the molar mixing ratio to 4:1 IsdHN2N3(Y642A):Fe(III)-Hb. Each of these strategies 
produced large single crystals that diffracted to ~5 Å. As the crystals had a solvent 
content of 60%, which is higher than the average of ~50% for a protein crystal (but within 
the normal range), dehydration was attempted but did not improve the diffraction 
resolution. Crystal annealing was also unsuccessful in improving the diffraction 
resolution. Numerous cryoprotectants were tested at a range of concentrations, however, 
diffraction data collected from crystals mounted in capillaries at room temperature also 
had a resolution limit of ~5 Å. Poor diffraction was therefore deemed to be a property of 
the crystals and not due to damage during cryo-soaks or the freezing process.A single 
crystal of the 2:1 IsdHN2N3(Y642A):Fe(III)-Hb complex, cryo-protected in 23% ethylene 
glycol, allowed X-ray diffraction data to be collected to 4.2 Å using synchrotron radiation 
(Table 3.2). Integration and scaling were performed with HKL-2000 and 
SCALEPACK241. 
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Figure 3.13. Crystallisation of the IsdHN2N3(Y642A):Fe(III)-Hb complex. (A) An SEC 
experiment indicating that a stable complex is formed between 2 IsdHN2N3(Y642A) 
molecules and one Hb tetramer.  (B) Initial crystalline formations obtained in the sparse 
matrix screen. (C) A grid screen to optimize pH and precipitant produced flaky crystals. 
(D) Addition of an organic solvent produced large single crystals. 
 
Figure 3.14. Anomalous signal in the four Hb haem pockets. Anomalous signal (blue) 
was present in the ! Hb (orange) and " Hb haem pockets. 
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The structure was solved using molecular replacement by searching in a stepwise fashion 
for domains using the crystal structures of dimeric Fe(III)-Hb (PDB 3P5Q), IsdHN2 (PDB 
4FC3) and IsdHN3 (PDB 2E7D and 2Z6F) as search models. CHAINSAW242 was used to 
prune side chains from the IsdHN2 PDB file and produce a poly-alanine search model as 
the intact model could not be placed in the asymmetric unit. An NMR model of the linker 
domain (PDB 2LHR) was also available, however, PHASER243 was unable to find a 
unique solution with this model. An initial search with PHASER placed two Hb dimers, 
four copies of the poly-alanine model of IsdHN2 and two IsdHN3 domains into the 
asymmetric unit, suggesting that four receptors were present in the complex, consistent 
with the volume of the asymmetric unit. Although the IsdHN2 and IsdHN3 domains are 
structurally very similar, PHASER unambiguously placed them in unique locations 
within the complex. Four regions of helical electron density corresponding to the linker 
domain for each of the IsdH molecules were evident in the FO-FC map providing 
confidence in the experimental model. The four linker domains were placed manually 
into the model as rigid bodies using the NMR structure 2LHR (the unstructured N- and C-
terminal residues of 2LHR were first removed). Haem groups were not included in the 
initial model, however, an anomalous signal was observed at the expected iron positions 
in the four globin chains, and haem groups were included in the final low resolution 
structure (Fig. 3.14). MOLREP244 was used to search for the two additional IsdHN3 
domains expected in the structure, however only one domain could be placed 
successfully. The electron density observed for the fourth IsdHN3 domain, which was 
expected to lie over the haem pocket of the other ! Hb subunit, was not sufficiently 
strong to place the IsdHN3 domain with confidence (dashed ellipse in Fig. 3.15 A), and it 
was therefore not included in the model.  
 
The solution was refined with Buster version 2.10.0245. Refinement was weighted heavily 
towards the geometry of the high-resolution structures used for molecular replacement, 
and included non-crystallographic symmetry restraints246 and translation/liberation/screw 
(TLS) refinement; groups were defined as single domains. MolProbity247 was used to 
verify the geometry and the Ramachandran statistics were as follows: 96.2 % of residues 
were found in favoured regions; 99.9% in allowed regions; 0.06% in disallowed regions. 
Coordinates and structure factors can be found at RCSB PDB, entry 4IJ2. 
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Table 3.2. Data collection and refinement statistics (molecular replacement) 
 IsdHN2N3(Y642A):Hb 
Data collection  
Wavelength (Å) 0.95369 Å 
Space group P 21 21 2 
Cell dimensions    
    a, b, c (Å) 132.90, 185.30, 103.21 
    !, ", #  (°)  90, 90, 90 
Resolution (Å) 49.7–4.23 (4.32–4.24) 
Rmerge (%) 9.2 (72.7) 
I / $I 10.17 (1.83) 
Completeness (%) 99.9  (100) 
Redundancy 3.8 (3.8) 
Refinement  
Resolution (Å) 29.15–4.24 (4.5–4.24) 
No. reflections 18511 (2862) 
Rwork / Rfree  0.299 /0. 310 (0.2911/0.2786) 
No. atoms  
    Protein 13375 
    Ligand/ion 172 
    Water - 
B-factors  
    Protein 86.14 
    Ligand/ion 65.65 
    Water - 
R.m.s. deviations  
    Bond lengths (Å) 0.008 
    Bond angles (°) 0.84 
Diffraction data were collected from a single crystal. Values in parentheses are for the 
highest-resolution shell. 
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The structure of the IsdHN2N3(Y642A):Fe(III)-Hb complex is shown in Figure 3.15. Four 
IsdH molecules were bound to one Hb tetramer in the asymmetric unit, with each ! or 
" Hb globin chain bound independently to one complete receptor molecule (3.15 A–C). 
The three domains of the receptor were arranged in a dumbbell structure with the globular 
IsdHN2 and IsdHN3 domains separated by the intervening helical linker domain (3.15 B–
E). This arrangement is consistent with inter-domain interactions detected in an NMR 
spectroscopic analysis of the free receptor167, which identified a minimal interface 
between IsdHN2 and the N-terminal end of the helical linker and a distinct interface 
between IsdHN3 and the C-terminal end of the three-helix bundle. The residues identified 
by NMR chemical shift differences are mapped on the crystal structure of the receptor in 
Figure 3.15 D and localise to the domain interfaces in the crystal structure. The IsdHN2 
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domains were bound to equivalent sites on the ! and " chains and their positions relative 
to the Hb subunits were consistent with the known IsdHN2 binding site (Fig. 3.15 B, C)175.  
 
The three complete IsdHN2N3(Y642A) molecules in the complex have essentially identical 
structures (backbone r.m.s.d <1.2 Å in pair-wise comparisons), indicating that IsdHN2N3 
binds to ! and " Hb in the same conformation. Some difference electron density was 
observed in the FO-FC map between the three domains of the receptors (Fig. 3.15 E, green 
mesh) suggesting that the missing residues (465–472 and 531–534), which are flexible in 
the NMR structure of the isolated linker domain167, are ordered in the context of the 
multi-domain receptor bound to Hb. In addition, positive heteronuclear NOEs for these 
residues, recorded from the three-domain IsdHN2N3(Y642A) receptor, argue that the 
inter-domain linking residues are ordered in the context of the three-domain assembly167. 
No attempt was made to build into this density due to the low resolution and absence of 
obvious secondary structure.  
 
The helical linker domain positions the IsdHN3 domain directly over the haem pocket of 
the bound globin subunit, such that the haem would need to move only ~12 Å, through 
the entrance to the globin haem pocket, to transfer to IsdH  (Fig. 3.15, B, C, F). Hence 
positioning of the IsdHN3 domain appears to be a critical feature of the receptor 
mechanism. Electron density at the haem-binding site of the IsdHN3 domains (Fig. 3.15 
F), together with weak anomalous signal (Fig. 3.15 E), suggests that the receptors have 
partial haem occupancy despite the inactivating Tyr642 to Ala mutation. It is not clear if 
this haem is derived from the bound globin, however reducing the occupancy of the haem 
groups bound to the globin chains resulted in residual density in the FO-FC map, 
suggesting that the globin haem sites are fully occupied. An alternative explanation is that 
IsdHN3 domain picked up haem that was released into the solution by denatured Hb 
present in the crystallization drop. Extensive precipitation of denatured Hb was evident as 
a thick brown skin on the surface of the crystallisation drop. On the basis that 
IsdHN2N3(Y642A) receptor cannot actively capture haem from Hb in solution (Section 
3.3.1)167 it is more likely the haem derived from solution may have bound weakly in the 
hydrophobic cleft. This is consistent with the observation that IsdHN2N3(Y642A) was 
expressed partially saturated (< 10%) with porphyrins derived from E. coli.   
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Juxtaposition of the two haem coordination sites provides a direct route for haem to 
transfer from Hb to the receptor (Fig. 3.15 F). In addition, rapid rates of haem 
transfer149,167 indicate that haem is actively removed from the globin through 
destabilisation of the globin-haem interaction. With the X-ray data at 4.2-Å resolution it 
was not possible to say if the globin haem pocket structure is altered by interaction with 
IsdHN3. In addition, the haem binding !-strands (residues Val-637–Gln-645) of IsdHN3 
are not well defined in the electron-density. It was possible to model this !-hairpin for 
one of the receptors bound to an " Hb chain, using the high resolution structures of 
isolated IsdHN3 (PDB 2Z6F and 2E7D). The conformation of the !-hairpin is 
substantially different in apo- and holo-IsdHN3 and the best fit to the density was that of 
the haem-bound domain (PDB 2Z6F). In this conformation the !-hairpin is in closer 
proximity to the globin haem pocket. Strategies that led to successful acquisition of X-ray 
diffraction data at higher resolution are described in Chapter 5. 
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Figure 3.15 Crystal structure of IsdHN2–N3 bound to Hb. (A) four IsdHN2–N3 receptors 
bind to one Hb tetramer in the asymmetric unit of the crystal. (B-C) Detail of the 
IsdHN2N3(Y642A):! (B, blue/orange) and IsdHN2N3(Y642A):" (C, teal/yellow) interaction 
complexes. Residues from the loop regions, which are not modeled in the structure, are 
shown with dashed lines. (D) Inter-domain interface residues identified by an NMR study 
of the free receptor (red)167 are shown mapped onto the crystal structure of IsdHN2N3 
receptor. (E) A stereo diagram showing the 2FO-FC electron density map for one full 
IsdHN2N3 receptor contoured at 1# (grey mesh). FO-FC electron density (green mesh) is 
shown at 3#, suggesting that the linking residues between the domains are ordered. 
Anomalous signal present at the haem coordination site (blue) is also shown at 3#. (F) 
The IsdHN2N3(Y642A):! Hb interface with FO-FC difference map shown at 3# (green), 
indicating electron density that is not accounted for by atoms of the IsdHN2N3:Hb model. 
The structure of haem-bound IsdHN3 (PDB 2Z6F, red) is superimposed to indicate the 
expected binding position of the haem group (sticks), which coincides with a peak of FO-
FC difference electron density in the IsdHN2N3:Hb complex (green). Haem transfer from 
globin to the IsdH receptor requires a relatively small translation of only 12 Å between 
the E and F helices of the globin. 
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The crystal structure of IsdHN2N3 bound to Hb was used to evaluate the SAXS data 
obtained for IsdHN2N3 free in solution to see whether any large changes in the 
conformation of the receptor occur upon binding to Hb. Theoretical X-ray scattering 
curves for the three full receptors present in the crystal structure were generated using the 
program CRYSOL248. These theoretical curves were fit to the solution scattering of 
IsdHN2N3(Y642A). All three theoretical curves fit extremely well to the experimental 
scattering, with ! values of 0.925 (chain E), 0.904 (chain F) and 0.866 (chain G) (Fig. 
3.16 A), suggesting that no major structural change occurs upon receptor binding and 
providing independent validation of the 4.2 Å crystal structure. Superposition of the 
crystal structure of the bound receptor and the ab initio model of IsdHN2N3(Y642A) using 
SUPCOMB249 reveals close agreement between the free model and bound structure 
(Fig. 3.16 B). These results argue that the domains of the receptor are pre-organized to 
position the haem acceptor site over the globin haem pocket. 
 
 
 
 
 
 
 
 
Figure 3.16 The domain organization of IsdHN2N3 in solution is same as that shown 
in the crystal structure. (A) Fit of the experimental solution scattering of free IsdHN2N3 
to the theoretical scattering curve generated for a single IsdHN2N3 molecule (chain E) 
from the crystal structure of IsdHN2N3(Y642A):Hb. (B) Ab initio shape reconstruction of 
the IsdHN2N3 receptor (spheres), overlaid with the crystal structure of IsdHN2N3(Y642A) 
(ribbon and sticks). 
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Under normal physiological conditions, small amounts of Hb are continually released into 
the serum by low levels of haemolysis, which occurs as part of the natural turn over of 
red blood cells. Extracellular Hb is bound by the serum scavenger protein haptoglobin 
(Hp), which inhibits globin denaturation and targets Hb to the scavenger receptor CD163 
on macrophages, resident in the liver and spleen. It is of interest to examine the 
interactions of IsdB/H with Hb:Hp complexes because83,145,147,205 access to this pool of 
Hb iron could be a significant factor in the early stages of S. aureus infection. IsdB/H can 
bind to Hb:Hp complexes83,145,147,205. Recently the structure of a porcine dimeric Hb:Hp 
complex was solved250. Superposition with the IsdHN2N3:Hb complex indicates that Hp 
does not present a steric impediment to IsdHN2N3:globin interactions (Fig. 3.17), 
suggesting that Hb:Hp is available as an iron source for S. aureus. In addition, binding of 
IsdHN2N3 might block the interaction of Hb:Hb with CD163 impacting on clearance of Hb 
from serum. 
 
IsdH has also been reported to bind directly to Hp83,145,147. Several functions for binding 
to Hp have been proposed. Direct capture of haptoglobin may function to enhance the Hb 
binding activity of the bacterial protein147. The Hb:Hp interaction is extremely high 
affinity (estimated to be > Kd = 10-15 M) and despite being non-covalent, it is considered 
to be irreversible250-253. Hence an interaction with Hp that retains the Hb binding interface 
could produce a very efficient Hb receptor tethered to the cell wall. Alternatively, 
decoration the bacterial surface with the host Hp, may allow S. aureus to escape detection 
by the host immune system147 or perform anti-inflammatory functions by inhibiting 
phagocytosis and oxidative killing83. Mutagenesis studies have suggested that IsdHN1 uses 
the same interface to bind to Hb or Hp147. Hb and Hp have distinct folds and a specific 
interaction with both proteins would imply that the NEAT domain fold is highly flexible 
in its capacity to recognise ligands. It is already known that the haem binding and Hb 
binding NEAT domains have evolved to use the same protein face to bind to their highly 
dissimilar ligands. Together with high stability and solubility, these properties would 
make the NEAT domain fold an interesting candidate for protein engineering for 
biotechnology applications.   
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There are three allelic forms of the Hp gene: Hp1F, Hp1S and Hp2. Proteins expressed 
from the Hp1 genes form simple dimers. However, the Hp2 protein can form a range of 
higher molecular weight homo or hetero oligomers253. IsdH was shown to interact with 
Hp from pooled human serum, which contains a range of Hp oligomers, and a construct 
containing IsdHN1 accounted for the majority of the Hp binding activity in ELISA and 
SPR experiments83,145,147.  
 
To investigate the proposed interaction between IsdHN1 and Hp, SEC and static light 
scattering experiments were performed with Hp1-1, which is the simplest oligomer of Hp. 
The data shown in Figure 3.18 A&B were provided by D. Gell. In Figure 3.18 A, IsdHN1 
eluted as a single mono-dispersed peak with a MW of 18.6 kDa. The Hp1-1 protein gave 
rise to a major peak (MW: 92.2 kDa) corresponding to Hp1-1 dimers and a second peak of 
contaminating higher molecular weight species (Fig. 3.18 A, upper panel; blue). A 
mixture of IsdHN1 and Hp1-1 did not show any evidence of an interaction as both the 
elution profile and MW measurements remained unchanged from those of the free proteins 
(Fig.3.18 A, lower panel; dashed line). Under the same conditions, Hp1-1 formed a 
complex with Hb (Fig. 3.18 B, lower panel; orange) with the expected molecular weight 
for a Hp1-1 dimer bound to two Hb dimers (MW: 152 kDa) indicating that the Hp protein 
was functional. IsdHN1 was able to bind to the Hb:Hp 1-1 complex, presumably through a 
site on !/" Hb, as indicated by a shift in elution volume and an increase in MW to 172 
kDa (Fig. 3.18 B, lower panel; dashed line). 
 
To test whether IsdH contains a binding site for any of the allelic forms of Hp, I 
performed SEC and static light scattering experiments with Hp purified from pooled 
human serum and an IsdH construct covering all three NEAT domains (IsdHN1N2N3). 
Details of the expression and purification of IsdHN1N2N3 can be found in Section 4.3.1. 
The pooled Hp protein produced several overlapping peaks arising from the different 
oligomers, with a measured MW range of 133 kDa – 1 MDa (Fig. 3.18 C, upper panel). 
IsdHN1N2N3 eluted as a single peak with a MW of 70.5 kDa (Fig. 3.18 C, upper panel). 
When IsdHN1N2N3 was mixed with the pooled Hp, the elution profile was identical to those 
of the free proteins and the measured MW’s remained unchanged (Fig. 3.18 C, lower 
panel). Hence no interaction between IsdHN1N2N3 and any of the Hp oligomers could be 
detected. In contrast, addition of Hb to the pooled Hp led to a change in the shape of the 
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elution profile with a shift to an earlier elution time, indicating that the Hp oligomers 
were bound to Hb (Fig. 3.18 D, lower panel, dashed line). When IsdHN1N2N3 was added to 
the mixture of Hp:Hb complexes, no free IsdHN1N2N3 peak was observed suggesting that 
IsdHN1N2N3 was bound to the Hb:Hp complexes. Hence, under the conditions tested, IsdH 
does not bind directly to purified Hp but can bind to Hb:Hp complexes, consistent with 
the model depicted in Figure 3.17. 
 
 
 
 
 
 
 
 
Figure 3.17 The Hb:Hp interaction is compatible with IsdHN2N3:Hb interaction. The 
crystal structure of porcine Hp 1-1 (green and yellow) bound to two Hb dimers (red and 
pink) (PDB 4F4O). Overlaid is a Hb dimer (orange) with two IsdHN2N3 molecules bound 
(blue and cyan). 
 
Figure 3.18 IsdH does not bind directly to Hp but can bind to Hb:Hp complexes. (A) 
Upper panel: SEC traces of free Hp 1-1 (blue) and IsdHN1 (grey). Lower panel: a mixture 
of Hp 1-1 and IsdHN1 (dashed line) indicates that IsdHN1 does not bind to Hp 1-1. (B) 
Upper panel: SEC traces of free Hp 1-1 (blue) and Hb (grey). Lower panel: A Hb:Hp 
complex (orange) will bind to IsdHN1 (dashed line). (C) Upper panel: SEC traces of free 
pooled Hp (blue) and IsdHN1N2N3 (grey). Lower panel: a mixture of pooled Hp and 
IsdHN1N2N3 (dashed line) indicates that IsdH does not bind to Hp. (D) Upper panel: SEC 
traces of free pooled Hp 1-1 (blue). Lower panel: A pooled Hp will bind to Hb (orange) 
and form a larger complex with IsdH (dashed line). 
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The structural studies presented in this chapter indicate that haem capture from Hb 
involves direct positioning of the haem capture domain adjacent to the globin haem 
pocket. The three domains work together by anchoring the receptor to Hb through the 
IsdHN2 domain and precisely placing the haem binding IsdHN3 domain via the scaffolding 
linker domain. IsdHN2N3 is ~ 60% sequence-identical to IsdB and ~ 50% sequence-
identical to the IsdB homolog of S. lugdunensis, suggesting that the mechanism of haem 
capture proposed here is applicable to the three known Hb receptors found in pathogenic 
staphylococcal species. 
 
SAXS studies indicate that the receptor does not undergo any major conformation 
changes upon binding to Hb suggesting that the domain architecture is pre-organised to 
strip haem from Hb. This does not rule out small inter-domain motions that do not change 
the radius of gyration of the protein, as these motions would not be detected by SAXS. 
The IsdHN3 and linker domains make contacts across a substantial interface consistent 
with the two domains behaving as a single entity, however minimal contacts are evident 
between the linker and IsdHN2 domain suggesting some flexibility here. Recent NMR 
relaxation measurements of the free IsdHN2N3 protein, confirm that the three domains 
predominantly behave as a single unit but that the IsdHN2 domain also undergoes limited 
motions in isolation from the rest of the IsdHN2N3 receptor (R. Clubb, unpublished 
results).  
 
Separation of the Hb binding and haem removal functions to distinct interfaces of IsdH 
may be necessary to achieve the task of haem capture from Hb. Release of haem from Hb 
is predicted to require unfolding of the globin haem pocket, hence recognition of a distant 
surface of Hb for specific binding might allow for localised changes in the globin haem 
pocket while maintaining the integrity of the receptor-binding site. Consistent with this 
idea, mutagenesis studies of the Hb receptor A (HgbA) from Gram-negative Haemophilus 
ducreyi and HmbR from Neisseria meningitidis indicate that there is likewise a physical 
separation of the Hb-binding and haem uptake interfaces134,135,139. This similarity suggests 
that an architecture involving multiple interaction interfaces might have a functional 
advantage for haem extraction from Hb in a range of systems. Multiple interaction 
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surfaces also increase the potential for targeted design of inhibitors. Haem capture by the 
haem binding domains was dependent upon interactions mediated by the IsdHN2/IsdBN1 
domains and hence blocking Hb binding or haem binding are viable avenues for 
inhibiting haem uptake. 
 
IsdH bound to ! and " Hb chains using the same interaction ‘mode’ and was able to 
capture haem from all four globin subunits. These structural and functional data suggest 
that the same mechanism of haem removal may operate for ! and " Hb. Consistent with 
this idea, Zhu et al., showed that haem is almost completely transferred from Hb to IsdB 
in under 2 min at 22 °C with a single rate constant149. The data presented in this chapter 
suggests that the receptors can access iron from Hb regardless of the Hb chain 
encountered or the oligomeric status of the protein. This versatility would enhance the 
likelihood of successful encounters with Hb as dissociation of the Hb tetramer is known 
to occur in vivo following erythrocyte lysis, due to dilution effects and autooxidation 
processes. In addition, removal of haem from one or more globin chains is expected to 
destabilize Hb, leading to increased formation of monomers167,169. 
 
Both Hb and Hb:Hp complexes have been shown to support S. aureus growth in the 
absence of other sources of iron83. While uptake of haem from Hb:Hp complexes by IsdH 
or IsdB has not been demonstrated, IsdH was able to bind to Hb:Hp complexes in gel 
filtration assays. In addition, the crystal structure of the IsdHN2N3:Hb complex indicates 
that concurrent binding to Hp would not disrupt the Hb targeting or haem capture 
interactions of the bacterial receptor. In contrast to previous reports, direct binding of 
IsdH to Hp was not observed. A discussion of why these results might differ form 
previous findings in given in Section 4.8. 
 
In conclusion, Chapter 3 has addressed the first aim of this thesis: to determine the 
molecular mechanism used by the multi-domain receptors, IsdH and IsdB, to capture 
haem from Hb. The experiments presented in this chapter have shown how the three 
domains of the receptors work synergistically to position the haem capture machinery at 
the globin haem pocket and bring about haem transfer. The molecular contacts that occur 
at this interface are investigated further in Chapter 6.   
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IsdH and IsdB possess a number of physical and functional similarities, including high 
sequence homology and similar rates of haem capture from Hb (see Sections 1.5.4.4 and 
3.1). The results presented in Chapter 3 show that the homologous regions of IsdH and 
IsdB, IsdHN2N3 and IsdBN1N2, are both able to quantitatively capture haem from ! and " 
Hb chains. In addition, SAXS showed that IsdBN1N2 and IsdHN2N3 adopt a similar shape, 
suggesting that the IsdHN2N3:Hb structure provides a good model for IsdBN1N2:Hb 
interactions. These similarities might predict that IsdBN1N2 and IsdHN2N3 perform similar 
functions in haem uptake in vivo. However, S. aureus strains with deletions of isdB have 
a much more pronounced growth deficit in media where Hb is the sole iron source, 
compared to !isdH strains (see Section 1.6.1). In addition, !isdB strains are more 
disabled than !isdH strains in most animal models of infection (see Section 1.6.1). I 
therefore hypothesised that differences exist in the way that IsdB and IsdH interact with 
Hb and/or transport haem. 
 
IsdB can transfer haem from Hb to IsdA or IsdC in a purified system149,230, providing a 
mechanism for haem relay to the IsdEF complex in the cytoplasmic membrane. The same 
haem relay function has not been demonstrated for IsdH. Conversely, Hb-binding 
attributes of IsdHN1 and IsdHN2, and IsdHN2N3 have been determined (Chapter 3 and 
Section 1.5.4.4), whereas the IsdB:Hb interaction is less well-characterised. Hence the 
aims of this chapter were (1) to determine whether both IsdB and IsdH function as haem 
transfer catalysts in vitro, and (2) to investigate the Hb binding properties of IsdB, and 
isolated NEAT domains of IsdB, in order to directly compare the Hb binding functions of 
IsdB and IsdH. 
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To investigate haem relay from IsdHN2N3 and IsdBN1N2 to IsdA and IsdC, the full-length 
sequences of IsdA and IsdC, lacking the N-terminal secretion signal and C-terminal 
sortase anchor, were cloned into pET-15b (see Section 2.3 and Appendix A). The 
constructs carried an N-terminal histidine tag and were purified by Ni-affinity 
chromatography, followed by gel-filtration. SDS-PAGE analysis of the purification 
process is shown in Figure 4.1. A–D. Apo-IsdC could be separated from partially haem 
bound preparations by ion exchange over DEAE resin or by acid acetone haem removal. 
The holo-IsdC and apo-IsdC spectra are shown in Figure 4.1, E. Titration of haem into 
apo-IsdC was monitored by UV-visible spectroscopy, as described in Section 3.2.1. The 
Apo-IsdC protein bound haem at a stoichiometry of ~1:1.2, close to the expected 1:1 ratio 
(Fig. 4.1 F).  
 
Figure 4.1. SDS-PAGE analysis of expression and purification of IsdC and IsdA. (A) 
Purification of IsdC by Ni-affinity chromatography: lane 1, Mark 12 protein standards; 
lane 2, bacterial lysate; lane 3, flow through; lane 4, 30 mM imidazole wash; lanes 5–9, 
100 mM imidazole elution fractions. (B) Purification of IsdC by gel filtration over a 
Superose 12 column (GE healthcare): lane 1, Kaleidoscope protein standards (Bio-Rad); 
lanes 2–10, elution fractions from gel filtration. (C) Purification of IsdA by Ni-affinity 
chromatography: lane 1, bacterial lysate; lanes 2–3, flow through; lane 4, 10 mM 
imidazole wash; lanes 5–9, 30 mM imidazole elution fractions; lane 10, Kaleidoscope 
protein standards. (D) Purification of IsdA by gel filtration over a Superose 12 column 
(GE healthcare): lane 1, Kaleidoscope protein standards; lanes 2–10, elution fractions 
from gel filtration. Arrows indicate overexpressed recombinant proteins. Stars indicate 
fractions collected for use from the final purification step. (E) The UV-visible absorption 
spectra of holo- (black) and apo- (grey) IsdC. (F) Titration of haem into apo-IsdC. Data 
points were fit, by linear regression, in two groups. A 1:1 binding stoichiometry 
(assuming accurate concentration determination and Kd << working concentration) would 
see the linear fits intersect at the vertical dashed line. 
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The relay of haem from Fe(III)-Hb to apo-IsdC was measured in the presence of small 
quantities (2–13% of the total haem concentration) of IsdBN1N2 or IsdHN2N3 (Fig. 4.2). 
When Fe(III)-Hb was mixed with 125% (measured as a % of the number of Hb haem-
binding sites in the reaction) apo-IsdC alone, the haem transfer was negligible (Fig.4.2 B, 
D, dashed lines). However, 13% IsdBN1N2 achieved complete haem transfer from Fe(III)-
Hb to IsdC in under 10 min at 4˚C (Fig. 4.2 A, B). In comparison 13% IsdHN2N3 resulted 
in slow relay of haem from Fe(III)-Hb to IsdC and the reaction did not reach completion 
within 35 min (Fig. 4.2 C, D).  
 
 
 
 
 
 
 
Figure 4.2. Haem transfer from Fe(III)-Hb to IsdC in the presence of IsdBN1N2 or 
IsdHN2N3. (A) Spectral recorded at 40-s intervals for a mixture of 1.5 mM Fe(III)-Hb 
tetramer in the presence of 125% apo-IsdC (measured as a % of the number of Hb haem 
sites in the reaction) and 13% apo-IsdBN1N2. (B) Normalised change in absorbance at 406 
nm for mixtures of Fe(III)-Hb with 125% apo-IsdC (per Hb haem) and 2–13% apo-
IsdBN1N2 (per Hb haem). (C) Spectra recorded at 40-s intervals for a mixture of Fe(III)-
Hb with 125% apo-IsdC (per Hb haem) and 13.3% apo-IsdHN2N3 (per Hb haem). (D) 
Normalised change in absorbance at 406 nm for mixtures of 1.5 mM Fe(III)-Hb with 
125% apo-IsdC (per Hb haem) and 2–13% apo-IsdHN2N3 (per Hb haem). These data are 
from single measurements. 
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An attempt was also made to measure haem relay from Fe(III)-Hb to IsdA in the presence 
of IsdHN2N3 and IsdBN1N2; however, apo-IsdA preparations produced by acid acetone 
haem removal appeared to have a large proportion of non-functional protein and 
underwent time-dependent precipitation. IsdA is a larger protein than IsdC (265 residues 
in mature IsdA vs 160 residues in mature IsdC), and contains an extensive region of 
unknown structure between the NEAT domain and the C-terminal sortase-recognition 
motif. It is possible that the larger IsdA protein did not refold properly after solvent 
extraction of the haem ligand and further optimisation of haem removal and protein 
refolding is required.  
 
Preliminary experiments were performed with apo-IsdA, immediately after refolding and 
before the protein had begun to precipitate. Fe(III)-Hb-tetramer was mixed 125% apo-
IsdA alone, or in the presence of 7% apo-IsdBN1N2, or apo-IsdHN2N3 (Fig. 4.3). Like IsdC, 
apo-IsdA alone did not capture haem from Hb (Fig. 4.3 C, dashed line). When IsdB was 
present an initial rapid change in the spectrum was observed that was faster than IsdB-
catalysed transfer from Hb to IsdC. However, this was followed by a slower phase and 
the reaction did not go to completion within the time course (Fig. 4.3 A, C), as judged by 
inspection of the final spectrum, which indicated the presence of Fe(III)-Hb and IsdB/A. 
IsdHN2N3 also transferred haem to IsdA (Fig. 4.3 B, C) more efficiently than to IsdC. In 
summary, IsdBN1N2 was more effective than the homologous region of IsdH (IsdHN2N3) at 
relaying haem from Hb to IsdA, or from Hb to IsdC. In addition, whereas IsdBN1N2 
transferred haem to IsdA or IsdC, IsdHN2N3 showed very limited ability to transfer haem 
to IsdC.     
 
 
Figure 4.3. Haem transfer from Fe(III)-Hb to IsdA in the presence of IsdBN1N2 or 
IsdHN2N3. (A) Spectral recorded at 40-s intervals for a mixture of 1.5 mM Fe(III)-Hb 
tetramer in the presence of 125% apo-IsdA (measured as a % of the number of Hb haem 
sites in the reaction) and 7% apo-IsdBN1N2 (per Hb haem). (B) Spectra recorded at 40-s 
intervals for a mixture of Fe(III)-Hb with 125% apo-IsdA (per Hb haem) and 7% apo-
IsdHN2N3 (per Hb haem). (C) Normalised change in absorbance at 406 nm for mixtures of 
Fe(III)-Hb with 125% apo-IsdA (per Hb haem) and 7% apo-IsdBN1N2 or 7% apo-IsdHN2N3 
(per Hb haem). These data are from single measurements. 
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In addition to the IsdB-homologous region, IsdH contains a further N-terminal NEAT 
domain (IsdHN1), which interacts with the ! chain of Hb146. The role of the IsdHN1 
domain in haem capture and transfer is unknown and it is possible that this domain is 
important for IsdH haem-transfer function. To investigate this, IsdHN1N2N3 was expressed 
and purified as for IsdHN2N3, yielding ~90% pure protein by SDS-PAGE analysis (Fig. 
4.4 A, B; cloning, expression and purification described in Sections 2.3 and 2.5). The 
apo-IsdH protein was produced by acid-acetone haem-extraction and, following 
refolding, apo-IsdH bound haem in a 1:1 stoichiometry (Fig.4.4 C). 
 
Fe(III)-Hb was incubated with excess apo-IsdHN1N2N3 and the spectral changes were 
recorded. Interestingly, after a 10-min incubation the spectrum had not completely 
converted to that of holo-IsdH, suggesting that, unlike IsdHN2N3, IsdHN1N2N3 took only a 
fraction of the haem groups (Fig.4.4 D, solid black line). A time course suggested an 
initial rapid uptake of ~50% of haem groups in ~60 s, which was similar to the activity 
seen for IsdHN2N3 (Fig. 4.4 E, F). However, removal of the remaining ~50% haem was 
dramatically slowed. The data suggest that IsdHN1 significantly inhibits haem transfer 
from ~50% of the globin chains. 
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Figure 4.4. Expression, purification, haem binding and haem capture properties of 
IsdHN1N2N3. (A) Purification of IsdHN1N2N3 by Ni-affinity chromatography: lane 1, 
Kaleidoscope protein standards; lane 2, bacterial lysate; lane 3, flow through; lanes 4–5, 
10 mM imidazole wash; lanes 6–7, 100 mM imidazole elution fractions; lane 1, 
Kaleidoscope protein standards. (B) Purification of IsdHN1N2N3 by anion exchange 
chromatography: lane 1, Mark 12 protein standards; lane 2, load condition; lanes 3, flow 
through; lanes 4–9, eluted fractions over a 50–300 mM NaCl gradient. (C) Titration of 
haem into apo-IsdHN1N2N3. Data points were fit, by linear regression, in two groups. A 1:1 
binding stoichiometry (assuming accurate concentration determination and Kd << 
working concentration) would see the linear fits intersect at the vertical dashed line. (D) 
UV-visible absorption spectra of Fe(III)-Hb (6 µM haem, corresponding to 1.5 µM 
tetramer), holo-IsdHN1N2N3 (6 µM) and apo-IsdHN1N2N3 (7.5 µM), showing that they are 
distinct. The spectrum of a mixture of Fe(III)-Hb (1.5 µM) and apo-IsdHN1N2N3 (7.5 µM) 
after a 10 min incubation at 4 °C is shown as a thicker solid line. (E) Spectra (taken at 40-
s intervals) of a mixture of Fe(III)-Hb (1.5 µM) and apo-IsdHN1N2N3 (7.5 µM), which was 
incubated at 4 °C. The spectrum of Fe(III)-Hb (1.5 µM) is overlaid for comparison. 
Arrows indicate the direction of spectral change. (F) A time course over 200 min showing 
the percentage of haem remaining bound to Fe(III)-Hb (1.5 µM) after mixing with apo-
IsdHN1N2N3 (7.5 µM). Time courses for Fe(III)-Hb mixed with apo-IsdHN2N3, apo-
IsdBN1N2 or IsdHN2N3(Y642A) are shown for comparison. These data are representative of 
two measurements. 
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Next the role of IsdHN1 domain in haem relay was assessed. Fe(III)-Hb to was mixed with 
125% apo-IsdC (measured as a % of the number of Hb haem sites in the reaction) and 
13% apo-IsdHN1N2N3. Strikingly, IsdHN1N2N3 did not transfer haem from Fe(III)-Hb to 
IsdC, indicating that the presence of the IsdHN1 domain strongly inhibits haem relay to 
downstream IsdC (Fig. 4.5 A, B). To explore the possibility that haem relay function was 
lost because IsdHN1N2N3 did not refold correctly during purification of the apo protein, the 
experiment was repeated using holo-IsdHN1N2N3 that was purified directly from E. coli 
without unfolding. The amount of haem contamination introduced by holo-IsdHN1N2N3 
was small (only ~10% of the available IsdC binding capacity) and so should not prevent 
haem relay from Hb being observed. Similar to apo-IsdHN1N2N3, holo-IsdHN1N2N3 was 
unable to enhance transfer of haem from Fe(III)-Hb to IsdC (Fig.  4.5 B, long-dashed 
line). In addition, IsdHN1N2N3 did not transfer haem from Fe(III)-Hb to IsdA (Fig. 4.5 C, 
D). Hence the IsdHN1 domain inhibits both haem capture and relay activity. 
 
Taken together, the results presented in Sections 4.2 and 4.3 show that IsdB is a more 
efficient haem relay protein than IsdH in vitro and predict distinct roles for these proteins 
in S. aureus haem capture in vivo. 
 
 
 
 
 
Figure 4.5. Haem transfer from Fe(III)-Hb to IsdC and IsdA in the presence of 
IsdHN1N2N3. (A) Spectra recorded at 40-s intervals for a mixture of Fe(III)-Hb with 125% 
apo-IsdC (measured as a % of the number of Hb haem sites in the reaction) and 13.3% 
(per Hb haem) apo-IsdHN1N2N3.  (B) Normalised change in absorbance at 406 nm for 
mixtures of 1.5 mM Fe(III)-Hb with a 125% apo-IsdC (per Hb haem) and 13.3% apo-
IsdHN1N2N3 (solid line) or holo-IsdHN1N2N3 (long dashed line). (C) Spectra recorded at 40 s 
intervals for a mixture of Fe(III)-Hb with 125% apo-IsdA (per Hb haem) and 7% (per Hb 
haem) apo-IsdHN1N2N3.  (D) Normalised change in absorbance at 406 nm for mixtures of 
1.5 mM Fe(III)-Hb with a 125% apo-IsdA (per Hb haem) and 20% apo-IsdHN1N2N3 (solid 
line).  
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To investigate interactions between IsdB/IsdH and Hb, SEC-RALLS experiments were 
performed. IsdHN1N2N3 eluted as a single peak and had a MW of 72.5±0.9 kDa determined 
by RALLS – close to the expected value based on sequence (68 kDa, Fig.4.6 Ai, Table 
4.1). The MW of HbCO was 55.2±2.0 kDa, consistent with the dimer-tetramer equilibrium 
constant (Kd = 1.5 µM, expressed in units of molar haem and measured at ~20°C in 50–
100 mM Na phosphate, pH 7.0254,255) and the working concentration; samples were 
loaded onto the column at ~136 µM haem (or 34 µM Hb tetramer), which is >10x Kd and 
therefore even with dilution on the column, Hb is expected to be predominantly 
tetrameric. A mixture containing one IsdHN1N2N3 per HbCO tetramer led to complete 
depletion of the Hb peak and a single broad peak eluting at an earlier time point (Fig.4.6 
Aii). RALLS analysis indicated that this peak contained a mixture of species with MW in 
the range 130–170 kDa. The smallest and the largest species in this peak are bigger than 
the expected MW of one IsdH molecule bound to one Hb dimer (100 kDa) or one Hb 
tetramer (132 kDa). Each IsdHN1N2N3 molecule contains two Hb binding NEAT domains 
that are separated by an unstructured linker and have the potential to independently bind 
to Hb chains from the same Hb molecule, or different Hb molecules, potentially leading 
to extended chains of IsdH-linked Hb. I did not investigate these interaction models 
further and the primary conclusion was that IsdH forms stable complexes with Hb. 
 
The full-length IsdB protein (residues 41–609) eluted as a single peak with a measured 
MW of 70.6 kDa, close to the expected value of 66.4 kDa (Fig.4.6 Bi, Table 4.1). When 
IsdB was mixed at a 1:1 molar ratio with HbCO (per Hb tetramer), two peaks were 
observed with MW practically the same as the MW of the free proteins (Fig.4.6 Bii, black 
dashed line; Table 4.1). Slight peak broadening and shift to an earlier elution volume 
provided some evidence of an interaction. At a 2:1 mixing ratio (Fig. 4.6 Bii, grey dashed 
line) the Hb peak was substantially broadened and the IsdB peak showed a change in 
mobility suggesting a very weak interaction (MW 80–90 kDa across peak). This behaviour 
contrasts with the stable binding observed for a 1:1 mixture of IsdHN1N2N3 and Hb (which 
has an equivalent number of Hb binding sites to the 2:1 IsdB:Hb mixture), indicating that 
IsdB and IsdH interact differently with Hb. 
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The presence of an additional domain in IsdHN1N2N3, or unstructured N- and C-terminal 
regions in IsdB, may modify the Hb-interaction functions of the conserved region. 
Therefore, to investigate if sequence differences in the homologous regions of IsdB and 
IsdH result in different interactions with Hb, a similar analysis to that described above 
was performed with the IsdHN2N3 and IsdBN1N2 constructs. The free IsdHN2N3 protein 
eluted as a single peak (Fig. 4.7 Ai), however had a MW of 57.7±0.5 kDa, which is larger 
than expected based upon the primary sequence (41.4 kDa) suggesting some aggregation 
of the protein. The molecular weight was reduced upon dilution (51.5±0.5 kDa), possibly 
indicating a concentration-dependent self-association. To determine whether the IsdHN2N3 
protein undergoes reversible or irreversible aggregation, a dilution series should be 
performed and MW measurements made over a 10-fold change in concentration. This was 
not investigated further as the small amount of aggregation did not prevent an interaction 
with Hb; a 2:1 mixture of IsdHN2N3 with HbCO produced a single SEC peak 
corresponding to a protein complex with a molecular weight of 124 kDa (Fig. 4.7 Aii). 
The MW measured for Hb (55.2±2.0 kDa) indicates that ~70% of mass is distributed as 
tetramers. Assuming one IsdHN2N3 bound to each !" dimer, and assuming the dimer-
tetramer equilibrium to be unaltered by the binding of IsdHN2N3, the expected MW would 
be 126 kDa, which is similar to the measured value.  
 
The free IsdBN1N2 protein eluted as a single SEC peak (Fig. 4.7 Bi), however also had a 
MW slightly larger than expected (48.8±0.2 kDa vs 42.3 kDa), again proving some 
evidence of aggregation. A 2:1 mixture of IsdBN1N2 with HbCO gave rise to a much 
smaller shift in peak elution time, compared to IsdHN2N3, and the MW measured across 
this peak (68 kDa) was only marginally greater than the MW of the free proteins (Fig. 4.7 
Bii, Table 4.1). Assuming that IsdB does not dramatically alter the dimer-tetramer 
equilibrium of Hb, these data suggest that interactions between IsdB and Hb are 
considerably weaker that interactions between IsdHN2N3 and Hb. 
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Table 4.1. MW measurements of IsdB and IsdH and their complexes with HbCO by SEC-
RALLS. 
Protein Concentration 
mg/ml (µM) 
MW Peak 1**† 
(kDa) 
MW Peak 2 
(kDa) 
HbCO 2.2 (34)* 55.2±2.0 - 
IsdHN1N2N3 2.6 (38) 72.5±0.9  (68) - 
IsdHN1N2N3:HbCO 1:1 4.6 130–170 - 
    
HbCO 2.2 (34) 46.4 - 
IsdB 2.5 (38) 70.6 (66.4) - 
IsdB:HbCO 1:1 4.5 71.5 48.4 
IsdB:HbCO 2:1 6.7 80–90 52.8 
    
HbCO 2.2 (34) 55.2±2.0 - 
Holo-IsdHN2N3 1 (24) 51.5±0.5 (41.4) - 
Holo-IsdHN2N3 2.9 (69) 57.7±0.5  (41.4) - 
Holo-IsdHN2N3:HbCO 2:1 5 123.8 - 
    
Holo-IsdBN1N2 2.7 (65) 48.8±0.2 (42.3) - 
Holo-IsdBN1N2 5.6 (132) 51.0±0.5 (42.3) - 
Holo-IsdBN1N2:HbCO 2:1 4.9 67.7 - 
*Calculated as Hb tetramer 
**Where given, errors are ± S.E. for two or three repeat measurements 
†Values in parentheses are the molecular weights calculated from primary sequence 
 
 
 
 
Figure 4.6. SEC of mixtures of Hb with IsdHN1N2N3 and IsdB. (Ai) SEC elution traces 
of free Hb (black) and IsdHN1N2N3 (blue). (ii) A 1:1 mixture IsdHN1N2N3 with Hb tetramer 
(black dotted line) and a 2:1 mixture of IsdHN1N2N3 with Hb tetramer (grey dashed line). 
(Bi) SEC elution traces of free Hb (black) and IsdB (orange). (ii) A 1:1 mixture IsdB with 
Hb tetramer (black dotted line) and a 2:1 mixture of IsdB with Hb tetramer (grey dashed 
line). 
 
Figure 4.7. SEC of mixtures of Hb with IsdHN2N3 and IsdBN1N2. (Ai) Upper panel: 
SEC elution traces of free Hb (black) and IsdHN2N3 (green). (ii) A 2:1 mixture of IsdHN2N3 
with Hb tetramer (grey dashed line). (Bi) Upper panel: SEC elution traces of free Hb 
(black) and IsdBN1N2 (purple). (ii) A 2:1 mixture of IsdBN1N2 with Hb tetramer (grey 
dashed line). 
 !
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To determine which globin chain forms the primary binding site for IsdH and IsdB, Hb 
was separated into isolated ! and " chains using p-hydroxymercuribenzoate (PMB), 
which modifies cysteine side chains at the !1"1 interface and prevents the formation of 
!" dimers256. The cysteine modification was reversed following chromatographic 
separation of the !PMB and "PMB chains, by the addition of excess DTT. The separated Hb 
chains used in this thesis were prepared by D. Gell and K. Krishna Kumar. 
 
The IsdHN1N2N3 protein, which is well resolved from the free globin chains (Fig. 4.8 Ai), 
generated a stable complex with ! Hb (Fig. 4.8 Aii). As ! Hb was added in increasing 
concentrations (0–2.5 molar equivalents) to IsdHN1N2N3 the MW increased to reach a 
plateau at 99 kDa (Table 4.2), close to the MW expected for a 2:1 complex of 
IsdHN1N2N3:! Hb of 98.2 kDa. The conclusion is that the IsdHN1 and IsdHN2 domains each 
bind to one ! Hb chain. The elution profile for a 1:1 mixture of IsdHN1N2N3 and " Hb is 
shown in Figure 4.8 Aiii, where a residual peak of unbound free " Hb suggests weaker 
binding to " Hb.  
 
Table 4.2. MW measurements IsdH and IsdH:CO-!Hb complexes by SEC-RALLS. 
Protein Concentration 
mg/ml (µM) 
MW Peak 1 
kDa (expected) 
MW Peak 2 
kDa 
!HbCO 0.48 (32) 15.4 (15.1) - 
IsdH 1 (15) 71 (68) - 
IsdH:!HbCO 1:0.8 1.13 88 - 
IsdH:!HbCO 1:1.6 1.27 95 - 
IsdH:!HbCO 1:2.2 1.58 96 - 
IsdH:!HbCO 1:2.5 1.72 99 19 
 
Similar SEC analyses showed that holo-IsdHN2N3 and IsdHN2N3(Y642A) formed stable 
complexes with ! Hb and displayed weaker binding to " Hb (Fig. 4.8 B, C), as seen for 
the full-length protein. The overall similarity in SEC traces for haem-bound IsdHN2N3 and 
the Tyr642-to-Ala mutant, which is unable to bind haem, indicate that the presence of 
haem did not prevent interaction with Hb, and therefore it is unlikely that uptake of haem 
causes a structural change in the receptor that triggers Hb to be released.  
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When IsdB was mixed with either ! or " Hb, only a small change in mobility of the free 
globin peak was observed, suggesting that IsdB interacts weakly with both globin chains 
(Fig. 4.8 D). By the same criteria, the haem bound IsdBN1N2 and IsdBN1N2(Y440A) 
constructs also formed a weak interaction with ! Hb (Fig. 4.8 E, F). Significant peak 
overlap made it difficult to determine the interaction with " Hb (Fig. 4.8 Eiii, Fiii). By 
analogy with IsdH, it was predicted that interactions between IsdB and Hb would be 
mediated through the IsdBN1 domain. To test this, the isolated IsdBN1 domain was 
produced. A small change in the mobility of ! Hb in the presence of IsdBN1 was evidence 
of weak interaction (Fig. 4.9 ii). No interaction with " Hb was detected (Fig. 4.9 iii). A 
comparison of " Hb peak mobility in Figure 4.8 Eiii, Fiii and Figure 4.9 iii suggested that 
binding to " Hb was stronger for IsdBN1N2 than for the isolated IsdBN1 domain. Thus, 
regions outside of the N-terminal NEAT domain, for example in the Linker domain 
and/or IsdHN3 domain, may contribute significantly to the binding affinity for " Hb. In a 
very recent publication, Bowden et al. measured Hb binding affinity of 422 nM for 
IsdBN1N2 by ITC and no interaction was detected between Hb and the isolated IsdBN1 
domain230. Taken together with the data of Bowden et al., the data presented in Figures 
4.8 and 4.9 support the conclusion that weak interactions, mediated by multiple IsdB 
domains, contribute to ! and " Hb binding in a cooperative fashion, and, that the Linker 
and IsdBN2 domains contribute a greater part of the overall binding affinity for the " Hb 
chain. In summary, IsdH makes stable interactions with ! Hb through both the IsdHN1 
and IsdHN2 domains and binds weakly to " Hb, while IsdB shows weak interactions with 
both globin chains. 
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Figure 4.8. SEC analysis of IsdH and IsdB binding to the isolated !  and "  chains of 
Hb. (A–F) SEC elution traces of IsdHN1N2N3 (A), holo-IsdHN2N3 (B), or IsdHN2N3(Y642A) 
(C), IsdB (D), holo-IsdBN1N2 (E) or IsdBN1N2(Y440A) (F) with, or without, addition of 
isolated ! and " Hb. In each of A–F, SEC traces are shown for (i) free ! Hb (red), " Hb 
(pink) and IsdH (blue) or IsdB protein (orange), (ii) a 1:1 molar mixture of IsdH/IsdB 
with ! Hb, and (iii) a 1:1 molar mixture of IsdB with " Hb. 
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Figure 4.9. SEC analysis of IsdBN1 binding to the isolated !  and "  chains of Hb.  (i) 
SEC elution trace of free IsdBN1 (orange). (ii) SEC elution traces of free ! Hb (black) 
overlaid with a 1:1 mixture of IsdBN1 and ! Hb (grey dashed line). (iii) SEC elution 
traces of free " Hb (black) overlaid with a 1:1 mixture of IsdBN1 and " Hb (grey dashed 
line).  
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It was hypothesised that the differences in Hb binding affinity between IsdH and IsdB 
may be responsible for the differences in haem relay activity by influencing the rate at 
which the receptor is recycled between consecutive Hb chains and IsdA/C. In order to 
rank the Hb binding affinities of IsdB, IsdH, and their isolated NEAT domains, SEC was 
used to detect the quantity of unbound Hb at a range of IsdB/H concentrations. To 
investigate binding to the ! chain, increasing concentrations of Isd protein were mixed 
with a fixed concentration of ! Hb (12.6 µM) and subject to SEC analysis. In Figure 4.10 
A–G the ! Hb peak alone is shown in black. The curves for mixtures containing ! Hb 
and 2.5–50 µM Isd protein (corresponding to 0.2–4 fold molar excess over ! Hb) are 
overlaid and coloured in a spectrum from blue to red. In Figure 4.10 A, C, E the single 
NEAT domains eluted at the same time as the free ! Hb peak and so elution traces were 
recorded at 410 nm; at this wavelength ! Hb can be detected by virtue of the constituent 
haem group, whereas IsdHN1, IsdHN2 and IsdBN1 do not absorb visible light. The 
full-length Isd proteins were well resolved from ! Hb and mixtures of these proteins were 
monitored at 280 nm (Fig. 4.10 D, F, G). To compare the ! binding behaviours the 
change in height of the free ! Hb peak was plotted against Isd:!Hb mixing ratio 
(Fig. 4.10 H).  
 
Upon addition of increasing concentrations of IsdHN1 the free !Hb peak was reduced to 
zero (a relative reduction in ! Hb peak height of ‘1’ in Figure 4.10 H) and the change in 
! Hb peak height with increasing IsdHN1 concentration was linear (Fig. 4.10 H, solid 
black line), indicating complete complex formation with each addition of IsdHN1. Hence 
the equilibrium dissociation constant for this interaction is presumed to be well below the 
working protein concentrations (~µM on the column). In this case, the [NEAT]/[!Hb] 
ratio at which the free ! Hb peak is depleted gives the stoichiometry, which for IsdHN1, 
occurs at a 1:1 molar stoichiometry (Fig. 4.10 A, H, filled circles, solid black line). For 
comparison, the same experiment was performed with ! Hb stabilising protein (AHSP), 
which forms a heterodimer with ! Hb with Kd = 20 nM257. AHSP caused the same 
quantitative depletion of ! Hb (Fig. 4.10 B, H) as seen with IsdHN1, indicating 1:1 
stoichiometry with sub-micromolar affinity. In contrast to IsdHN1, 2–4 molar-equivalents 
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of IsdHN2 (Fig. 4 C, H) or IsdHN2N3(Y642A) (Fig. 4.10 D, H) were required in order to 
reduce the free ! Hb peak to undetectable levels, indicative of weaker ! Hb binding 
compared to IsdHN1. Note, an additional peak eluting after ! Hb in Figure 4.10 D is a 
contaminating species that was present in the IsdHN2N3(Y642A) sample used in this 
experiment. 
 
The addition of up to 4 molar equivalents of IsdBN1, IsdBN1N2 or IsdBN1N2(Y440A) did 
not deplete the free ! Hb peak but caused peak broadening consistent with a very weak 
interaction (Fig. 4.10 E–G). An alternative explanation for changes in peak 
shape/mobility might be that Isd proteins are inducing haem loss from ! Hb leading to 
globin aggregation. However IsdHN2, IsdHN2N3(Y642A), IsdBN1 and IsdBN1N2(Y440A) 
did not induce changes in the UV-visible spectrum of Hb (see Section 3.3.1)167,230 
suggesting that this is unlikely. 
 
Based on the curves shown in Figure 4.10, Isd domains were ranked in order of 
decreasing affinity for !Hb as follows: IsdHN1 > IsdHN2 ! IsdHN2N3 >> IsdBN1 ! IsdB. A 
comparison with the independently determined binding affinity of ! Hb for IsdHN1 (Kd = 
20–100 nM)145-147 suggests that the Kd > 100 nM for all other interactions tested here. 
Peak overlap between Isd:" Hb complexes and free " Hb prevented a similar analysis of 
" Hb interactions. Unlike native " Hb chains which are in equilibrium between 
monomeric, dimeric and tetrameric species, modified "PMB chains are predominantly 
monomeric258 and so are predicted to be well separated from Isd:"PMB complexes. 
Therefore, the PMB modified " chains could be used in future studies to compare the 
strength of Isd:" Hb interactions. As the PMB modification is on the !1"1 interface, 
away from the Isd interaction surface, it is not expected to prevent Isd:" Hb interactions.  
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Figure 4.10. Relative affinities of IsdH and IsdB constructs for isolated !  Hb by 
SEC titration experiments. (A–G) The UV trace of 12.6 !M ! Hb (black) overlaid with 
traces of 12.6 !M ! Hb mixed with 0.2 (blue), 0.4 (cyan), 0.8 (green), 1.2 (yellow), 2 
(orange) or 4 (red) molar equivalents of: IsdHN1 (A), AHSP (B), IsdHN2 (C), 
IsdHN2N3(Y642A) (D), IsdBN1 (E), IsdB (F), or IsdBN1N2(Y440A) (G). Traces were 
recorded at 280 nm or 410 nm (arbitrary units) with the wavelength remaining the same 
for each titration series. (H) The fraction changes in ! Hb peak height at different mixing 
ratios with Isd protein. 
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To explore the possibility that haem transfer from Hb might lead to unfolding of the 
globin chain and subsequent dissociation of the IsdH:Hb complex, mixtures of apo-
IsdHN2N3 and Fe(III)-Hb were assessed by SEC. To demonstrate that the refolded apo 
protein was competent to bind Hb, it was first mixed with HbCO and the elution profiles 
and measured molecular weights were compared to those of holo-IsdHN2N3:Hb complexes 
(Fig. 4.11 A, Table 4.3). Figure 4.11 Aii shows that apo-IsdHN2N3 formed a complex with 
Hb at both 1:1 and 2:1 mixing ratios and that the elution profiles were similar to those of 
the holo-IsdHN2N3:Hb complexes. In addition, the average molecular weights for the holo 
and apo complexes were unchanged (Table 4.3), indicating that the apo-protein is fully 
functional to bind to Hb. 
 
Next, apo-IsdHN2N3 or the control, holo-IsdHN2N3, was mixed with Fe(III)-Hb. The protein 
mixtures were incubated overnight and then separated by gel filtration. A 5:1 molar 
excess (per Hb tetramer) was used to ensure that all of the haem could be transferred to 
the apo-receptor. Haem content was determined by UV-visible absorption spectra using 
an inline UV-detector, or by collecting the peaks as they eluted off the column and then 
recording spectra. The elution profiles of Fe(III)-Hb mixed with apo-IsdHN2N3 or holo-
IsdHN2N3 are overlaid in Figure 4.11 B; each profile contains two peaks. The UV-visible 
absorption spectrum of Peak 1 derived from the holo-IsdHN2N3:Fe(III)-Hb mixture 
contained contributions from both IsdH and Hb (Fig. 4.11 C, green trace) and the 
molecular species eluting in Peak 1 had a MW of 130 kDa, indicating that an holo-
IsdHN2N3:Fe(III)-Hb complex was formed. The UV-visible spectrum of Peak 1 of the apo-
IsdHN2N3:Fe(III)-Hb mixture resembled haem-bound IsdH only (Fig. 4.11 C, blue trace), 
and the MW of species in this peak was 110 kDa. These data suggest the presence of a 
holo-IsdHN2N3:apo-Hb complex, and therefore that, despite haem transfer, the IsdH and 
Hb proteins remained in a complex. To confirm identity and stoichiometry of the 
polypeptides in each peak, elution fractions should be collected across the two peaks for 
the holo and apo complexes, and analysed by SDS-PAGE. In both samples, Peak 2 had a 
UV-visible spectrum characteristic of haem-bound IsdHN2N3 (Fig. 4.11 D) and the MW 
measured across the peak was consistent with IsdHN2N3 monomer (Table 4.3), thus Peak 2 
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corresponded to the excess unbound receptor. Hence, haem transfer to IsdH does not 
appear to trigger disassembly of the complex. 
 
Table 4.3. MW measurements apo-IsdH and apo-IsdH:Hb complexes by SEC-RALLS. 
Protein Concentration 
mg/ml (µM) 
MW Peak 1 
kDa (expected) 
MW Peak 2 
kDa 
HbCO 0.5 (8) 32.1±0.1* - 
    
Holo-IsdHN2N3 0.65 (16) 51 (41.4) - 
Holo-IsdHN2N3:HbCO 1:1 0.82 98 40 
Holo-IsdHN2N3:HbCO 2:1 1.15 116 - 
    
Apo-IsdHN2N3 0.65 (16) 61 (41.4) - 
Apo-IsdHN2N3:HbCO 1:1 0.82 95 39 
Apo-IsdHN2N3:HbCO 2:1 1.15 120 - 
    
Holo-IsdHN2N3:Fe(III)-Hb 5:1 2.1 132 62 
Apo-IsdHN2N3:Fe(III)-Hb 5:1 2.1 110 64 
Holo-IsdHN2N3:HbCO 5:1 2.1 130 62 
*Error is given as ± SE for two measurements 
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Figure 4.11. SEC analysis of the interaction of apo-IsdHN2N3 with Hb. (Ai) SEC 
elution traces of free CO-Hb (black), holo-IsdHN2N3 (green) and apo-IsdHN2N3 (blue). (ii) 
A 1:1 molar mixture of holo-IsdHN2N3 with CO-Hb tetramer (black solid line) overlaid 
with a 2:1 molar mixture of holo-IsdHN2N3 with CO-Hb tetramer (grey solid line), a 1:1 
molar mixture of apo-IsdHN2N3 with CO-Hb tetramer (black dashed line) and a 2:1 molar 
mixture of holo-IsdHN2N3 with CO-Hb tetramer (grey dashed line).  (B) A 5:1 molar 
mixture of holo-IsdHN2N3 (green) or apo-IsdHN2N3 (blue) with Fe(III)-Hb. Mixing ratios 
are per Hb tetramer. (C) The UV-visible absorption spectra of Peak 1 collected from the 
SEC runs shown in B. (D) The UV-visible absorption spectra of Peak 2 collected from 
the SEC run shown in B. The holo-IsdHN2N3:Hb complex is coloured green while the apo-
IsdHN2N3:Hb complex is coloured blue. 
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IsdB but not IsdH was able to rapidly and quantitatively capture haem from Hb and 
catalyse its transfer to the downstream haem binding proteins IsdA and IsdC in vitro. This 
is the first biochemical study to identify a difference in activity between IsdH and IsdB 
and provides a rationale for the observation that IsdB but not IsdH is required for S. 
aureus growth using Hb as an iron source in in vitro growth assays8,84. This difference in 
function predicts that IsdB and IsdH will have distinct roles in haem uptake during 
infection, and is consistent with a different requirement for IsdB or IsdH during 
colonisation of different organs in in vivo infection models84,174,203. 
 
The work in this chapter has established an inverse correlation between haem relay 
activity and Hb binding affinity. It is possible that a weak interaction with Hb may be an 
important part of the haem relay mechanism, because a weak interaction would allow for 
rapid recycling of the receptor. The ‘handclasp mechanism’ of haem transfer between 
IsdA and IsdC involves an interaction between the haem pockets of donor and acceptor 
proteins170,171. Based on the structure of IsdHN2N3 bound to Hb (Chapter 3) such an 
interaction could not occur without large conformational changes in the IsdB/H receptors 
or dissociation of the complex. The hypothesis that a weak interaction with Hb is 
important for catalysis of haem relay by IsdB is explored further in Chapter 5.  
 
Previous measurements of IsdB:Hb affinity have ranged from 55 nM (obtained by 
SPR)8,145 to 422 nM (obtained by ITC)230, however, the SEC experiments performed here 
suggest that the interaction is much weaker – in the mM–µM range259. The reasons for 
this discrepancy are unclear; however, the preparations of IsdB used in this thesis are 
clearly competent to capture haem from Hb and rapidly transfer this haem to IsdA/C with 
much higher activity than IsdH constructs, hence it is presumed that IsdB preparations are 
correctly folded and active. A systematic analysis of all Hb binding NEAT domains via 
multiple biophysical methods is required to provide accurate measurements of Hb binding 
affinities and to allow further comparisons of Hb binding activity. 
 
It has been suggested that IsdB is the protein that is primarily responsible for binding Hb 
to the surface of S. aureus, as Hb binding is largely abolished in !isdB strains208,260. This 
is at odds with the higher affinity binding to Hb demonstrated by IsdH compared to IsdB. 
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Part of the answer might be that IsdB is more highly abundant than IsdH on the cell 
surface under low iron conditions5,6,98,202 and therefore the contribution from IsdH may be 
masked. Fluorescence imaging studies performed by Pishchany et al., indicated that, 
while Hb and IsdB colocalise on surface, Hb fluorescence is punctate and IsdB 
fluorescence is diffuse260. They concluded that either multiple IsdB molecules are 
required to bind Hb (avidity effect) or that an additional factor may be involved in Hb 
binding by IsdB. 
 
Interestingly, the relative Hb binding affinities of IsdHN1, IsdHN2 and IsdBN1 determined 
in Section 4.6 correlate with the reported binding activities for Hp. IsdHN1 binds to Hp 
with higher affinity (Kd 5–35 µM)145,146 than IsdHN2 (binding observed but affinity not 
determined), and no binding has been observed for IsdB83,145. Pilpa et al., showed that 
mutagenesis of the Hb binding interface of IsdHN1 removes interaction with Hp147. These 
findings have suggested that the same interface of NEAT domain can interact with the 
unrelated folds of Hb and Hp. However, the SEC experiments in Chapter 3 failed to 
detect an interaction with Hp and an alternative explanation is that apparent IsdH:Hp 
interactions are a result of binding though contaminating Hb. Hp has exceptionally high 
affinity for Hb, making it is possible that preparations of Hp from human serum contain 
small amounts of contaminating Hb. The presence of contaminating Hb may not be seen 
in a gel filtration experiment, which observes the bulk response, while SPR or ELISA, are 
expected to be more sensitive to a less abundant species. 
  
IsdH showed impeded haem capture and almost no haem relay activity compared to 
IsdHN2N3; hence, the additional N-terminal domain inhibits both of these functions. 
IsdHN1 and IsdHN2 interact with the same interface of ! Hb146,175, and thus the higher 
affinity of IsdHN1 could prevent binding of IsdHN2. Because IsdHN2 is critical for 
positioning the IsdHN3 haem capture domain (Chapter 3) this competition for ! Hb 
binding could potentially interfere with haem uptake from this Hb subunit.  Indeed, rapid 
capture of 50% of the globin haems by IsdHN1N2N3 is consistent with only the " haems 
being accessible. To investigate whether IsdH is limited to accessing the " haem pockets, 
Hb carrying differently labelled haem in the ! and " chains could be used to track haem 
transfer. One such potential experiment is presented in schematic form in Figure 4.12, 
and is outlined below. Hb that is chain-selectively labelled so that either the ! or " haem 
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pockets carried 15N labelled haem groups could be produced according to the protocol of 
Simplaceanu e. al.,261. In Figure 4.12 A, Hb is selectively labelled so that the 
! chains only cary 15N labelled haem. Isotopic labelling could be confirmed by mass 
spectrometry (Fig. 4.12 B). The selectively labelled Hb could then be mixed with sub-
stoichiometric amounts of IsdH to allow haem transfer (Fig. 4.12 C), and the mixture 
separated using Ni-affinity chromatography (native Hb binds to the column and IsdH is 
collected in the flow-through). Mass spectrometry could then be used to identify whether 
an excess of labelled or unlabelled haem was transferred to IsdH and hence whether IsdH 
accesses one or both of the " and ! haems (Fig. 4.12 D). 
 
The requirement for IsdH in haem uptake has not been established and the high affinity 
binding to Hb, compared to IsdB, suggests that IsdH may have a function that relies on a 
stable interaction with Hb, as opposed to haem relay by IsdB, which is facilitated by weak 
interactions with Hb. One possibility is that the high affinity binding to Hb by the IsdHN1 
domain will provide an advantage in Hb capture under conditions where Hb availability is 
low. Alternatively, IsdH may have a role that is independent of nutrient haem acquisition, 
such as a role in immune evasion. Visai et al., showed that expression of IsdH was 
involved in evasion of phagocytosis by neutrophils and in bacterial survival in human 
blood205. It is also possible that peroxidase activity of Hb and Hb:Hp complexes262 bound 
to IsdH on the bacterial cell is harnessed in order to escape oxidative damage by reactive 
oxygen species generated and released by immune cells. A similar activity has been 
suggested for the S. pyogenes Hb receptor, Shr263. 
 
In conclusion, the experiments presented in Chapter 4 have addressed the second broad 
aim of this thesis: to investigate how haem is relayed by IsdB/H from Hb to IsdA/C.  
Towards this goal, the haem relay activity and Hb binding properties of IsdB and IsdH 
were compared. Differences in haem relay activity were correlated with Hb binding 
affinity. The superior haem relay activity of IsdB, together with a weaker binding to Hb, 
suggest that short-lived interactions with Hb are a feature of efficient haem relay. This 
hypothesis is explored further in Chapter 5. 
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The goal of the experiments in this section was to identify residues in the Hb-targeting 
NEAT domains that determine binding affinity for ! and " Hb, and to engineer Isd 
variants with altered Hb-binding properties. These IsdB and IsdH variants were then used 
to investigate the mechanism of haem relay to IsdA/C, and to obtain new stable 
complexes for crystallographic studies aimed at understanding the mechanism of haem 
release from Hb. 
 
The ‘rigid’ structure of the conserved three-domain region in IsdB and IsdH (as described 
in Section 3.5) predicts that the receptor:Hb complex must dissociate in order for the 
receptor to dock with downstream IsdA/C. Hence the receptor must strike a compromise 
bewteen binding to Hb tightly enough to promote haem release, but weakly enough to 
release the globin on a time-scale that is useful for transport through IsdA/C. The results 
in Section 4.6 provide evidence that the Hb binding affinity of IsdB is tuned to achieve 
efficient haem relay, whereas IsdH has high affinity interactions with Hb and does not 
efficiently relay haem. To further investigate this model of haem relay I set out to test the 
hypothesis: IsdB mutants with increased Hb binding affinity will have reduced rates of 
haem transfer to IsdA/C. 
 
The crystal structure of the IsdHN2N3:Hb complex presented in Chapter 3 revealed that the 
haem pocket of IsdH sits directly adjacent to the globin haem coordination site. The haem 
transfer kinetics discussed in Section 3.1 show that interactions must occur on this 
interface to destabilise the Hb fold and promote haem release. However, because this 
interface was not well defined at a data resolution of 4.2 Å it was not possible to 
determine the molecular contacts across the interface or to identify changes in the globin 
fold. Hence improved data resolution is required in order to probe the mechanism of 
induced haem release. Attempts to improve crystal quality by traditional approaches such 
as changing the Isd:Hb mixing ratio, seeding, optimising cryoprotection, and crystal 
annealing were unsuccessful. The findings of Chapter 3 indicate that the Hb capture and 
haem transfer functions are separated between two spatially distinct interfaces (involving 
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the N- and C-terminal NEAT domains, respectively). Based on these findings, I devised a 
strategy to introduce mutations that alter receptor:Hb stoichiometry and stability (with 
aim of obtaining more ordered crystals) without altering the haem transfer interface of 
interest.  
 
The first step was to identify potential causes of disorder in crystals of the original 
complex. The positioning of the four receptors is such that the IsdHN3 domains butt up 
against each other. The electron density at these interfaces was weak and the haem 
binding !-hairpins were poorly defined or absent. Attempts to model the haem binding 
!-hairpins based upon structures of the free IsdHN3 domain indicated that these structures 
might clash in two adjacent domains. In addition, one whole IsdHN3 domain, belonging to 
one of the four IsdHN2N3 molecules, could not be built into the IsdHN2N3:Hb structure, 
presumably because the position of this domain was not consistent throughout the crystal 
lattice. Together these observations provide evidence that four receptors do not fit on the 
surface of one Hb tetramer without steric interference between the IsdHN3 domains. The 
receptor for which the IsdHN3 domain could not be modelled was bound to a ! Hb 
subunit. As IsdHN2N3 binds with much lower affinity to the ! Hb chains than to " Hb 
chains it was reasoned that engineering IsdHN2N3 to remove the interaction with ! Hb 
(and retain or enhance the interaction with " Hb) would lead to a more “crystallisable” 
complex. 
 
Section 5.2 describes point mutations in IsdB that cause diminished binding to Hb, which 
were introduced into S. aureus to investigate the role of Hb binding in vivo. The 
remaining sections detail the approach taken to rationally engineer IsdB and IsdH 
receptors to enhance Hb binding, primarily in order to facilitate crystallisation of high-
resolution receptor:Hb complexes, with the secondary aim of identifying the determinants 
of Hb affinity and testing the role of ‘weak’ protein-protein interactions in haem relay. 
Analysis of the resulting crystal structures is presented in Chapter 6.   
 !
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In collaboration with the laboratory of Dr Eric Skaar (Vanderbilt University School of 
Medicine) we set out to investigate the importance of Hb-targeting interactions for the 
survival of S. aureus in a mouse model of infection. The strategy was to make S. aureus 
strains carrying point mutations that knock out Hb binding. Because IsdB appears to play 
a greater role than IsdH in Hb utilisation84,260 it seemed necessary to make the mutants in 
IsdB; however, the molecular contacts that determine binding of IsdB to Hb were 
unknown. Residues of IsdB that might be involved in Hb binding were identified based 
upon conservation with the Hb binding interface of IsdHN1 and IsdHN2. The ! 
Hb-targeting faces of the IsdHN1 and IsdHN2 domains comprise a short aromatic helix in 
loop 2 and loops 4, 6 and 8 (Fig. 5.1 A; residues known to make direct contacts with ! 
Hb are coloured red). The primary sequence of IsdBN1 is 67% identical to IsdHN2 and so 
is predicted to adopt the same fold and use the same interface to contact Hb (Fig. 5.1 A; 
residues in IsdHN2 predicted to make contact with ! Hb are bold). Few residues on the ! 
Hb binding interface are conserved between the all three Hb binding NEAT domains 
(Fig. 5.1 A; conserved residues are underlined). One highly conserved feature is the 
aromatic motif on loop 2 of IsdHN1, IsdHN2 and IsdBN1. The role of this motif in IsdHN1 
has previously been investigated by alanine scanning mutation. This study observed a 40–
150-fold reduction in Hb binding affinity when residues 125–129 (YYHFF) were 
individually replaced with Ala, indicating that the aromatic motif is indispensible for 
binding to Hb147. The primary sequence of this motif is conserved in IsdHN2 and IsdBN1 
(QFYHYF), and varies in IsdHN1 (QYYHFF). To investigate the role of this motif in Hb 
binding by IsdB, and in S. aureus virulence, single Ala substitutions were introduced into 
IsdB to replace Gln, Tyr or His residue at positions 1, 3 and 4 of the QFYHYF motif. In 
the crystal structures of IsdHN1:Hb and IsdHN2:Hb, the equivalent Tyr is involved in 
contacts with Hb, while Glu163 and His166 make intra-molecular interactions that are 
expected to stabilise the conformation of loop 2 when bound to Hb146,175. Hence 
mutations in Glu163, Try165 and His166 were predicted to abrogate the interaction with 
Hb and produce observable effects in vivo. An additional mutation, in which the FYHYA 
motif of IsdB was substituted with the YYHFF sequence, was made to investigate 
whether the two aromatic motifs are interchangeable. isdB genes carrying the loop 2 
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mutations were introduced into S. aureus by allelic replacement in the Skaar laboratory 
and the strains harbouring these mutations were tested for their ability to bind Hb to the 
cell-surface208. Recombinant mutant IsdB proteins carrying the same substitutions 
(residues 41–609 of IsdB with a intact N-terminal histidine affinity tag), together with 
ferric Hb, were produced by Dr Skaar’s laboratory and shipped as lyophilised proteins.  
 
Gel filtration was used to assess the interaction of purified IsdB mutants with ferric Hb. 
Hb was first reacted with CN to minimise precipitation of unstable Fe(III)-Hb on the 
column. IsdB or IsdB mutants were mixed in a 2:1 molar ratio (per Hb tetramer) with 
CN-Fe(III)-Hb and subject to SEC analysis. Wild-type IsdB showed evidence of weak 
interaction with Hb (Fig. 5.1 Bi), as expected based on results of Section 4.4. As both the 
Hb and IsdB protein used here were produced by the Skaar laboratory this is good 
corroboration of the findings in Chapter 4 that weak binding to Hb is a functional 
property of IsdB. Substitution of Gln163, Tyr166 or His166 attenuated the interaction 
(Fig. 5.1 Bii–iv). In particular, The Tyr165Ala mutation removed any indication of an 
interaction (Fig. 5.1 Biv). This mutation also dramatically reduced the binding of Hb to 
the surface of S. aureus208. In IsdHN1 and IsdHN2 this tyrosine packs against the A-helix 
of the globin at the centre of the interface and so is likely to play a key role in stabilising 
the interaction between Hb and IsdB. To determine whether the aromatic motifs are 
interchangeable the motif of IsdB was substituted with the IsdHN1 sequence. The loop 
FYHYA!YYHFF substitution also attenuated binding to Hb indicating that in the 
context of IsdB the YYHFF motif of IsdHN1 cannot effectively bind to Hb (Fig. 5.1 Bv).  
 
It was predicted that disrupting interactions through the IsdBN1 domain would reduce or 
block haem uptake by the IsdBN2 domain. To investigate this, the IsdB proteins carrying 
mutations in IsdBN1 loop 2 were mixed in a 4:1 ratio with Fe(III)-Hb and haem transfer 
was monitored using UV-visible absorption spectroscopy (as described in Section 2.7). 
The change in peak height at 406 nm over time, normalised to the starting absorbance 
(spectrum of Fe(III)-Hb), is shown in Figure 5.1 C. All of the IsdBN1 loop 2 mutations 
had a substantial effect on haem capture from Hb. The spectral change was fitted to 
single- or double-exponential expressions and the calculated rates are shown in Table 5.1. 
The Gln163Ala, His166Ala, and FYHYA164!168YYHFF mutations result in 15–20-
fold reductions in haem transfer rate compared to wild-type IsdB. Transfer rates to IsdB 
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carrying the Tyr165Ala are ~50-fold slower than for wild-type IsdB. Hence the conserved 
aromatic residues of loop 2 of IsdB are vital for both Hb binding and haem transfer 
activity of IsdB. These residues likely play a role in stabilising the fold of loop 2 as well 
contributing to the Hb binding surface. 
 
Using a mouse model of systemic infection, Pishchany et al., demonstrated that an 
S. aureus strain expressing IsdB(Y165A) had significantly reduced ability to colonise the 
kidneys and hearts of infected animals208. S. aureus carrying the Tyr165-to-Ala mutation 
had similar virulence to an isdB deletion strain, with close to a 100-fold decrease in 
colony forming units isolated from infected tissues when compared to the wild type 
strain. Hence interactions between IsdB and Hb are necessary for haem capture from Hb 
in vitro and contribute to the virulence of S. aureus in vivo. 
 
Table 5.1. Rates of haem transfer from Hb to IsdB at 4°C. 
IsdB construct k1 min-1 k2 min-1 
IsdB 1.08 ± 0.24 0.114 ± 0.024 
IsdB(FYHYA!YYHYF) 0.066 ± 0.001 - 
IsdB(H166A) 0.042 ± 0.001 - 
IsdB(Q163A) 0.051 ± 0.002 - 
IsdB(Y165A) 0.020 ± 0.004 - 
UV-vis data were fitted to single or double-exponential expressions. Rate measurements are 
average ± 1SD from 2–3 experiments. 
 !
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Figure 5.1. Hb binding and haem capture properties of IsdB proteins carrying 
mutations in conserved residues in the Hb binding domain. (A) Sequence alignment 
of selected regions of IsdHN1, IsdHN2 and IsdBN1. Residues that contact ! Hb are coloured 
red. Residues that are predicted to contact ! Hb in IsdBN1 are bold. Residues conserved in 
all three sequences are underlined.  (B) Gel filtration analysis of Hb (brown) overlaid 
with traces acquired for samples of Hb mixed with wild type IsdB, or IsdB carrying 
mutations in the Hb binding domain. Traces for wild-type IsdB and IsdB(Y165A) alone 
are shown as dashed lines. These data were recorded by D. Gell. (C) The absorbance at 
406 nm measured over a 35-min time period for Fe(III)-Hb alone (brown) or Fe(III)-Hb 
mixed with IsdB proteins. The absorbance was normalised to the starting condition 
(spectrum of Fe(III)-Hb). These data are representative of two-three measurements. 
 
 !
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Section 5.2 showed that mutating residues in loop 2 of IsdBN1, that are conserved in 
IsdHN1 and IsdHN2, led to a loss of Hb binding and reduced haem transfer. This enabled 
the Skaar lab to demonstrate the importance of Hb binding in S. aureus pathogenesis, but 
does not contribute to the main goal of this chapter, which was to understand how 
differences in NEAT domain sequences lead to differences in Hb-binding and haem relay, 
and engineer IsdB/H variants with altered Hb binding properties. Side chains that might 
confer differences in !/" binding affinity and selectivity were identified based on 
comparison of the native IsdHN1, IsdHN2 and IsdBN1 sequences. Sequence features 
common to IsdHN1 and IsdHN2 (which share similar ! binding properties) but not shared 
by IsdBN1 (which has much lower affinity for ! Hb), were identified as potential 
determinants of high-affinity binding to ! Hb. Thus, IsdHN1 and IsdHN2 share a common 
sequence in loop 4 that is not present in IsdB (Fig. 5.2 A). Site directed mutagenesis was 
used to replace Gln190, Ser191 and Phe194 in loop 4 of IsdBN1, or Lys391 in loop 4 of 
IsdHN2, with the corresponding sequence of IsdHN1 (Fig. 5.2 B). The mutations were 
introduced into IsdBN1N2, comprising residues 120–459, and IsdHN2N3, comprising 
residues 326–660. Primer sequences used for mutagenesis, and protein sequences of the 
templates can be found in Appendices B and C. Substitution of Lys391 in IsdHN2N3 with 
Asn (Fig. 5.2 C, compare panels i and ii) or substitution of Gln190 in IsdBN1N2 with Asn 
(Fig. 5.2 D, compare panels i and ii) had minimal effect on ! Hb binding. These results 
are consistent with a previous study, which showed that replacing Asn151 of IsdHN1 with 
Ala caused only a 1.4-fold decrease in Hb binding affinity147. Substitution of IsdB Phe194 
with Thr (IsdBN1N2(F194T)) abolished binding to ! Hb (Fig. 5.2 Diii). However, when all 
three interfacial loop 4 residues in IsdB were replaced with their counterparts in IsdHN1 
(IsdBN1N2(QSF!NTT)) there was a dramatic increase in ! Hb binding affinity (Fig. 5.2 
Div). Overall, the binding properties of IsdBN1N2(QSF!NTT) were comparable to 
IsdHN2N3 (Fig. 5.2, compare Div, with Ci). Together, these results suggest that a TxxT 
motif in loop 4 is an important determinant of high-affinity ! Hb binding.  
 
In IsdHN1, Thr152 makes hydrogen-bonding interactions with Lys11 of ! Hb, while 
Thr155 forms a hydrogen bond with Thr8 of ! Hb (Fig. 5.2 E)146,175. Pilpa et al, showed 
 154 
that substitution of Thr155 in IsdHN1 led to a 10-fold decrease in Hb binding affinity, 
supporting a role for this residue in high affinity binding to ! Hb147. Asn151 of IsdHN1 
makes hydrogen-bonding interactions with !Lys11 through both the side chain amide and 
backbone carbonyl group (Fig. 5.2 E)146. In IsdHN2 the backbone carbonyl of Lys391 
makes intra-molecular hydrogen bonds and the "-amino group is within hydrogen 
bonding distance of the !Ala71 backbone carbonyl. However, these residues do not 
contribute significantly to ! Hb binding according to results in Figure 5.2 C and from 
Pilpa et al.147. 
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Figure 5.2. !  Hb binding properties of IsdH and IsdB proteins carrying mutations 
in loop 4 of their Hb binding NEAT domains. (A) Sequence alignment of selected 
regions of IsdHN1, IsdHN2 and IsdBN1. Residues that contact ! Hb are coloured red. 
Residues that are predicted to contact ! Hb in IsdBN1 are bold. (B) Mutations introduced 
into loop 4 of NEAT2 of IsdHN2N3 or NEAT1 of IsdBN1N2 are indicated in green. (C) SEC 
analysis of 12.6 !M !Hb (black) overlaid with traces acquired for samples of 12.6 !M 
!Hb mixed with 0.2 (blue), 0.4 (cyan), 0.8 (green), 1.2 (yellow), 2 (orange) or 4 (red) 
molar equivalents of: (i) IsdHN2N3Y642A, or (ii) IsdHN2N3K391N. (D) As for C with IsdB 
proteins. For IsdB constructs carrying the Q109N (ii) and F194T (iii) mutations, additions 
of 0.4 (cyan), 0.8 (green) and 2 (orange) molar equivalents of IsdB protein are shown. (E) 
The ! Hb binding interface of IsdHN1 (blue) bound to ! Hb (orange). Thr152 and Thr155 
of the TxxT motif are shown in green and interact with residues of ! Hb coloured cyan. 
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Having established the effect of mutations in loop 4 of the NEAT domain on ! Hb 
binding, I next investigated interactions with " Hb. The monomer-tetramer 
self-association of " Hb resulted in extensive peak overlap with the Isd proteins making 
titration experiments similar to those shown in Figure 5.2 impractical. However, as shown 
in Figure 5.3 Ai, interaction between wild type IsdHN2N3 and " Hb was clearly detectible. 
By a similar measure, all loop 4 mutations in IsdBN1N2 or IsdHN2N3 (except 
IsdBN1N2(Q190N), which was not tested) resulted in diminished, or loss of, " binding 
(Fig. 5.3 Aii, Bii, Biii). Thus the main conclusion from these experiments was that the 
TxxT sequence motif is important for high affinity ! binding.  
 
Loss of binding of IsdBN1N2(F194T) to ! and " Hb indicates that loop 4 of IsdB forms 
part of the binding site for both ! and " Hb. Interestingly, multiple substitutions in loop 4 
were required to enhance ! Hb binding affinity, while single mutations had no effect or 
reduced the interaction. One hypothesis is that a single Phe194Thr mutation does not 
allow the Thr hydroxyl to approach closely enough to the ! or " Hb surface to hydrogen 
bond, leaving a cavity, whereas substitution of QSF!NTT (replacing both of the large 
Gln and Phe residues) allows loop 4 to move closer to ! Hb and satisfy multiple 
hydrogen bonds with !Lys11 and !Thr8 as seen in the IsdHN1:! Hb crystal structure 
(Fig. 5.2 E). The most obvious difference between ! Hb and " Hb at this face is the 
position of !Lys11, which is occupied by Thr12 in " Hb. It has previously been shown 
that substitution of !Lys11 with Thr abrogates the interaction between IsdHN1 and ! Hb, 
demonstrating the importance of interactions in this region146. Further structural 
characterisation is required to determine how loop 4 of IsdB allows for binding to the 
distinct surfaces of ! Hb and " Hb. 
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Sequence features that are common to IsdHN2 and IsdBN1 (which share ability to bind 
! Hb), but not IsdHN1 (which does not bind ! Hb), were identified as potential 
determinants of ! Hb interactions. This identified an FxxYA motif in the loop 2 helix and 
a KxY motif in loop 6 (Fig. 5.4 A). Considering first the aromatic sequence in loop2, 
crystal structures of the IsdHN1:Hb and IsdHN2:Hb complexes both show a Phe side chain 
buried at the interface with " Hb (Fig. 5.4 B). These Phe side chains are separated in the 
sequence alignment by the equivalent of one helical turn (YxxxF vs FxxxA); 
nevertheless, they are oriented to make similar interactions with " Hb (Fig. 5.4 B). To 
determine whether differences in the two aromatic motif sequences confer Hb chain 
selectivity, Phe164 and Ala168 of IsdB, and Phe365 and Ala369 of IsdHN2N3, were 
replaced with Tyr and Phe residues (Fig. 5.4 C). Tyr167 and Tyr368, of IsdB and IsdH, 
respectively, were left unchanged because this position is solvent exposed on the 
periphery of the Hb binding interface and, therefore, was not expected to play a major 
role in binding.  
 
The IsdB and IsdHN2N3 proteins carrying the loop 2 mutations were assessed for their 
ability to bind to " and ! Hb using the SEC-titration assay. The FYHYA#YYHYF 
mutation caused little or no change in " Hb binding affinity compared to native IsdB or 
IsdHN2N3 (Fig. 5.4 D, compare panel ii with panel i, and compare panel iv with panel iii). 
However, the FYHYA#YYHYF mutation caused IsdHN2N3 to lose binding to ! Hb (Fig. 
5.4 E, compare grey dot-dashed lines in panels i and ii). The interaction of IsdB carrying 
the FYHYA#YYHYF mutation with ! Hb was not tested. These results suggests that 
FxxxA and YxxxF sequences are similarly compatible with " Hb binding, but that only 
the Phe side chain positioned as FxxxA is compatible with ! Hb binding. The most likely 
explanation for loss of ! Hb binding is that a small hydrophobic side chain, like Ala, is 
needed at position 5 to avoid steric clash with the ! Hb surface. In complex with ! Hb, 
the aromatic side chain at position 1 could potentially be oriented as seen for Tyr125 of 
IsdHN1 or Phe365 of IsdHN2 on " Hb (Fig. 5.4 B, F). Single substitutions of Phe!Tyr 
(position 1) and Phe!Ala (position 5) could be made in both IsdHN1 and IsdHN2 to 
investigate this further.   
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In summary, selectivity for ! Hb was successfully engineered into the IsdHN2N3. More 
extensive mutagenesis studies that target residues in the globin chains as well as single 
point mutations of NEAT loop 2 and structural studies of NEAT:" Hb complexes are 
necessary to explain why the YYHFF motif is not compatible with binding to " Hb and to 
understand how the FYHYA motif is more versatile in its ability to recognise the surfaces 
of both ! Hb and " Hb. 
 !
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Figure 5.4. Mutagenesis of loop 2 on the Hb binding interface of IsdH and IsdB. (A) 
Sequence alignment of selected regions of IsdHN1, IsdHN2 and IsdBN1. Residues that 
contact ! Hb are coloured red. Residues that are predicted to contact ! Hb in IsdBN1 are 
bold. (B) A ribbon diagram of the loop 2 sequence of IsdHN1 (green) and IsdHN2 (orange) 
and its interactions with the A and E helices of ! Hb (PDB 4F3C and 3SZK). Phe129 of 
IsdHN1 and Phe365 IsdHN2 adopt conformations that allow the side chains to occupy the 
same position at the interface. (C) Mutations introduced into loop 2 of NEAT2 of 
IsdHN2N3 or NEAT1 of IsdBN1N2 are indicated in green. (D) SEC analysis of 12.6 !M 
! Hb (black) overlaid with traces of 12.6 !M ! Hb mixed with 0.2 (blue), 0.4 (cyan), 0.8 
(green), 1.2 (yellow), 2 (orange) or 4 (red) molar equivalents of: (i) IsdHN2N3Y642A, (ii) 
IsdHN2N3 carrying the FYHYA"YYHYF mutation, or (iii) IsdBN1N2. (iv) SEC analysis of 
12.6 !M ! Hb (black) overlaid with traces of 12.6 !M ! Hb mixed with 0.8 (green) or 2 
(orange) molar equivalents of IsdBN1N2 carrying the FYHYA"YYHYF mutation. (E) 
SEC traces of # Hb mixed with equimolar amounts of: (i) IsdHN2N3, or (ii) IsdHN2N3 
carrying the FYHYA"YYHYF mutation. (F) The ! Hb binding interface of IsdHN1 
(blue) bound to ! Hb (orange). Phe129 and Tyr125 of loop2 are shown in green and 
interact with residues of ! Hb coloured cyan. 
 !
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To improve the selectivity of IsdBN1N2 and IsdHN2N3 for binding to ! Hb over " Hb, I 
combined mutations in multiple interfacial loops (Fig. 5.5 A, B). IsdB carrying both the 
QSF#NTT (loop 4) and FYHYA#YYHYF (loop 2) substitutions bound to ! Hb with 
higher affinity than wild type IsdB, and showed no measurable binding to " Hb (Fig. 5.5 
D, F). ! Hb binding by this mutant was indistinguishable from IsdB carrying the 
QSF#NTT mutation alone (Table, 5.2), consistent with the earlier conclusion that the 
aromatic loop 2 sequences are similarly compatible with ! Hb. In the same way, IsdHN2N3 
carrying K391N and FYHYA#YYHYF mutations showed features that could be 
predicted based on the activities of the single-loop mutants: ! binding was only 
marginally affected and binding to " was abrogated (Fig. 5.5 C, E; Table 5.2). 
 
 
 
 
 
Figure 5.5. Hb interactions of IsdH and IsdB constructs carrying mutations on loop 
2 and loop 4 of the Hb targeting domains. (A) Sequence alignment of selected regions 
of IsdHN1, IsdHN2 and IsdBN1. Residues that contact ! Hb are coloured red. Residues that 
are predicted contact ! Hb in IsdBN1 are bold. (B) Mutations introduced into loops 2 and 
4 of NEAT2 of IsdHN2N3 or NEAT1 of IsdBN1N2 are indicated in green. (C) SEC analysis 
of 12.6 !M !Hb (black) overlaid with traces of 12.6 !M ! Hb mixed with 0.2 (blue), 0.4 
(cyan), 0.8 (green), 1.2 (yellow), 2 (orange) or 4 (red) molar equivalents of 
IsdHN2N3Y642A (i) or IsdHN2N3 carrying the K391N and FYHYA#YYHYF mutations 
(ii). (D) SEC analysis of 12.6 !M ! Hb (black) overlaid with traces of 12.6 !M ! Hb 
mixed with 0.2 (blue), 0.4 (cyan), 0.8 (green), 1.2 (yellow), 2 (orange) or 4 (red) molar 
equivalents of IsdBN1N2 (i) or IsdBN1N2 carrying the QSF#NTT and FYHYA#YYHYF 
mutations (ii). (D) SEC traces of " Hb mixed with equimolar amounts of IsdHN2N3 (i) or 
IsdHN2N3 carrying the K391N and FYHYA#YYHYF mutations (ii). (E) SEC traces of 
" Hb mixed with equimolar amounts of IsdBN2N3 (i) or IsdBN1N2 carrying the QSF#NTT 
and FYHYA#YYHYF mutations (ii). 
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For further crystallographic studies, my aim was to generate mutations with increased 
binding to ! Hb and decreased (or abrogated) binding to " Hb. Although increased ! Hb 
binding was achieved for IsdB, none of the IsdHN2N3 mutations that were tested showed 
enhanced binding to ! Hb. This suggests that residues outside of helix 2 and loop 4 are 
responsible for the stronger interaction with !  Hb observed for IsdHN1, compared to 
IsdHN2. Two other loops, which contribute to the ! Hb binding interface, show primary 
sequence differences between IsdHN1 and IsdHN2 (Fig. 5.6 A). To investigate the role of 
loop 6 and loop 8 in ! Hb binding affinity, 5 residues in loop 6 of IsdHN2 were replaced 
with their counterparts in IsdHN1 and two residues (Tyr443 and Glu449) were replaced on 
loop 8 (Fig. 5.6 A–C). All mutations in loop 6 and 8, in combination with the loop 2 and 
loop 4 changes, led to dramatic reductions in ! binding (Fig. 5.6 D). Thus, although all 
residues at the IsdHN2:! interface were changed to match residues of IsdHN1, the ! 
binding function of IsdHN1 was not transplanted. It is possible that the mutations caused 
changes in the folding of the protein, which should be investigated by recording NMR 
and CD spectra; note that IsdN2N3 is a large (>40 kDa) protein and signal overlap, together 
with line broadening, might make NMR unsuitable. An alternative explanation is that 
regions outside of the direct binding interface are important for ! Hb binding affinity, for 
example the "-sheet adjacent to and contacting loop 2, which has different sequence in 
IsdB and IsdH, may influence the loop 2 conformation when bound to Hb.  
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Figure 5.6. Mutations outside of loops 2 and 4 did not enhance the !  Hb binding 
affinity of IsdHN2N3. (A) Sequence alignment of selected regions of IsdHN1, IsdHN2 and 
IsdBN1. Residues that contact ! Hb are coloured red. Residues that are predicted contact 
! Hb in IsdBN1 are bold. (B) Mutations introduced into multiple loops of IsdHN2N3 are 
indicated in green; ‘1’ denotes IsdHN2N3(K391N,FYHYA!YYHYF,Y264I,E270T), ‘2’ 
denotes IsdHN2N3(K391N,FYHYA!YYHYF,loop6), ‘3’ denotes 
IsdHN2N3(K391N,FYHYA!YYHYF,loop6,Y264I,E270T). (C) The ! Hb binding 
interface of IsdHN1 (blue) bound to ! Hb (orange). The position of residues on loops 6 
and 8 that were substituted in IsdHN2N3 are shown in green. Residues of ! Hb that are 
involved in hydrogen bonding with loop 6 are coloured cyan. (D) SEC analysis of 12.6 
!M ! Hb (black) overlaid with traces of 12.6 !M ! Hb mixed with 0.2 (blue), 0.4 (cyan), 
0.8 (green), 1.2 (yellow), 2 (orange) or 4 (red) molar equivalents of IsdHN2N3Y642A (i); 
panels (ii-iv) show mixtures with IsdHN2N3Y642A proteins carrying multiple mutations 
(proteins ‘1’, ‘2’ and ‘3’as indicated in (B)). 
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From the SEC experimetents described above, a qualitative measure of the relative ! and 
" Hb binding affinities for each of the IsdH and IsdB mutants was made, and is provided 
in Table 5.2.  
 
Table 5.2. Summary of the !  and "  Hb interactions of IsdH and IsdB proteins carrying 
mutations in the Hb binding domains, detected by SEC 
Protein  ! Hb " Hb  
IsdHN2N3(Y642A) +++ + 
IsdHN2N3(K391N) +++ +/- 
IsdHN2N3(FYHYA!YYHYF) +++ – 
IsdHN2N3(K391N,FYHYA!YYHYF) +++ – 
IsdHN2N3(1) † ++ NA 
IsdHN2N3(2) †† + NA 
IsdHN2N3(3) ††† + NA 
   
IsdBN1N2 + + 
IsdBN1N2(Q190N) + NA 
IsdBN1N2(F194T) – – 
IsdBN1N2(QSF!NTT) +++ – 
IsdBN1N2(FYHYA!YYHYF) + NA 
IsdBN1N2(QSF!NTT,FYHYA!YYHYF) +++ – 
† (1) IsdHN2N3(IsdHN2N3(K391N,FYHYA!YYHYF,Y264I,E270T) 
†† (2) IsdHN2N3(IsdHN2N3(K391N,FYHYA!YYHYF,loop6) 
††† (3) IsdHN2N3(IsdHN2N3(K391N,FYHYA!YYHYF,loop6,Y264I,E270T) 
– indicates no detectable binding  
NA, not tested 
+/- indicates a possible interaction which could not be clearly detected using the SEC assay 
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The work in Chapter 4 revealed an inverse correlation between haem relay activity and 
Hb binding affinity for IsdH, IsdHN2N3 and IsdB. The mutants of IsdB with altered Hb 
binding properties, described above, provided the opportunity to further explore the 
relationship between Hb binding affinity and haem relay activity. IsdBN1N2(F194T) or 
IsdBN1N2(QSF!NTT) were first tested to see whether the changes in Hb binding affected 
haem capture from Hb. IsdBN1N2(F194T) or IsdBN1N2(QSF!NTT) were mixed at 
different molar ratios with Fe(III)-Hb and the change in the visible absorption spectrum 
recorded over time. The change in spectra was converted to the fraction of haem 
remaining in Hb over time, as described in Section 3.2.3, and is shown in Figure 5.7 A. A 
2:1 mixture of IsdBN1N2(QSF!NTT) or IsdBN1N2(F194T) with Hb (where the mixing 
ratio was per Hb tetramer) resulted in the depletion of ~41% and ~45% of haems from Hb 
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respectively, after 10 min (Fig. 5.7 A). Note that some difference in the haem transfer 
curve for a 2:1 molar ratio of IsdBN1N2(QSF!NTT):Hb and the wild-type mixture was 
observed (Fig. 5.7 A). This may indicate a defect in haem capture from Hb, evident at 
low mixing ratios, however the experiment will need to be repeated to have confidence in 
this difference (limitations are discussed in Section 5.7 below). At a 5:1 molar ratio, 
IsdBN1N2(QSF!NTT) and IsdBN1N2(F194T) captured ~90% and ~94% of haem groups 
from Hb after 10 min (Fig. 5.7 A). This is similar to the amount of haem captured by 
wild-type IsdBN1N2 reported in Chapter 3 (45±0.5% and 89±0.3%, for 2:1 and 5:1 
mixtures respectively; errors are given as ± S.E. from three-to-four experiments). As 
haem was quantitatively depleted by the IsdB proteins, the haem transfer curves are the 
result of transfer out of both Hb chains, despite undetectable binding to one or both Hb 
chains, by IsdBN1N2(QSF!NTT) and IsdBN1N2(F194T) respectively, in the SEC assay 
(see Table 5.2). Although the former interactions were not detected by SEC, interactions 
mediated by the IsdBN1 domain are required for haem capture from all four globin chains, 
as the isolated IsdBN2 domain was unable to capture haem from Hb (see Section 3.2.4). 
Hence both IsdBN1N2(F194T) and IsdBN1N2(QSF!NTT) must retain some level of 
specific binding to both globin chains albeit with greatly reduced affinity. Therefore, 
haem transfer within the complex occurs more rapidly than dissociation of even the ultra-
weak complexes.     
 
By contrast, IsdBN1N2 carrying the QSF!NTT and FYHYA!YYHYF substitutions, 
showed substantially reduced rates of haem capture from Hb (Fig. 5.7 A). After 10 min, 
37% and 75% of globin haem groups were transferred in the 2:1 and 5:1 mixtures with 
IsdBN1N2(QSF!NTT,FYHYA!YYHYF); ~ 80% of the haem transferred to the 
wild-type protein. Since the FYHYA!YYHYF mutation did not affect binding to " Hb 
in the SEC experiments but removed binding to # Hb (Table 5.2), these results suggest 
that the defect in haem capture from Hb results from dramatic loss of binding at # sites. 
Hence the FYHYA motif contributes to recognition of and haem capture from # Hb. 
 
To measure the effect of altered Hb binding affinity on haem relay to IsdC, Fe(III)-Hb 
was mixed with excess apo-IsdC and catalytic amounts of the IsdB mutants, and the 
change in absorbance at 406 nm was measured over time (Fig. 5.7 B). Small amounts of 
IsdBN1N2(F194T) (7 or 13% of the haem concentration) transferred haem from Fe(III)-Hb 
 171 
to IsdC at wild-type rates (Fig. 5.7 B, compare red and orange curves), indicating that the 
reduced affinity of IsdBN1N2(F194T) for ! and " Hb did not affect haem relay. In contrast, 
the IsdBN1N2(QSF!NTT) protein showed considerably lower haem relay activity (Fig. 
5.7 B, cyan). Based on the similar haem capture by IsdBN1N2(QSF!NTT) compared to 
wild-type IsdB and IsdBN1N2(F194T)  (Fig. 5.7 A), the slower transfer to IsdC might be, at 
least partly, due to tighter binding to ! Hb and a consequent slower release of haem-
bound IsdB. 
 
The haem relay function of IsdB with the combined QSF#NTT and FYHYA#YYHYF 
changes was even more attenuated (Fig. 5.7 B). Catalytic amounts (7 or 13% of the IsdC 
concentration) of IsdB carrying the QSF#NTT and FYHYA#YYHYF mutations 
initially produced similar spectral changes to IsdB carrying QSF#NTT alone (Fig. 5.7 B, 
compare cyan and blue curves); however, a second slower phase was evident for the 
double mutant. It is tempting to speculate that the bi-phasic nature of haem relay to IsdC 
by IsdB(QSF#NTT,FYHYA#YYHYF) (Fig. 5.7 B) is related to different rates of haem 
uptake from the ! and " Hb subunits. As mentioned above, ! Hb binding is insensitive to 
the loop 2 mutation suggesting that the slower phase corresponds to relay from the " 
subunits. In summary, the weak binding of IsdB to ! and " Hb is sufficient to achieve 
effective haem capture and haem relay. The activity of the IsdB proteins carrying 
mutations in the Hb targeting domain indicates that substantially weaker binding prevents 
haem uptake and much stronger binding prevents efficient haem relay. 
 
Figure 5.7. Haem capture and relay properties of IsdB proteins with altered Hb 
binding affinity. (A) The figure shows the fraction of haem remaining in Fe(III)-Hb (1.5 
µM Hb or 6 µM haem) after mixing with a 2-fold (3 µM) or 5-fold (7.5 µM) excess of 
apo-IsdB (red), apo-IsdB(QSF#NTT) (cyan), apo-IsdB(F194T) (yellow) or apo-
IsdB(QSF#NTT,FYHYA#YYHYF) (blue). Error bars are shown for the wild-type IsdB 
protein and represent S.E. from three-to-five experiments. (B) Haem relay from Fe(III)-
Hb (1.5 µM Hb or 6 µM haem) to excess apo-IsdC (7.5 µM or 125% measured as a % of 
the number of Hb haem sites in the reaction) in the presence of 7% or 13% apo-IsdB 
(red), apo-IsdB(QSF#NTT) (cyan), apo-IsdB(F194T) (yellow) or apo-
IsdB(QSF#NTT,FYHYA#YYHYF) (blue). These data are from single measurements. 
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The experiments described above provide evidence that weak binding between IsdB and 
Hb is necessary for rapid haem capture and haem relay. However, there are some 
limitations to this work.  
 
First, the correct folding of each of the mutant constructs should be demonstrated by CD 
or NMR spectroscopy. In addition a quantitative measure of Hb binding by IsdB, IsdH 
and their mutants is required in order to effectively rank their relative binding affinities 
and interpret haem relay activity. For example, the IsdBN1N2(QSF!NTT) protein showed 
reduced haem relay activity (Fig. 5.7 B), however, it was not possible to say with 
confidence whether this reduced activity was due to a higher affinity interaction with ! 
Hb or substantially reduced binding to " Hb. Although an interaction between 
IsdBN1N2(F194T) and " Hb could not be detected here, IsdBN1N2(F194T) relayed haem 
with wild-type activity implying an interaction. If the defect in binding to " Hb by 
IsdBN1N2(QSF!NTT) was of greater magnitude than that of IsdBN1N2(F194T), it may fall 
below the threshold required for haem capture from Hb, in turn affecting haem relay. In 
addition, kinetic measurements of complex formation and dissociation should be made 
for comparison with the rates of haem transfer. 
 
Second, the rapid haem capture from Hb means that the start of the haem transfer curve 
cannot be effectively captured on a conventional spectrometer, preventing accurate 
measurements of the haem transfer rates. To study and compare the transfer kinetics for 
the different IsdB/H proteins, the experiments should be repeated with stopped-flow 
equipment. 
 
Third, interpretation of haem capture and relay measurements are complicated by 
reactions occurring at both ! and " haem pockets. Future studies could aim to simplify 
the measurements by blocking haem transfer from one globin haem site by using a non-
iron porphyrin. Alternatively, haem transfer from the isolated ! and " Hb chains could be 
measured. Finally, to support the argument that a difference in Hb binding affinity 
between IsdB and IsdH is responsible for the difference in haem relay activity, it is 
important to produce an IsdH protein with reduced affinity for Hb and to demonstrate a 
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gain of function for haem relay speed. One possibility would be to introduce the loop 4 
sequence of IsdB into IsdHN2N3 to reduce ! Hb binding affinity. 
 
Recently, Bowden et al., demonstrated that IsdB can catalyse haem transfer from Hb to 
IsdA230. The rate of IsdB-catalysed haem relay of from Fe(III)-Hb to IsdA was shown to 
be ~400 times slower than haem transfer from IsdB to IsdA and similar to the rate of 
haem extraction from Hb230, suggesting that haem capture from Hb is the rate-limiting 
step in the haem relay process. The work presented in this chapter may add to this model 
by providing evidence that dissociation of the Isd:Hb complex is rate-limiting in haem 
relay reaction; the relationship between Hb binding and haem relay should now be 
investigated further. In addition, Bowden et al., proposed an alternative mechanism for 
haem relay that involves the formation of a ternary complex between Hb, IsdB and 
IsdA230. The formation of a ternary complex may be compatible with a mechanism that 
requires weak binding to Hb as catalysis of haem transfer from consecutive globin haem 
pockets will still require rapid release of Hb. However, in the absence of a large 
conformational change in the receptor, the buried haem transfer interface of IsdB and 
IsdH in X-ray crystallography structures of the IsdH:Hb and IsdB:Hb complexes (see 
Chapters 3 and 5) argue against haem relay in a ternary complex. No evidence for a large 
conformational change was detected by SAXS (Chapter 3).  
 
The related Hb receptor of Staphylococcus lugdunensis (slIsdB) was identified as a 
homologue of IsdB and contains the three-domain architecture involved in Hb receptor 
function264. However, sequence alignment reveals that slIsdB contains the TxxT motif in 
loop 4, suggesting that the receptor has similar ! Hb binding properties and haem transfer 
function to IsdHN2N3. Hb binding studies conducted by D. Gell and E. Devenish indicate 
that slIsdB does bind to ! Hb with an affinity more similar to IsdHN2N3 than to IsdBN1N2 
(unpublished data).  It will be interesting and informative to see whether the haem relay 
activity of slIsdB also correlates with Hb binding affinity. The higher affinity binding to 
Hb by slIsdB compared to IsdB, also makes this homologue a good candidate for 
crystallisation trials. Preliminary screening with the slIsdB protein, containing the 
Tyr491-to-Ala mutation in the haem binding domain, did not lead to any hit conditions, 
and it was not possible to optimise the screening strategy within the time-frame of this 
PhD.  
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In summary, Chapter 5 has investigated residues that determine the Hb binding affinity of 
IsdB and IsdH with the goal of addressing both of the main aims of this thesis: to 
investigate the mechanism of haem capture from Hb and to investigate the process of 
haem relay. The relationship between Hb binding affinity and haem relay suggests that 
the weak IsdB:Hb interaction is optimised to allow for both haem transfer and haem 
relay. Crystallisation of IsdH and IsdB constructs with altered Hb binding properties is 
described in the following chapter. 
 !
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The aim of this Chapter was to determine the structure of the IsdH:Hb haem transfer 
interface with the goal of understanding the mechanism of haem release from Hb. In 
Chapter 5, Isd receptors with altered Hb binding properties were generated and 
characterised and receptors that bound only to the " chain of Hb were carried forward for 
structural studies on the premise that these might form more ordered crystals. IsdHN2N3 
carrying the FYHYA!YYHYF mutation was selected for crystallisation trials because 
this mutation effectively removed the interaction with # Hb, yet had minimal impact on 
the interaction with " Hb. In addition, the Y642A mutation that inhibits haem binding 
was introduced into the IsdHN3 domain with the aim of trapping a pre haem-transfer 
complex. The resulting IsdHN2N3 mutant protein was mixed with Hb at a 2:1 molar ratio 
and subject to sparse-matrix crystallisation screening at 21 °C. Beautiful hexagonal 
crystals (Fig. 6.1 A) grew reproducibly in 0.2 M K/Na tartrate, 0.1 M tri-sodium citrate 
pH 5.6, 2 M ammonium sulfate. In a fine screen, crystals of identical morphology were 
obtained over a pH range of 5.4–5.8 and a precipitant concentration of 2–2.2 M 
ammonium sulfate. Ethylene glycol, glycerol and MPD were tested as cryoprotectants. 
The crystals cracked in well solution containing ethylene glycol or MPD, but survived 
soaking for 10–30 s in well solution containing 10, 20 or 30% glycerol before being flash 
cooled in liquid nitrogen. Because UTas does not posses a home x-ray source, the cryo-
conditions could not be screened to determine effects on diffraction quality before taking 
the crystals to the synchrotron. 
 
An initial diffraction data set was collected at the Australian Synchrotron on the MX1 
beam line to a resolution of 2.96 Å and was used for molecular replacement. A 
subsequent data set that was used for refinement was collected to a resolution of 2.45 Å 
on the MX2 beam line after using the micro-focus beam to screen for the best regions 
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within the crystals. The asymmetric unit of the crystals had one very long axis (Table 
6.1). To accommodate this long axis, a longer sample-to-detector distance was selected to 
limit spot overlap at the expense of resolution. The beam-line set up did not allow for 
changes to the goniometer ! angle to realign the long axis of the crystal parallel with the 
rotation axis. The diffraction data were indexed with XDS265 and scaled with 
AIMLESS266; see Table 6.1 for collection and refinement statistics. 
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The structure of IsdHN2N3Y642A carrying the FYHYA"YYHYF bound to Hb was 
solved by molecular replacement. The search models included: one # Hb and one $ Hb 
monomer derived from a 2-Å resolution crystal structure of human Fe(III)-Hb (PDB 
3P5Q); IsdHN2 (PDB 4FC3); IsdHN3 with the haem binding $-hairpin removed (PDB 
2Z6F); and the helical linker (PDB 4IJ2). Molecular replacement, performed with 
PHASER243, gave rise to a single solution. Multiple rounds of restrained refinement were 
performed with REFMAC 5.7267 and model building was completed with Coot268. In later 
rounds of refinement, translation/liberation/screw refinement was introduced, with groups 
defined as single domains (where the linker-N3 unit was considered to be a single group). 
The PDB_REDO server269 was used periodically to validate and bench-mark the 
refinement process. PDB_REDO performs an automated iterative refinement strategy that 
aims to optimise TLS parameters, B-factor refinement, and weighting of geometry, 
amongst other parameters. The models generated by REFMAC were validated using 
MolProbity247. Ramachandran statistics for the final model are as follows: 96.6 % of 
residues were found in favoured regions; 100 % in allowed regions; 0% in disallowed 
regions. A final check of geometry will be performed before the structure factors and 
coordinates are submitted to the PDB. 
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Table 6.1. Data collection and refinement statistics (molecular replacement) 
IsdHN2N3Y642A-FYHYA!YYHYF:Hb 
 Molecular replacement Refinement 
Data collection   
Wavelength (Å) 0.96580 0.95370 
Space group P 65 2 2 P 65 2 2 
Cell dimensions     
    a, b, c (Å) 92.475,   92.475,  365.296 92.29,   92.29,  365.34 
    ", #, $  (°)  90, 90, 120 90, 90, 120 
Resolution (Å) 182.65–2.96 (3.14-2.96) 79.93–2.45 (2.51-2.45) 
Rmerge (%) 7.1 (35) 9.9 (79.6) 
I / %I 20.6 (4.7) 12.3 (1.6) 
Completeness (%) 99.8 (99.3) 99.62 (97.85) 
Redundancy 12.4 (12.2) 8.9 (6.4) 
Refinement   
Resolution (Å)  79.93 -2.45 (2.51-2.45) 
No. reflections  33226 
Rwork / Rfree   2.41/2.74 (3.95/4.38) 
No. atoms   
    Protein  4748 
    Ligand/ion  94 
    Water  9 
B-factors   
    Protein  75.1 
    Ligand/ion  84.1 
    Water  54.2 
R.m.s. deviations   
    Bond lengths (Å)  0.004 
    Bond angles (°)  0.780 
Values in parentheses are for the highest resolution shell. 
!
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The asymmetric unit contained a single IsdHN2N3(Y642A,FYHYA!YYHYF) receptor 
bound to the " chain of an "# Hb dimer (Fig., 6.1 B). Two "# Hb dimers make contacts 
across the "1#2 and "2#1 interfaces; however, the tetramers do not adopt any of the 
well-known Hb quaternary structures. Residues 384–389 (comprising loop 3 which is 
away from the " Hb binding interface) and 467–472 (which connect IsdHN2 and the 
Linker domain and are located adjacent to loop 3) are absent from the model as the 
electron density in these regions was weak. The structure of the receptor overlayed with 
each of the three receptors in the previously solved IsdH:Hb complex (4IJ2, see Chapter 
3) with backbone r.m.s.d.’s of 0.92, 1.13 and 1.78 Å; the closest match was to one of the 
" bound receptors in 4IJ2 (chain G, Fig. 6.1 C). The three domains assembled in the 
expected positions on the surface of " Hb, with close alignment of the IsdHN2 domain 
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(r.m.s.d of 1.22 Å over 128 C! atoms), indicating that the introduced mutations do not 
interfere with how the receptor assembles on Hb (Fig. 6.1 C). Molecular contacts at the 
interface between ! Hb and IsdHN2 are the same as observed for the 2.3-Å resolution 
IsdHN2:Hb crystal structure (PDB 4F3C, Fig. 6.1 D) with the exception of contacts made 
by the introduced Tyr365 and Phe369 side chains in Loop 2 of IsdHN2. The conformation 
of the loop 2 helix of IsdHN2 in the mutant receptor (Fig. 6.1 E and Fig. 6.1 F, purple) is 
essentially identical to the loop 2 helix in IsdHN1:Hb (Fig. 6.1 F, cyan, PDB 3S48), 
showing that the ! Hb-interaction face of IsdHN1 was successfully transplanted onto 
IsdHN2.  
 
 
 
 
Figure 6.1.  Crystal structure of IsdHN2N3Y642A, carrying the FYHYA"YYHYF 
mutation, bound through the !  chain of Hb. (A) Crystals of the engineered complex. 
(B) The crystal structure of the engineered IsdHN2N3 complex was determined at a 
resolution of 2.5 Å. The crystallographic asymmetric unit contained one IsdHN2N3 
receptor (purple) bound though the ! chain (orange) of an !# Hb dimer. (C) The 
structure of the engineered IsdHN2N3 complex (purple) is shown overlaid with an 
IsdHN2N3(Y642A):! Hb dimer (red, PDB 4IJ2). (D) The figure shows a comparison of the 
! Hb binding faces of engineered IsdHN2N3 (purple) and wild-type IsdHN2 (PDB 4F3C; 
red). Interfacial contacts are the same in both complexes, with the exception of residues 
in the mutated aromatic helix in loop 2. (E) The introduced Phe369 on aromatic helix in 
loop 2 (purple) is buried between the A and E helices of ! Hb (orange). The 2FO-FC 
density is shown contoured at 1.5 $. (F) The side chains of Phe369 and Try365 in the 
mutated receptor (purple) adopt the same conformation as in IsdHN1 (cyan). The wild type 
IsdHN2 domain is also shown for comparison (red). Only the residues of the mutated 
receptor are labelled.  
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In the IsdHN2N3(Y642A,FYHYA!YYHYF) receptor, the haem binding !-strands of the 
IsdHN3 domain adopt a conformation that is different from both the holo- and apo-
structures of the free IsdHN3 domain. In the IsdHN2N3(Y642A,FYHYA!YYHYF) 
receptor the !7–8 turn projects towards, and makes contact with, the CD loop and F-helix 
of " Hb (Fig. 6.2 A). Three hydrophobic residues in the !7–8 turn  – Val637, Ala638 and 
Leu640 – pack against side chains of " Hb – Tyr42, Pro44, His45, His89 and Leu91 – 
forming one wall of the haem transfer chamber. Anomalous signal was detected at the 
globin haem iron sites but not in the receptor haem pockets (Fig. 6.2 B), indicating that 
haem transfer did not occur, presumably due to the Y642A mutation. In addition, the 
absence of difference electron density indicates that the receptor haem pocket is not 
occupied by a ligand that might block haem transfer (e.g., Mack et. al., observed that 
IsdC was recovered from E. coli expression with non-metallated protoporphyrin-IX 
bound229). These results reinforce the view that difference density seen in the receptor 
haem binding sites in the 4.2-Å resolution structure (Chapter 3) may have been due to 
haem from denatured Hb in the crystallization drop, or an uncharacterized ligand picked 
up during purification or crystallisation. Crystallization conditions for 
IsdHN2N3(Y642A,FYHYA!YYHYF) did not produce large amounts of Hb precipitate, 
as was the case for the 4.2-Å resolution structure. 
 
 
 
 
Figure 6.2. (A) Hydrophobic residues on the IsdHN3 !7–!8 hairpin (purple spheres) pack 
against the " Hb CE and FG loops (green spheres) in the 
IsdHN2N3(Y642A,FYHYA!YYHYF):Hb complex. The structures of isolated holo-
IsdHN3 (PDB 2Z6F, blue) and apoIsdHN3 (PDB 2E7D, red) are overlaid, to show the 
different conformations of the haem binding beta strands. (B) Anomalous signal (green) 
contoured at 3 # and 2Fo-Fc density contoured at 1.5 # (grey) are seen in the " Hb haem 
pocket (orange) but not in the IsdHN3 haem pocket.  
 
 
!
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Overall, the backbone conformation of ! Hb in IsdHN2N3(Y642A,FYHYA!YYHYF):Hb  
is unchanged from native Fe(III)-! Hb  (r.m.s.d. of 0.32 Å over 105 C! atom pairs, 
excluding Val73–Arg92, with PDB 3P5Q). However, localised conformational changes 
occur across a contiguous region of residues (Val73–Arg92) that comprise the F-helix 
and the FG loop (Fig. 6.3 A, coloured red). The largest changes are seen for residues 
Leu86–Leu91 (Fig. 6.3 B, residues coloured red or pink). A number of salt bridges and 
hydrogen bonding interactions are evident between IsdH (Linker and IsdHN3 domains) 
and the E and F helices and haem group of ! Hb, (Fig. 6.3 C, green and cyan side chains). 
For example, Tyr495 and Lys499 of IsdHN3 form a hydrogen bond and salt bridge with 
!Asp85.  !Asp85 marks the boundary between segments of the F-helix with native and 
non-native conformation. At the opposite side of the interface, Glu562 of IsdHN3 
hydrogen bonds to Gln54 on the E-helix of ! Hb. Interestingly, the side chain of Tyr646 
(Fig.. 6.3 D, cyan), which in holo-IsdHN3 interacts with the haem coordinating tyrosine to 
stabilize haem binding, makes hydrogen bonding interactions with one of the haem 
propionates. Due to the change in the conformation of the F-helix upon IsdH binding, the 
side chain of !His89 is moved ~11 Å to a new position adjacent to the haem pocket 
entrance and, together with the imidazole side chain of !His45, makes hydrogen bonding 
interactions with the same haem propionate that contacts IsdH Tyr646 (Fig. 6.3 D). 
 
His and Tyr side chains are suitable ligands for haem iron and it is tempting to speculate 
that one or more of His89, His85 and Tyr646 might act as an intermediate haem ligand 
during haem transfer process. However, it is important to recognise that mutation of 
Tyr642-to-Ala in this structure may have influenced the positions and interactions of 
other side chains at the interface. In Figure 6.3 D the wild-type holo-IsdHN3 domain is 
overlaid to show the location of Try642 (yellow) in the native IsdHN3 domain. In the 
presence of the Tyr642-to-Ala mutation, the side chain of Val637 partially occupies this 
location, indicating some compensatory local adjustments in the structure in the Tyr642-
to-Ala mutant. It is clear that a steric clash would prevent !His89 and IsdH Tyr642 from 
both adopting the positions shown in Figure 6.3 D. Thus, in the native structure, Tyr642 
might displace His89 from its position in the current structure. Even if the Tyr642-to-Ala 
mutation causes minimal perturbation of the interface, it is a limitation of the study that 
the position of Tyr642, a key residue, cannot be determined. One way to address this 
limitation would be to introduce a Try642-to-Phe mutation; the Phe side chain occupies a 
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similar volume to Tyr but is unable to bind haem. Alternatively, a previously described 
Tyr646-to-Ala mutation, which is unable to bind specifically to haem or capture haem 
from Hb155,160 but retains the haem coordinating Tyr642, could be trialled. Other possible 
ways to block haem transfer, but retain the native Tyr642 and Tyr646 side chains, would 
be to introduce amino acids with large side chains that protrude into the haem binding 
cavity and present a steric impediment to haem binding. In the ! subunit, "His45 and 
"His89 are replaced by !Ser44 and !Asp94, neither of which can act as ligands for the 
haem iron. Hence, if intermediate iron ligands do prove to be involved in haem transfer 
from " Hb to IsdH, different mechanisms would be expected for transfer from ! Hb 
chains.  
 
Notwithstanding the caveats above, the haem transfer interface provides a potential 
explanation for receptor-induced haem loss from the globin. In native Hb, the haem 
pocket residues limit the rate of haem loss from the globin haem pocket in several ways. 
The F-helix of native " Hb contains the haem-coordinating His residue (His87) and also 
contributes three residues, Leu83, Leu86 and Leu91, which together with Val93, Phe98 
and Leu136 form a hydrophobic surface of the proximal haem pocket that interacts with 
the hydrophobic porphyrin ring (Fig. 6.3 E). These six hydrophobic residues enclose 
His87 and protect and stabilise the interaction between the imidazole side chain and the 
haem iron. These interactions are critical for the stability of the globin:haem interaction 
because histidine can be readily displaced by water. The proximal haem pocket residues 
act to prevent water from competing with His87 for the haem iron coordination270,271. The 
six hydrophobic residues are conserved in ! Hb (Fig. 6.3 F) and their function is also 
conserved in myoglobin (Mb). In complex with IsdHN2N3(Y642A,FYHYA!YYHYF) 
two hydrophobic residues, Leu86 and Leu91, are displaced from their native positions 
and are peeled away from the haem pocket (Fig. 6.3 G). In this complex the side chain 
and C" of Ala88 move into the position occupied by Leu91 in native " Hb, under haem 
pyrrol II; however, the smaller methyl side chain is unlikely to compensate for loss of the 
larger Leu91 and Leu86 residues. Numerous studies with both Hb and Mb have shown 
that disrupting the hydrophobic barrier through mutagenesis both removes favourable 
hydrophobic contacts with the haem group and introduces water into the proximal haem 
pocket leading to greatly increased rates of haem loss270-272. In addition, a range of 
unstable Hb variants arise from single amino acid substitutions to hydrophobic residues in  
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the F-helix and FG loop. These include (but are not limited to): Hb Boras, ! Leu88Arg273; 
Hb Les Andelys, " Leu83Pro274; Hb Santa Ana, ! Leu88Pro275; and Hb Köln, ! 
Val98Met272,276. All of the aforementioned show increased haem loss and instability 
attributed to increased solvation of the distal haem pocket and disruption to the F-helix 
conformation. Hence, by unravelling the F-helix, the receptor undermines measures that 
the globin has evolved in order to protect and stabilise the globin-haem interaction. 
 
Conformational flexibility of the F-helix is necessary for haem insertion during globin 
chain synthesis277,278. The F-helix is also an important component of the allosteric 
mechanism that achieves cooperative oxygen binding279. In addition, the chaperone " Hb 
stabilizing protein (AHSP) causes conformational changes in the " Hb haem pocket, to 
regulate metal oxidation, by introducing strain into the globin F-helix280-283. Removal of 
the haem group must also require unfolding of the globin haem pocket and the results 
shown here suggest that the IsdH receptor targets the F-helix, a region of the protein in 
which conformation plasticity is required for function. 
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Figure 6.3. The haem transfer interface. (A) The ! Hb subunit from the 
IsdHN2N3(Y642A,FYHYA"YYHYF):Hb complex (orange and red) overlaid with native 
Fe(III)-Hb (PDB 3P5Q, cyan). A localized change in backbone conformation occurs 
across the F-helix (red).  (B) Close up of the haem pocket E and F helices. Residues of 
the F-helix that have altered conformation are shown as sticks (red, pink and green) and 
the corresponding 2FO-FC electron density is shown at 1.5 #.  (C) The haem transfer 
interface. The IsdHN2N3 receptor (purple) makes hydrogen bonds and one salt bridge with 
the ! Hb polypeptide and haem propionates through four side chains (cyan). The 
Tyr642Ala mutation is shown as a yellow sphere. Residues of ! Hb that are involved in 
hydrogen bonds with the receptor are coloured green while the two His of ! that interact 
with the haem propionate are coloured pink. The rest of the F-helix of ! Hb that has 
altered conformation is coloured red. (D) The IsdHN2N3(Y642A,FYHYA"YYHYF):Hb 
interface, with holo-IsdHN3 (PDB 2Z6F) overlaid. The position of Tyr642 in PDB 2Z6F is 
shown as yellow sticks. (E-F) The haem pocket of native Fe(III)-! Hb (E), and native 
Fe(III)-$ Hb (F). Hydrophobic residues of the proximal haem pocket (spheres) contact the 
haem group and protect the haem coordinating histidine (red) against hydration. (G) At 
the IsdHN2N3(Y642A,FYHYA"YYHYF):Hb interface some of the proximal haem 
pocket residues (spheres) are displaced from their native positions. 
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Two, symmetry-related, !" dimers make !1"2 and !2"1 interfaces; however, the 
quaternary interactions do not represent either R or T state Hb. The positioning of the two 
dimers is more similar to T state Hb, but involves a greater rotation of the 
!2"2 unit relative to the !1"1 unit. Table 6.2 lists Hb subunit interactions that are 
characteristic of R state and T state Hb, respectively, and the Hb subunit interactions seen 
in the IsdHN2N3:Hb complex. Three of the salt-bridge and hydrogen-bonding interactions 
which are characteristic of T state Hb are present in 
IsdHN2N3(Y642A,FYHYA!YYHYF):Hb. On the whole, far fewer specific contacts are 
seen when the receptor is present than in either native Hb conformations, suggesting that 
the Hb tetramer is held together more loosely. The altered quaternary structure does not 
appear to be the result of changes in the ! or " Hb monomer structure, or changes in the 
!1"1 (or !2"2) interfaces: !" dimers align with an r.m.s.d. of 0.43 Å over 233 C! atom 
pairs. Interestingly, the crystal structure provides some evidence that receptor binding 
induces strain in the native Hb tetramer conformation. The "-hairpin of an IsdHN3 
molecule that is bound to an ! Hb subunit in the !1"1 dimer, projects across to contact 
the C-helix of a " Hb subunit in the neighbouring !2"2 dimer (Fig. 6.4 A). If the Hb 
tetramer were to adopt either the R or the T state quaternary conformation then the 
C-helix would sterically clash with the Leu640 and Gly641 of the receptor (Fig. 6.4 A, 
B). Using ESI-mass spectrometry, Spirig et al., observed dissociation of Hb tetramers 
into dimers in the presence of the IsdHN2N3 receptor independent of haem removal from 
the globin haem pocket167. Based on these findings they proposed a mechanism whereby 
binding of the receptor induced dissociation of Hb into dimers in order to accelerate haem 
release from Hb. The steric interaction between IsdHN3 and the " Hb subunit across the 
!1"2 interface provides a molecular basis for such a mechanism. 
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Table 6.2. Quaternary state interactions 
Region Interactions 
 R-state T-state IsdHN2N3:Hb 
Switch region 
!C:"FG 
Side chain 
positioning 
His97 positioned 
between Thr38 and 
Thr41 
Asp99 positioned 
between aTyr41 and 
aTyr42 
Asp99 positioned 
between aTyr41 and 
aTyr42 
    
    
Terminal salt 
bridges* 
!1His146 – !1Val1 
 
"1Arg141 – "2Asp126 
"1Arg141 – "2Lys127 
!1His146 – "2Lys40 
!1His146 – !1Asp94 
 
!1His146 – "2Lys40 
    
Hydrogen-bonding 
interactions 
characteristic of 
quaternary state  
"1Asn97 – "1Tyr42 
!2Trp37 – !2Asn102 
!2Asn102 – "1Asp94 
"1Val1 – "2Ser138 
 
"1Asn97 – !2Asp99 
"1Tyr42 – !2Asp99 
!2Trp37 – "2Asp94 
!1Val1 – !1Leu78 
"1Lys127 – "1Val1 
"1Asn97 – !2Asp99 
"1Tyr42 – !2Asp99 
 
*Functional groups involved are: "His146 !-carboxyl; "Val1 !-amino; !Arg141 
!-carboxyl; !Arg141 guanidinium; !Asp126 "-carboxyl; "His146 imidazolium; !Lys40 
#-amino; "Asp94 "-carboxyl.  
 !
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Figure 6.4. Steric interactions between the receptor and the !2 subunit across the 
"1!2 interface. (A) The IsdHN2N3 receptor (purple) is shown bound through the " chain 
of the Hb tetramer. The "1!1 and "2!2 dimers are coloured yellow and orange, 
respectively.  The !-hairpin of IsdHN3 sits between the C and F helices (red) of the !2 
subunit. The T state Hb tetramer (2ND2; "1!1 and "2!2 dimers coloured grey and blue, 
respectively) is overlayed with IsdHN2N3(Y642A,FYHYA#YYHYF):Hb, by 
superposition of the "1!1 dimers in both complexes. Residues of the receptor and T state 
Hb that would clash are shown are spheres. (B) An enlarged image of the boxed region in 
(A). Hydrogen bonding between the !-hairpin of IsdHN3 and !2 Hb is represented by red 
dashed lines. Predicted steric clashes that would occur if IsdH bound to T state Hb are 
represented by black dashed lines. 
 !
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During the course of performing UV-Vis experiments described in Section 3.3.1 it was 
noticed that the spectrum of Fe(III)-Hb mixed with IsdHN2N3(Y642A) was not identical to 
that of Fe(III)-Hb alone. Immediately after mixing at 4 °C a small red-shift in the Soret 
band (~400 nm) and changes in the Q band region (peaks at ~500–580 nm) were 
observed (Fig. 6.5 A). Importantly, after the first spectrum (~40 s) no further changes 
were observed over the next 30 min of incubation at 4 °C (Fig. 3.9 B). Two possible 
explanations for the observed spectral change are: (i) a change in the structure of the 
globin haem pocket upon IsdHN2N3(Y642A) binding in the absence of haem transfer or 
(ii) a minor proportion of haem groups transfer to reach a point of equilibrium in <40 s. 
There is no obvious physical mechanism that would lead to rapid transfer of such a small 
proportion of haem groups. Therefore, small changes in the spectrum of 
IsdHN2N3(Y642A):Hb may may be evidence of structural changes in solution, similar to 
those seen in IsdHN2N3(Y642A,FYHYA!YYHYF):Hb crystal structure. Spectral 
changes were also observed immediately upon mixing Hb with IsdBN1N2Y440A 
(Fig. 6.5 B), suggesting that IsdB may also induce conformational changes in the globin 
haem pocket. In summary, the spectroscopic studies provide some evidence that the 
structural changes observed in the crystal structure also occur in solution.  
 
 
 
 
 
 
 
Figure 6.5. (A) The spectrum of Fe(III)-Hb alone and in the presence of excess 
IsdHN2N3(Y642A). The spectrum of the complex is shown immediately after mixing and 
after 7.5 min, indicating that no change occurs over time. (A) The spectrum of Fe(III)-Hb 
alone, and in the presence of excess IsdBN1N2Y440A. Minimal changes occur in the 
spectrum over 7.5 min. 
 $
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To build a more comprehensive picture of the haem transfer reaction, crystallisation 
screening was performed with complexes of the receptor that had a wild type haem 
pocket. The aim was to capture a complex after haem had been transferred out of the 
globin haem pocket to visualise the final step in the haem capture process. Crystallisation 
trials were performed with two different complexes that were competent to undergo haem 
transfer. First, a 2:1 complex of apo-IsdHN2N3(FYHYA!YYHYF) with Fe(III)-Hb, and 
second, a 2:1 complex of apo-IsdBN1N2 (carrying the QSF!NTT and FYHYA!YYHYF 
mutations as described in Chapter 5) with Fe(III)-Hb was prepared. Finally, because the 
structure of IsdB in complex with Hb has not been determined in the pre- or post-transfer 
state, IsdBN1N2(QSF!NTT,FYHYA!YYHYF) was prepared with an addition 
Tyr440Ala mutation which inhibits haem binding and combined 2:1 with Fe(III)-Hb. All 
three complexes produced crystals or crystalline formations in the initial trials. 
Optimisation of crystal growth was attempted for each of the complexes; however, during 
the timeframe of this PhD only the apo-IsdBN1N2:Hb complex produced diffraction 
quality crystals.  
 
!"#"4$ 5)6+/(773+(/3&0$ &1$ (8&9:+*;<4<=$ 2())630>$ /,-$ ?@A!<%%$ (0*$
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Crystalline formations grew in 0.15 M DL-malic acid, pH 7.0, 20% (w/v) PEG 3350. 
Addition of isopropanol or ethanol to 10–20% (v/v) led to small, layered crystals. Larger 
crystals were grown in 16–17% PEG 3350 at pH 7.2–7.4. Finally, multiple rounds of 
streak seeding produced large crystals in 0.1 M DL-malic acid, pH 7.2, 16% (w/v) PEG 
3350, 15% isopropanol (Fig. 6.6 A). Although the crystals appeared single they had an 
unusual morphology with a slot in one side, suggesting that they were in fact clusters. The 
crystals dissolved in well solution containing glycerol and so were cryo-protected in well 
solution containing 25% ethylene glycol. Diffraction data were collected on the 
Australian Synchrotron MX2 beam line to 3.7 Å. The crystal contained multiple lattices, 
but a single lattice could be indexed with XDS265 and scaled with AIMLESS266; see Table 
6.3 for collection and refinement statistics. 
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Molecular replacement was performed with PHASER243 using !" Hb dimers (PDB 
3P5Q), the holo-IsdBN3 domain (PDB 3RTL) and a poly-alanine model of IsdHN2 (PDB 
4FC3), which was produced by removing all the side chains from the PDB file using 
CHAINSAW242. The volume of the asymmetric unit was consistent with two Hb 
tetramers and four IsdH receptors – a total of 20 domains! The initial solution contained 
four !" Hb dimers, two IsdBN2 domains and two IsdHN2 domains. REFMAC267 was used 
to perform an initial round of rigid body refinement after which MOLREP was able to 
place another IsdBN2 domain, followed by an IsdHN2 domain. Helical density was present 
in the FO–FC electron density map between each of the NEAT domain pairs, allowing the 
three-helix linkers to be built using Coot268 (Fig.. 6.6 B). Model building and refinement 
is incomplete, however, the statistics for the model at time of writing are given in table 
6.3.  
 
Table 6.3. Data collection and refinement statistics (molecular replacement) 
IsdBN1N2 (QSF#NTT, FYHYA#YYHYF):Hb 
Data collection  
Wavelength (Å) 0.95370 
Space group C 2 2 2 
Cell dimensions    
    a, b, c (Å) 154.07,   268.695,  153.74 
    !, ", $  (°)  90, 90, 90 
Resolution (Å) 48.14–3.701 (3.88-3.70) 
Rmerge (%) 11.0 (63.0) 
I / %I 9.7 (1.9) 
Completeness (%) 99.2 (96.0) 
Redundancy 3.7 (3.7) 
Refinement  
Resolution (Å) 44.59–3.70 (3.797-3.701) 
No. reflections 32378 
Rwork / Rfree  0.32/0.33 (0.38/0.36) 
No. atoms  
    Protein 17117 
    Ligand/ion 301 
    Water - 
B-factors  
    Protein 63.77 
    Ligand/ion 75.28 
    Water - 
R.m.s. deviations  
    Bond lengths (Å) 0.004 
    Bond angles (°) 0.74 
Values in parentheses are for the highest resolution shell. 
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Although the structure is not fully refined, inspection of the preliminary model reveals 
some interesting features. The four IsdBN1N2(QSF!NTT,FYHYA!YYHYF) receptors 
are bound through the " Hb chains (Fig. 6.6 C–D). The three domains of a single IsdB 
receptor bind to a single " Hb chain, to generate separate Hb-capture and haem-transfer 
interfaces as seen for IsdHN2N3:Hb interactions (compare Figure 6.6 D with Figure 3.15 
B). The IsdBN2 domain anchors the receptor to the A and E helices of " Hb. The helical 
linker domain contacts the globin F-helix and an interaction between "Asp85 and Tyr293 
is evident in the electron density as seen for IsdH (Fig. 6.3C). The haem binding domain, 
IsdBN2, is positioned next to the globin haem pocket. With the exception of a small 
difference in the arrangement of the three helices of the IsdBN1N2 Linker, the overall 
architecture of IsdBN1N2 and IsdHN2N3 is the same (Fig. 6.6 E). Thus the two homologous 
regions of the S. aureus Hb receptors, IsdB and IsdH, have a conserved structure and are 
likely to extract haem from Hb via a conserved mechanism.  
 
At the haem transfer interface, clear electron density is seen in the haem pocket of the 
IsdBN2 domain while the " Hb pockets are empty, indicating that haem has been 
transferred to the receptor (Fig. 6.6 B and F). The low resolution, and the fact that the 
structure is not yet fully refined, makes any comment on the conformation of the " Hb 
pockets speculative; however, the F-helix appears more similar to native " Hb than to the 
“pre-transfer” complex of IsdHN2N3(Y642A,FYHYA!YYHYF). This would suggest that 
contacts that impart the initial strain on the globin haem pocket are removed after haem 
transfer has occurred.  
 
 $
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Figure 6.6. Crystal structure of IsdBN1N2 (carrying the QSF!NTT and 
FYHYA!YYHYF mutations) bound through the a chain of Hb. (A) Photos of the 
hanging drop experiments showing multiple rounds of streak seeding. (B) The IsdB 
receptor (blue) with 2FO-FC electron density shown at 1.5 " (grey mesh) and FO-FC 
density shown at 3 " (green mesh), generated from a model without the helical Linker 
domains or haem groups. Difference electron density is present for three #-helices of the 
Linker domain, the haem group, and the missing side chains in the IsdBN1 domains. (C) 
The two IsdBN1N2:Hb complexes in the asymmetric unit. The four receptors (grey, blue, 
purple and green) are bound through the # subunits of Hb (orange). The $ subunits are 
coloured yellow. (D) The three domains of IsdBN1N2 bind to one # Hb chain to create 
separate Hb capture and haem transfer interfaces as seen in the IsdHN2N3:# Hb complex 
(Fig. 3.15 B). (E) The two complete IsdBN1N2 molecules (yellow and lavender) overlaid 
with the 2.5 Å structure of IsdHN2N3 (purple). (F) The haem transfer interface of IsdBN1N2 
and # Hb. 2FO-FC electron density is shown at 1.5 " (grey mesh). 
 !
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The structures of engineered IsdHN2N3 and IsdBN1N2 suggest that the haem binding NEAT 
domain (IsdHN3 or IsdBN2) and the Linker domain both contribute to the haem transfer 
interface. The structure of the “pre-transfer” complex could now be used as a starting 
point for molecular dynamics (MD) simulations to investigate the haem transfer reaction. 
The IsdB:Hb “post-transfer” complex provides means to validate the outcomes of MD 
simulations. To confirm the involvement of specific residues in haem transfer, mutations 
could be introduced into the Isd receptors or the globin chain. For example, Tyr495 and 
Lys499 on the IsdH linker domain interact with !Asp85, which marks the boundary 
between sections of the F-helix that have native and non-native conformations in the pre-
transfer IsdHN2N3 complex. These interactions also appear to be conserved in IsdB:Hb 
interactions. This interaction, along with contacts at the haem pockets, could be targeted 
through mutagenesis, and haem capture and relay activity could be assessed in vitro as 
was done for the mutations disabling Hb binding in Chapter 5. Pishchany et al., 
introduced IsdB genes carrying mutations in the Hb binding domain into the 
staphylococcal genome and demonstrated inhibited binding of Hb to S. aureus cells, 
reduced bacterial growth using Hb as an iron source, and reduced bacterial virulence208. If 
mutations at the interface between the haem binding NEAT domains and Hb, or the 
Linker domain and Hb, inhibit IsdB/H function in vitro and S. aureus growth in vivo, this 
opens up the possibility that inhibitors of these interactions might have utility against S. 
aureus infection.  
 
The approach taken to rationally engineer the IsdHN2N3 receptor, successfully produced 
crystals with better diffraction properties than those grown from the wild type complex. A 
comparison of the 2.5-Å IsdHN2N3(Y642A,FYHYA!YYHYF):Hb structure and the 
4.2-Å IsdHN2N3Y642A:Hb structure reveals a slight repositioning of the Linker and 
IsdHN3 domains. The whole Linker-IsdHN3 unit appears to have pivoted from the start of 
helix 1, close to the attachment point of the linker with the IsdHN2 domain. The result is 
that the "7–8 turn and the helical lip have moved ~ 7 Å in the direction of the ! Hb haem 
pocket. In addition, the haem binding "-hairpin of IsdHN3 is clearly defined in the 
electron density map, supporting the hypothesis that in the 4.2 Å structure, the IsdHN3 
domains were hindered in their binding to ! Hb due to steric interference. Hence the 
strategy to selectively remove low-affinity interactions between IsdH and " Hb to capture 
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the IsdH:! Hb haem pocket interactions has been successful. The IsdB/H:" Hb interface 
has not yet been characterised and a similar approach to enhance " Hb interactions and 
remove ! Hb interactions may allow for the crystallisation of an IsdB/H:" Hb complex. 
One possible target for mutagenesis is loop 4 of IsdBN1 or IsdHN2. In Chapter 5, the 
primary sequence of loop 4 was shown in to be a determinant of high affinity binding to 
! Hb.  In IsdH, residues of loop 4 interact with Lys11 of ! Hb. Thr12 occupies the same 
position of " Hb and it may be possible to tailor loop4 to be more complementary to the 
size and charge of "Thr12. An alternative strategy may be to introduce mutations into the 
" Hb sequence; a Thr12-to-Lys mutation in the " chain of Hb was previously shown to 
enhance the binding of IsdHN2 to Hb146.   In addition, it may be possible to block the ! Hb 
sites with the isolated IsdHN1 domain by virtue of the higher affinity binding of the 
IsdHN1 domain to ! Hb detected in Chapter 4. Structural information on the haem transfer 
interface at the " Hb haem pockets will confirm whether a similar or distinct haem-
transfer mechanism operates at the two globin haem pockets. This may be relevant for the 
design of inhibitors that aim to prevent uptake of haem from both Hb chains.  
 
In conclusion, the structural studies performed in Chapter 6 have addressed the aim of 
determining the molecular mechanism used by IsdB and IsdH to liberate haem from Hb. 
The structure of the engineered IsdHN2N3 protein bound to Hb has revealed direct contacts 
at the Hb haem pocket, and an altered Hb haem pocket conformation, providing a 
potential mechanism for facilitated haem release from Hb. The contribution of these 
molecular contacts to haem transfer can now be tested through mutagenesis studies that 
target the haem transfer interface.   
 205 
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Haem is relayed through the bacterial cell wall, a distance of up to ~90 nm, via an 
energy-independent mechanism that involves the formation of protein-protein complexes 
between Isd proteins to transfer the haem ligand149,167,168,170,171. Haem transport across the 
membrane is achieved by an ABC transporter (of which two components are IsdE and 
IsdF), and, is therefore presumed to be ATP-dependent. At the onset of this project it was 
known that interactions between Hb and the Hb receptors, IsdH and IsdB, facilitate the 
release of haem from Hb, leading to rapid haem capture149,167. The nature of these key 
interactions and the molecular mechanism of facilitated haem release were unknown.  
 
Towards understanding this mechanism, the structures of the intact homologous regions 
of the Hb receptors were investigated, free and in complex with Hb. IsdBN1N2 and 
IsdHN2N3 adopt a conserved supra-domain structure that is preserved upon binding to Hb. 
The three domains of a receptor are arranged to contact a single globin chain such that 
two interfaces are formed: a Hb targeting interface and a haem transfer interface. The use 
of multiple interaction surfaces may allow for localised conformational changes in the 
globin fold, which are necessary for haem release, without disrupting the receptor:Hb 
complex. The engineered pre-transfer complex of IsdHN2N3 bound to Hb revealed that the 
Linker and IsdHN3 domains contribute a limited number of specific molecular contacts at 
the haem transfer interface that could not be identified in the lower resolution 
IsdHN2N3(Y642A):Hb complex. These contacts promote unfolding of the globin F-helix. 
The proposed mechanism of haem release is that unfolding of the F-helix disrupts the 
hydrophobic seal that protects the iron-histidine bond and destabilises the globin-haem 
interaction, and also widens the entrance through which haem can move out of the globin. 
 
Besides IsdH and IsdB, only two other interactions with Hb have been structurally 
characterised. These are Hb complexes with the mammalian proteins AHSP281-283 and 
Hp250. AHSP binds the free ! chain of Hb while Hp binds to an !" dimer. In each case 
the binding site is distant from the haem pocket and distinct from the surface contacted by 
the Isd proteins. Hp binds to !" Hb dimers (blocking tetramer formation) and stabilises 
the native globin fold, preventing haem loss and autooxidation250. Binding of AHSP 
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introduces structural changes into the ! Hb haem pocket to induce a bishistidyl haem 
ligation that is protective against oxidative damage by limiting redox cycling of the haem 
iron281,282.  To bring about these structural changes in the haem pocket, AHSP introduces 
strain into the ! Hb structure that is transmitted though the globin F-helix and proximal 
His to weaken the Fe–O2 bond in oxygenated ! Hb280,283. Interestingly, AHSP binding 
accelerates haem loss from Fe(III)-! Hb by a factor of 2, presumably though increased 
hydration of the haem pocket (the physiological significance of this effect, if any, is 
unknown)284. In conclusion, it is likely that any disturbance of the native haem pocket 
structure will result in increased autooxidation and haem dissociation, and this is 
exploited by the IsdB/H receptors to promote haem release. 
 
The three-domain architecture necessary for direct haem capture is specific to IsdBN1N2 
and IsdHN2N3 and the related protein slIsdB, implying that the putative Hb receptors in 
Gram-positive S. pyogens, B. cereus, B. anthracis and L. monocotogenes69,163,183,187, 
which have different domain architectures, may function via a distinct mechanism. The 
putative Hb receptors, Shr, IlsA, IsdX1, Hal and Hbp2 (see Section 1.5.4.5) are multi-
domain proteins, and it is hypothesised that some of these domains might bind to Hb, 
whilst the conserved NEAT domain(s) capture haem, in a fashion analogous to the two-
interface mechanism of IsdB/H.  
 
While the Hb interactions of the putative Hb receptors are yet to be characterised, the 
structure of the IsdH:Hb complex may help to interpret some of the available data. 
Structures are available for the isolated IsdX1-NEAT and IsdX2-NEAT5 of B. 
anthracis154,184. In both cases residues of 310 helix were implicated in Hb binding and 
haem capture. In the IsdH:Hb structure, the helical lip is adjacent to the globin C-E loop 
and the E-helix, where Glu562 of IsdHN3 hydrogen bonds to !Gln54. Assuming that the 
IsdX NEAT domains dock to the globin haem pocket in the same orientation as IsdHN3 
then Gln29 of IsdX-NEAT2, which was shown to be required for haem scavenging from 
Hb157, is in a position to interact with !Gln54 (Fig. 7.1). Interactions between the 310 
helix of the IsdX proteins and the globin E-helix may act to tether the receptor to the 
haem pocket surface, although the interaction is expected to be weak without an 
additional Hb targeting domain. The two haem binding tyrosines are also present in 
conserved positions with Tyr642 and Tyr646 of IsdHN3. In contrast, the rest of the haem 
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binding !-hairpin is dissimilar to IsdHN3 and it is difficult to predict whether interactions 
will occur with this surface and the globin F-helix. The rate of haem capture by IsdX1 or 
IsdX2 from Hb has not been determined, so it is not known if this is limited by passive 
dissociation from Hb chains, or if IsdX1/2 facilitates haem release as is the case for 
IsdB/H. If the latter is true, additional contacts that destabilise the haem pocket are 
expected. The five NEAT domains of IsdX2 could potentially perform multiple roles in 
binding/destabilising Hb and binding to haem. To determine whether the Gram-positive 
Hb receptors function through similar mechanisms to IsdH and IsdB, kinetic 
measurements of haem transfer together with structural studies of the intact receptors in 
complex with Hb are required. 
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Figure 7.1. Possible interactions of IsdX2-NEAT5 with the haem pocket of !  Hb. 
The isolated NEAT5 domain of IsdX2 (blue; PDB 4H8P) is shown overlaid with IsdHN3 
(purple) at the haem transfer interface of ! Hb (orange). A hydrogen bond between 
Glu562 of IsdHN3 (cyan) and Gln54 of ! Hb (green), present in the crystal structure of 
IsdHN2N3(Y642A,FYHYA!YYHYF) is shown. Gln29 (red) of IsdX2-NEAT5 is 
positioned such that it could possibly interact with Gln54 of ! Hb. Side chain rotamers of 
IsdX2-NEAT5 have not been optimised for hydrogen bonding with ! Hb. 
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Despite a conserved mechanism of haem capture, IsdB and IsdH show differences in 
haem relay function, with IsdB but not IsdH catalysing haem transfer from Hb to IsdA/C. 
Higher haem relay activity was found to correlate with lower Hb binding affinity. Thus, 
IsdB showed considerably weaker affinity for ! Hb and " Hb than IsdH or IsdHN2N3 but 
showed much greater haem relay activity. To investigate the relationship between Hb 
affinity and haem relay further, I introduced mutations into the Hb targeting domain of 
IsdB that enhanced or reduced the interaction with Hb. The haem relay activity of IsdB 
proteins with altered Hb binding affinity was consistent with the hypothesis that Hb 
binding affinity is optimised to allow for both a specific interaction and rapid haem relay 
(discussed in Section 5.6). A mechanism in which rapid dissociation of the Isd:Hb 
complex is necessary for efficient haem relay is consistent with the IsdHN2N3 and IsdBN1N2 
structures presented in Chapters 3 and 6, because the haem pockets of IsdB and IsdH are 
not accessible to IsdA/C when bound to Hb. No large conformational changes were 
observed between the free and the bound forms of the receptor; hence, the structure 
studies predict that the complex must dissociate for haem relay to occur.  
 
Ligand-transfer pathways, which involve relay of a ligand though a network of proteins, 
often rely on transient or weak associations between protein partners. These interactions, 
with typical dissociation constants in the range of mM–µM, allow for rapid and repeated 
interactions between the donor and acceptor proteins to convey the ligand172,173,285. Weak 
or transient interactions occur at multiple stages in the Isd pathway as transfer of haem 
between IsdA and IsdC involves an ‘ultra-weak’ interaction (Kd ~5 mM)171. Hence low 
affinity protein-protein interactions are likely to be a general feature of bacterial haem 
relay pathways. 
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The superior haem relay activity of IsdB identified in this project provides a biochemical 
basis to understand why IsdB is the primary receptor involved in haem import from Hb in 
vivo8,84. This raises the question, if IsdB is more efficient at haem uptake from Hb than 
IsdH, why does S. aureus produce IsdH? IsdH may have alternative roles in infection (as 
discussed in section 4.8); however, the high-affinity Hb binding and haem extraction 
functions presumably play some role. One possibility is that IsdH and IsdB play 
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complementary roles under different conditions of Hb abundance (Fig. 7.2). In 
environments where the concentration of Hb is high, encounters between IsdB and Hb 
will occur frequently and rapid association and dissociation of complexes is expected to 
allow for efficient haem relay to IsdA/C. In contrast, IsdH provides two higher affinity ! 
Hb binding domains and may provide an advantage in Hb capture under conditions where 
Hb concentration is low. The IsdHN1 domain was shown to be connected to the protein 
via an unstructured linker domain of ~ 100 residues (K. Krishna Kumar and D. Gell, 
unpublished), which may further increase the chances of binding Hb through a ‘fly-
casting’ mechanism. In addition, when haem is in excess, IsdH may act as a reservoir for 
haem, buffering against a change in conditions. A buffering role has been proposed for 
the second NEAT domain of Shr, which binds to haem but does not rapidly transfer this 
haem to Shp178,179, and for the multiple NEAT domains of IsdX2184. IsdB and IsdH may 
have diverged in their Hb capture and haem relay activities in order to optimise haem 
uptake at different sites of infection within the host that offer different Hb availability. 
Bacillus anthracis also produces numerous Hb/haem receptors, IsdX1, IsdX2, Blsk and 
Hal86,157,183,186,286. Indeed, the expression of multiple factors that play complementary 
functions in iron import is common amongst bacterial pathogens. Recently, it has been 
shown that the siderophores, pyoverdine and pyrochelin, produced by Pseudomonas 
aeruginosa, operate in iron uptake under different conditions of iron availability287. 
Pyoverdine has a high affinity for iron but is metabolically more expensive to produce 
than the lower-affinity iron chelator, pyrochelin. Varying the relative abundance of these 
two siderophores was shown to provide a competitive advantage in an environment 
fluctuating in iron availability. 
 
Future work should investigate the model that IsdH and IsdB play distinct roles in haem 
uptake. One possibility would be to measure growth of genetically engineered S. aureus 
strains that are deficient in either IsdB or IsdH production under a range of conditions 
with different Hb availability. Competition assays with deletion vs wild type strains may 
determine whether expression of both proteins provides a growth advantage across 
different Hb concentrations. An alternative possibility is that IsdH may contribute to 
haem capture from Hb:Hp complexes. Hp may stabilise the Hb fold and prevent haem 
loss250 and IsdB/H may differ in their ability to extract haem from Hb in the presence of 
Hp. The role Hp in haem uptake by IsdB/IsdH should now be investigated.  
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Figure 7.2. A schematic model describing potential complementary roles for IsdB 
and IsdH in environments with different concentrations of available Hb. Under 
conditions where Hb is highly abundant, weak interactions between IsdB and Hb will 
allow for efficient relay of haem from Hb to the haem carrier proteins IsdA/C (black). 
Under conditions where Hb is scarce, the high affinity Hb binding domain of IsdH 
(white), attached to a freely diffusing linker, may provide an advantage in Hb capture. Hb 
that is bound by this domain may be delivered to the haem extraction domains of IsdH or 
IsdB (light grey). Slow haem relay from IsdH may provide a haem reservoir to buffer 
against fluctuations in Hb availability. 
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Iron is an essential nutrient for S. aureus growth and inhibiting iron uptake is a possible 
target for antibiotic development. S. aureus employs multiple iron uptake systems during 
infection, including the Isd system. Inactivating elements of the Isd pathway significantly 
reduces S. aureus growth and infectivity however does not render S. aureus avirulent. 
While inhibiting the Isd system in isolation is unlikely to be effective in curing S. aureus 
infection, a combinatorial approach that targets each of the redundant iron import 
systems, including the Isd system, may be highly effective. In addition, the Isd system 
may be exploited as a route to import antibacterial agents that have been liked to 
porphyrin mimetics. Since the Isd system is specific to S. aureus, a drug that is imported 
by Isd system may have the advantage of not killing commensal and beneficial bacteria. 
 
The Isd system has received considerable interest as a target for antimicrobial therapies. 
Current avenues being explored include the development of porphyrin inhibitors that bind 
to Isd proteins but cannot be relayed through the pathway288, non-iron metalloporphyrin 
complexes that hijack the haem uptake pathways to import bactericidal metals176,221,289, 
and vaccine design using Isd proteins as antigens290-293. 
 
A new possibility, based on the work from this thesis and elsewhere, may be to develop 
molecules to inhibit the Isd:Hb, protein-protein interactions. Haem transfer experiments 
in Chapters 3 and 5, together with previous studies167,208, indicate that specific 
interactions at both the Hb binding interface and the haem transfer interface are required 
for haem uptake from Hb. Blocking Hb:Isd interactions through mutagenesis of Hb or the 
IsdB receptor, reduces (in the case of Hb mutants)146 or largely abolishes (in the case of 
IsdB mutants)208 S. aureus growth using Hb as an iron source. In infection models, an S. 
aureus strain expressing an IsdB mutant that cannot bind to Hb shows reduced 
colonisation of kidneys and hearts208. Hence disrupting the Isd:Hb interactions may be of 
therapeutic benefit for infections of these organs. S. aureus is an important cause of 
infective endocarditis, and is associated with high mortality, meaning that new treatments 
are certainly required. If used in combined therapies, inhibitors of Isd:Hb interactions 
may enhance the action of porphyrin based inhibitors, by favouring uptake of the 
antibiotic molecule rather than Hb-derived haem. Since the antimicrobial porphyrin 
compounds identified to date have a lower affinity for the Isd proteins than haem, this 
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effect may be significant166,221. The Isd:Hb structures indicate that both NEAT domains 
and the linker contribute to the Hb binding surface, providing several potential faces to 
target. IsdH and IsdB use the same surfaces to contact Hb and many of the interactions 
are conserved and so it might be possible design an inhibitor to knock out both 
interactions with Hb. Compounds that target any of these sites may be identified through 
fragment screening or in silico methods (computer aided drug design), followed by 
structure determination and lead optimisation294-297.  
 
An alternative anti-microbial therapy is vaccine development. The Isd proteins are 
expressed in S. aureus strains isolated from infected tissues260 and are highly 
immunogenic290,298,299. Preliminary vaccination trials and passive transfer of antibodies 
against IsdA, IsdB and IsdH show protective effects in mouse and bovine 
models174,290,291,300. However, preliminary vaccination trials using recombinant IsdB have 
failed to provide significant protection in humans299. More recently fusion proteins 
combining several fragments of immunogenic proteins, including IsdB, have shown 
greater efficacy in mouse models292,293. From the IsdH/B:Hb structures it may be possible 
to  identify functional regions and regions that are conserved between IsdB/H which 
could improve fusion vaccine design.    
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The ability to import iron from host proteins is an important aspect of bacterial virulence. 
Many pathogenic bacteria utilise the abundant protein Hb as a source of nutrient iron 
during colonisation of a mammalian host. This thesis presents structural and functional 
data that provide insights on how the Hb receptors of S. aureus function to capture haem 
from human Hb. This is the first structural characterisation of an intact Gram-positive Hb 
receptor in complex with Hb and may inform our understanding of Hb receptor function 
in other Gram-positive species.   
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